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CHAPTER I 
 
INTRODUCTION 
 
Overview 
 
Signaling networks and pathways regulate a variety of essential cellular 
functions.  Identifying molecular responses to changes in signaling events is 
crucial not only for understanding the molecular mechanisms intrinsic to a 
signaling pathway, but also for evaluating the biological processes driving 
phenotypes.   Activities of pathways are controlled by posttranslational 
modification of key pathway intermediates, such as signaling receptors and their 
downstream effectors, which undergo reversible phosphorylation and other 
modifications.  Direct analysis of phosphorylated proteins is the most commonly 
employed method to assess signaling networks.  Antibody and mass 
spectrometry-based techniques have proven useful to monitor phosphorylation 
events. However, these approaches are complicated by the transient nature of 
protein posttranslational modifications, their low abundance relative to 
unmodified proteins, potential artifacts due to uncontrolled pre-analytical 
variables or specificity of available antibodies.   Given these considerations, more 
robust approaches to measure signaling networks are needed to overcome the 
challenges of direct phosphoproteome analyses. 
  2
The epidermal growth factor receptor (EGFR) is one of the most 
extensively studied receptor tyrosine kinases and represents a nexus of 
biological signaling events and influences a broad range of biological processes.  
Upon receptor activation, signal transduction occurs by recruitment of adaptor 
proteins and downstream kinases.  Given EGFR involvement in multiple 
biological processes, it is not surprising that mutations and aberrant expression 
of the receptor have been linked to a number of human cancers types and can 
modify responsiveness to EGFR inhibiting drugs.  Despite the rapid growth of 
information about EGFR signaling networks, identification of robust molecular 
markers linking network status and therapeutic response remains an ongoing 
challenge.  We asked whether changes in global protein expression levels could 
produce distinct protein signatures indicative of a cellular response to EGFR drug 
modulation. 
The work described in this dissertation presents results demonstrating the 
potential for monitoring signaling pathway changes through global protein 
responses.  I hypothesize that changes in global protein expression signatures 
are indicative of a distinct response to drug treatment.  Using two clinically 
available EGFR-targeted inhibitors (gefitinib and cetuximab), the EGFR signaling 
axis was modulated in human cancer cells and differences in protein expression 
were compared between treatments.  The resulting changes represent a 
signature of differential protein expression and were assessed in multiple cancer 
cell lines, tissue models and human tissue samples.   The following chapters 
detail a mass spectrometry-based approach for identifying and quantifying 
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changes in global protein signatures in response to EGFR perturbation.   In 
addition, a comparison between two quantitative mass spectrometry methods for 
detecting phosphorylated proteins is discussed.  The remainder of Chapter I will 
provide background on EGFR biology, discuss the role of the receptor in cancer, 
address variability in response to treatment, and outline the rationale for the 
approach described herein. 
 
The Epidermal Growth Factor Receptor 
 
Structure and organization  
The epidermal growth factor receptor (EGFR) is a 170 kDa 
transmembrane glycoprotein that is one of the four members of the ErbB family 
of protein tyrosine kinase receptors along with ErbB2, ErbB3 and ErbB4 (HER2, 
3 and 4 respectively) (1-3 ).  A key mediator in many signaling pathways, EGFR 
regulates complex biological processes such as growth, differentiation, motility 
and cell death.   As seen in Figure I-1A, EGFR is composed of several functional 
domains including: the extracellular (EC) domain, transmembrane domain, 
juxtamembrane domain, tyrosine kinase domain and the carboxy-terminal tail (2).   
The EC portion of the receptor has cysteine-rich regions, is highly glycosylated, 
and is capable of binding several different ligands including EGF, HB-EGF, 
epigen, amphiregulin, epiregulin, transforming growth factor alpha (TGF-α), and 
betacellulin (Figure I-1A).  Binding of ligand to this EC domain induces the 
formation of homodimers with another EGFR molecule or heterodimers with 
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other members of the c-ErbB receptor tyrosine kinase family (4).   This EC 
portion consists of four sub-domains referred to as L1, CR1, L2, and CR2 (Figure 
I-1C).  Ligands bind between sub-domains L1 and L2 when the receptor adopts 
an extended confirmation to create a ligand binding pocket (5).  The CR1 and 
CR2 domains consist of small modules 
                   
 
 
Figure I-1 Schematic of EGFR, ErbB family members, receptor dimerization 
and extracellular domain.  ECD = extracellular domain, TMD = transmembrane 
domain, JMD = juxtamembrane domain, TKD = tyrosine kinase domain and CT = 
carboxy-terminal tail.  A) Identifies the domains and ligands for EGFR and the 
other ErbB family members.  HER2 binds no ligand, while HER3 has no active 
kinase domain.  EGF = epidermal growth factor, TGF-α = transforming growth 
factor alpha, AR = amphiregulin, EPG = epigen, BTC betacellulin, EPR = 
epiregulin, NRG1-4 = neuregulin.  B) Illustrates ligand binding and receptor 
homo-/hetero- dimerization.  C) Enlarged view of the extracellular sub-domains of 
EGFR (L1-2) = ligand binding, (CR1-2) = cysteine rich domains. 
EGFR (ErbB1)       HER2(ErbB2)     HER3(ErbB3)         HER4(ErbB4)   
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containing disulfide bonds, and a large loop protruding from the back of the CR1 
domain, which makes contact with the CR1 domain of other receptors and is 
necessary for dimerization (6, 7) (Figure I-1B).   
 
Receptor activation 
Upon dimerization, the intrinsic tyrosine kinase activity of the receptor is 
activated (8, 9) and catalyzes the transfer of the γ-phosphate of bound ATP—to 
autophosphorylate several specific sites (e.g., Y992, Y1045, Y1068, Y1148 and 
Y1173) in the cytoplasmic tail (CT) as well as endogenous substrates (10-12).  
The ATP binding pocket sits between an N-terminal lobe and a larger C-terminal 
lobe within the kinase domain (13).  The internal phosphorylated residues serve 
as docking sites for Shc, Grb2, Src, phospholipase C and a host of other adapter 
proteins and activators of intracellular substrates (14-16)—typically  with 
phosphotyrosine binding (PTB) and Src homology (SH2) domains (17-20).  
These recruited partners can be subsequently phosphorylated through the 
activated TKD of EGFR and form multi-component signaling complexes that 
activate intracellular signaling pathways.    
Numerous reviews have addressed the pathways involved in EGFR 
receptor signaling (21-24).  For example, Shc and Grb2 recruitment to the tyrosine 
phosphorylated receptor activates the Ras/Raf mitogen-activated protein kinase 
(MAPK) pathway—through a Grb2–bound exchange factor SOS—ultimately 
regulating transcription factors such as Elk-1 and c-fos (15).  Another example is 
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the activation of the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway 
(Figure I-2) through  EGFR  binding  protein Gab1 (25, 26).  These and other 
 
 
 
Figure I-2.  EGFR signaling.  Upon ligand binding, EGFR adopts an extended 
conformation allowing the receptor to dimerize through Domain II (CR1) of the EC 
portion of the receptor.  Subsequent autophosphorylation (green stars) of residues 
in the cytoplasmic tail of the receptor occurs and present themselves as docking 
sites for adapter proteins.  These adapter proteins and enzymes form multi-
component signaling complexes capable of mediating downstream signaling 
events responsible for an array of biological processes. 
 
 
 
EGFR-driven pathways regulate biological processes from cellular proliferation 
and gene expression to inhibition of apoptosis and survival (16, 27). 
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Additional mechanisms of receptor activation 
In addition to EGFR activation by canonical ligand binding, receptor 
signaling can also be influenced via alternative mechanisms of transactivation 
(Figure I-3).    Cytokines  such as  growth  hormone  and  prolactin  have been  
 
 
 Figure I-3.  Alternate methods of receptor activation.   Schematic illustrating 
non-canonical mechanisms of EGFR activation.  In addition to a number of stress 
stimuli, the growth hormone receptors and g-protein coupled receptors (GPCR) 
have been demonstrated to indirectly activate EGFR. 
 
 
 
observed to indirectly activate EGFR through Janus tyrosine kinase (Jak2) which 
phosphorylates tyrosine residues within the CT domain of EGFR promoting GRB2 
association, MAP kinase activation, and c-Fos induction (28, 29}.  Additionally, 
EGFR has been found to be exploited by G-protein coupled receptor (GPCR) 
LPA, thrombin, 
endothelin, ANG II
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α
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mitogenic signaling involving assorted ligands including lysophosphatidic acid 
(LPA), endothelin, and angiotensin II (30, 31). 
These activated GPCRs stimulate metalloproteinases capable of cleaving 
membrane bound EGF-like ligands and releasing them for enhanced receptor 
signaling (32).  In addition, activated GPCRs indirectly activate the non-receptor 
tyrosine kinase Src, which can phosphorylate various residues on EGFR leading 
to increased receptor signaling (33-35).  In some cells, particularly those of the 
nervous system, EGFR intracellular signaling pathways can be evoked by cellular 
changes in electrical activity.   Moreover, angiotensisn II has been reported to 
induce Ca2+-dependent trasnsactivation of EGFR (36).  In PC-12 cells, an influx of 
Ca2+ through membrane depolarization results in increased levels of EGFR 
phosphorylation, while growth factor and insulin receptor phosphorylation remains 
unaffected (37, 38).  This is believed to occur indirectly via a Src-activation 
mechanism similar to that for activated GPCR (39, 40).  Other non-canonical 
means of EGFR activation include stress stimuli such as  UV radiation (41, 42),  
gamma radiation (43), oxidants (44) and heat shock (45).  
 
EGFR: Cancer and Targeted Inhibitors  
 
EGFR expression in cancer 
EGFR is found expressed or overexpressed in several human cancers 
including: non-small cell lung cancer (NSCLC) (46, 47), head and neck (48, 49), 
breast (50, 51), colorectal (52), prostate (53), gliomas (54), and bladder cancer 
  9
(55).  Increased expression of EGFR has been associated with advanced tumor 
stages, resistance to traditional therapies, poor prognosis in patients and 
increased metastasis (56-60). 
 
EGFR inhibitors  
These findings led a surge in clinical focus on EGFR as a target for drug 
development, as demonstrated by the FDA approval of five drugs directed at this 
tyrosine kinase receptor from 2003-2007, including gefitinib and cetuximab, which 
will be further addressed in this section.  Both of these drugs have been approved 
for the treatments of cancer including colorectal cancer (CRC), head and neck 
cancer, and non-small cell lung cancer (NSCLC).  While both gefitinib and 
cetuximab target EGFR specifically, these two types of inhibitors block EGFR 
activation by different mechanisms (Figure I-4).  Cetuximab is a chimeric 
(human:mouse), monoclonal antibody directed at the EC domain and competes 
for binding sites with endogenous ligands (61).  Cetuximab binding to Domain III 
(L2) prohibits conformational changes and dimerization of the receptor monomer 
and results in the downregulation from the membrane surface, thus inhibiting 
further EGFR signaling (62, 63).  Cetuximab treatment, in cell cultures with human 
cancer cells,  exhibits growth inhibition, decreased angiogenesis and induction of 
apoptosis (64-66) and is characterized similarly in vivo by tumor regression, 
inhibited growth and angiogenesis, and  increasing  tumor sensitivity  to 
radioresponse (61, 67-71).    Gefitinib,  however,  is  a  small-molecule receptor 
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Figure I-4. Schematic of EGFR inhibition with gefitinib and cetuximab.   TKI 
= tyrosine kinase inhibitor, EGF epidermal growth factor receptor.  Gefitinib 
competes for binding near the ATP binding site inhibiting activation of the tyrosine 
kinase domain.  Cetuximab binds to domain III (L2) of the extracellular portion of 
the receptor inhibiting dimerization and resulting in receptor down regulation. 
 
 
tyrosine kinase inhibitor (TKI) designed to penetrate the cell membrane and 
compete with adenosinetriphosphate (ATP) for binding to the tyrosine kinase 
domain of EGFR (72).  Similar to studies with cetuximab, studies both in vitro and 
in vivo demonstrated the ability of gefitinib to suppress tumorigenesis in mouse 
models and increase radiosensitivity (73-76). 
 
Variable Response to EGFR-targeted Therapies 
 
EGFR overexpression 
Despite the broad importance of EGFR as a therapeutic target, varying 
responses to EGFR-targeted drugs in vitro and in vivo imply varying degrees and 
alternative mechanisms of signaling pathway activation and thus present a 
EGF
Endosome
TKITKI
ATP
Gefitinib Cetuximab
EGFEGF
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significant clinical problem in assessing efficacy of therapy.   There are multiple 
methods by which EGFR can become activated implying interplay of signaling 
mechanisms resulting in variable responses.  Certainly, overexpression of EGFR 
is the most evident mechanism of increased receptor signaling and occurs several 
cancer types including glioma, colorectal, esophageal, and breast cancers (50, 
54, 56, 57).  However, conflicting reports in the literature make EGFR 
overexpression an inconsistent predictor of response to EGFR inhibiting drugs.  
For example, studies from esophageal and metastatic colorectal cancer patients 
reported by Janmaat et al. (77) and Yen et al. (78) have demonstrated a 
correlation between increased EGFR expression and gefitinib or cetuximab 
sensitivity, whereas studies in a number of cancer cell lines by Ciardiello et al. 
(79) and in patients with advanced colon cancer by Cascinu et al. (80) reported no 
significant correlation.    
 
Heterodimerization and cross-talk with heterologous receptors 
Extensive evidence supports heterodimerization with other ErbB receptors 
or cross-talk of EGFR with heterologous receptors as additional mechanisms of 
enhanced receptor activation, providing another possible explanation for the 
varying responses to EGFR inhibitor treatment.  Reported overexpression of Her2 
and Her3 was associated with resistance to gefitinib, but not to cetuximab in 
HNSCC cell lines (81).  Cell models of liver metastases from gastric cancers with 
gefitinib resistance show EGFR and HER2 co-expression with an increase in 
EGFR expression over gefitinib-sensitive cell lines (82).  Conversely, NSCLC and 
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breast cancer cell lines with HER2 overexpression showed increased sensitivity to 
gefitinib (83, 84).  In addition, similar results were reported in breast cancer 
tumors by Hirch et al., who noted increased sensitivity to gefitinib in tumors 
overexpressing HER2 (85).   Similar studies by Patel et al. in human xenograft 
models of gastric carcinoma showed that cetuximab treatment decreased EGFR-
HER2 signaling and resulted in tumor growth inhibition (86).  Again, discrepancies 
in the literature emphasize the complex nature of signaling responses and support 
the need for additional metrics of response to EGFR-inhibiting therapies.   
Numerous examples in the literature link cross-talk of EGFR and 
heterologous receptor signaling pathways to human cancers (87-90).  In 
pancreatic ductal adenocarcinomas and colon cancers, co-expression of the 
insulin-like growth factor receptor (IGR) and EGFR correlated with poor outcome 
(91, 92).  Furthermore, studies in NSCLC cells and glioblastomas describe a role 
for the insulin-like growth factor receptor in a mechanism of resistance to gefitinib 
(93, 94).  Additional mechanisms of cross-talk between EGFR signaling and the 
receptor tyrosine kinase c-Met (hepatocyte growth factor receptor) have been 
reported in vitro and in vivo (95, 96) with increased Met activation associated with 
resistance to gefitinib and anti-epidermal growth factor antibodies in lung cancer 
cells and to gefitinib in glioblastoma multiform mouse models  (97,98, 99).  In 
patients treated with cetuximab for metastatic colorectal cancer, c-MET 
overexpression significantly correlated with shorter progression-free survival and 
overall survival (100).  These findings describe the interplay of EGFR with other 
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signaling pathways to influence the outcome of response to EGFR-targeted 
inhibitors.  
 
Feedback loops 
Signaling through autocrine feedback loops involving one or more EGFR 
ligands co-expressed with EGFR add an additional layer of complexity to EGFR 
signaling.  Increased expression of EGF, TGF-α, or other EGF-like proteins has 
been noted in colorectal carcinoma and in advanced gliomas (101, 102) and 
expression of EGF, TGF-α, or amphiregulin correlates with poor prognosis or 
lowered survival in patients with breast and lung adenocarcinomas (103-106).  In 
contrast, increased gene expression of amphireguiln and epiregulin was 
associated with longer progression free survival in patients with metastatic 
colorectal cancer (107).  HNSCC cell lines with increased amphiregulin 
expression were significantly more likely to be growth inhibited by both gefitinib 
and cetuximab than those that produced minimal or no amphiregulin (108).     
  
EGFR and downstream mutations 
A large body of evidence indicates that responses to EGFR-targeted drugs 
are affected by EGFR mutations.   Mutations affect intrinsic sensitivity or 
resistance at the level of the target receptor.  EGFRvIII is an example of a 
truncated form of the receptor due to a deletion of exons 2 through 7, which 
results in a loss of amino acid residues 6 to 276 of the receptor EC domain (109); 
this variant of EGFR is constitutively active and is not downregulated by 
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endocytosis (110, 111).   Overexpression of EGFRvIII has been noted in NSCLC 
and prostate cancer tissue (112, 113), and in studies in vitro and in vivo involving 
glioblastoma cells.  EGFRvIII expression correlates with enhanced tumorgenicity 
in breast cancers and HNSCC (114-116).  No significant response to cetuximab or 
gefitinib treatment was observed in HNSCC or in glioblastoma cells expressing 
EGFRvIII (116, 117).   Activating mutations in the kinase domain, including L858R 
or deletion of residues l746-750 have been repeatedly found in non-small cell lung 
cancers and sensitize patients to gefitinib drug treatments (118, 119).   
An interesting observation is the occurrence (either prior to or post-gefitinib 
treatment) of a T790M point mutation in NSCLC patients, which confers 
resistance to treatment with gefitinib (120-122).  Furthermore, recent laboratory 
studies have suggested that the antitumor effect of cetuximab is not affected by 
the EGFR mutations, including the TKI-resistance mutation T790M (122, 123).  
However, it should also be noted that not all activating mutations in the kinase 
domain of EGFR (e.g., L861Q) similarly affect sensitivity to inhibition of the 
receptor tyrosine kinase by gefitinib (124).   
Finally, some mutations or alterations in downstream signaling components 
are negative predictors of response to EGFR targeted therapies and afffect 
outcomes to drug treatments.  Mutations in KRAS constitutively activate MAPK 
signaling and block cellular response to EGFR inhibiting drugs (120, 125, 126).  
Similarly, mutations in PIK3CA also confer resistance to the effects of EGFR 
inhibition by cetuximab (127-129).   
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Increased receptor and receptor ligand expression, cross-talk with HER2 
or other receptors, co-expression of EGFR mutants, and mutations affecting 
downstream signaling components are all mechanisms that can alter EGFR 
signaling output and potentially modify response to EGFR inhibitors.  These 
alternate modes of EGFR activation and highly variable responses observed for 
EGFR-targeting drugs highlight the need for robust molecular markers linking 
signaling network status and therapeutic response.  Despite the complexity of 
EGFR-driven signaling pathways, endpoints and biomarkers linked to clinical 
responses are ultimately most needed to guide clinical application.  Indeed, skin 
rash remains one of the most effective early indicators of clinical response to 
EGFR inhibitors (130).   
 
Strategies for Assessing Response to EGFR-targeted Drugs 
 
Monitoring phosphorylation events  
Given the complex nature of EGFR signaling, direct analysis of 
phosphoprotein intermediates in signaling networks presents a logical analysis 
approach.   Antibody-based methods are most commonly used for identifying 
protein and phosphoprotein changes in response to drugs.  Numerous studies 
have employed immunohistochemical analysis of tissues to detect changes in 
response to treatment (131-133), although the lack of a standardized scoring 
system and subjective appraisal of staining make this method prone to 
inconsistencies.   Additionally, western blot analysis is a convenient technique for 
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monitoring changes in total protein or phosphorylation status of a given signaling 
system (73, 134).  Both techniques can be cumbersome when analyzing 
numerous targets.  Protein and phosphoprotein analyses in tumor tissues by 
reverse phase protein arrays represent a new high through-put approach to 
identify putative signatures for EGFR inhibitor responses (135-138).  A major 
drawback shared by all of these detection methods is the reliance on antibody 
specificity and limited availability of specific reagents to detect many target 
proteins.   
Recently, mass spectrometry (MS)-based proteomic approaches aimed at 
the detection of protein phosphorylation have proven useful in the investigation of 
cellular signaling events (139-141) and have been shown to identify protein 
phosphorylation changes in response to drug treatments (142).  Studies in cell 
models using global phosphoproteomics and targeted analysis of EGF pathway 
phosphoprotein intermediates have provided the most comprehensive analyses 
of EGFR-driven signaling networks (139, 143-145).  Due to the low abundance of 
phosphorylation modifications relative to unmodified proteins, these methods 
typically require affinity techniques to enrich phosphorylated proteins and 
peptides for MS analysis (139, 141, 142, 146).    
Cell culture models enable well-controlled experiments to study the status 
of phosphoprotein signaling networks. However, analysis of tissue specimens is 
complicated by sample heterogeneity, the transient nature and potential 
instability of phosphorylation modifications and limiting amounts of available 
tissue.   In addition, acquisition practices for biopsies and surgical resections do 
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not permit rigorous control of preanalytical variables, such as ischemic time and 
temperature, which trigger stress responses that may obscure the status of 
network intermediates in vivo (147-149).   These considerations suggest a need 
for robust assays capable of detecting signaling changes in response to EGFR 
drug treatments in patient tissue samples.    
 
MS-based approaches:  global shotgun proteomic analysis 
While mass spectrometry approaches using phosphoproteomic techniques 
have proven useful in elucidating molecular mechanisms of drug response, the 
limitations involved in analyzing modified proteins demonstrates the value of 
additional assays to assess signaling changes.  Shotgun proteomics, a method 
first described by Yates et al. (150), is now routinely used to identify the proteins 
present in complex biological mixtures (151, 152, 153l, 154).  Shotgun proteomics 
(Figure I-5) involves digestion of a protein mixture into a collection of peptides 
subsequently separated on-line with a tandem mass spectrometer (151).  Tandem 
mass spectra (MS/MS), which encode the peptide sequences, are collected for as 
many peptides as possible, and the resulting peptide identifications are searched 
against databases to identify the proteins in the original mixture (151, 155).   
A critical element of shotgun proteomic analysis is the separation of 
peptides and proteins using multidimensional separation techniques to fractionate 
the complex peptide mixtures prior to MS/MS analysis (156).  Each fraction 
presents a simplified peptide mixture for tandem MS analysis enabling acquisition 
of   MS/MS  spectra  for  lower  abundance peptides.   A  variety  of  separation 
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Figure I-5.  Shotgun proteomics workflow.  Proteins in sample are digested to 
peptide mixtures which are separated into multiple fractions before reverse-phase 
liquid chromatography tandems mass spectrometry analysis.  Each MS/MS 
spectrum collected encodes a peptide sequence.   Observed spectra are 
searched against a database to identify peptide sequences.  Identified  peptide 
sequences are mapped to proteins. 
 
 
 
techniques from gel-enhanced protein separation (157), to strong-cation 
exchange (158), to isoelectric focusing (159) have been reported as the first 
dimension of separation in conjunction with shotgun proteomic analysis.   
The collection of identified peptide sequences is then assembled into an 
inventory of proteins that can account for the peptide identifications.  Because the 
likelihood of collecting an MS/MS spectrum of a peptide increases with the 
amount of the peptide in a sample,  the numbers of MS/MS spectra that map to 
each protein provide a preliminary estimate of the amount of each protein in the 
sample (160, 161) (Figure I-6).  Therefore, comparison of the MS/MS datasets  
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Figure I-6.  Estimating protein abundance using spectral counting.  The 
amount of peptides present in a digested protein sample correlates to the protein 
abundance.  Thus, spectral counting approximates protein abundance based on 
observed peptides 
 
 
 
from differentially treated cells (e.g., treated versus non-treated) or different tissue 
specimens (e.g., normal vs. cancer) facilitates the identification of proteome 
differences, which are distinct to one treatment or tissue type versus another.  
Global shotgun mass spectrometry-based techniques have been used to identify 
protein expression profiles in small systems such as proteins involved in a specific 
signaling network, and have proven robust enough to identify protein changes at 
the cellular and tissue levels (144, 162, 163).  In addition, mass spectrometry 
approaches have reported distinct proteome profiles for cancer cells responsive or 
non-responsive to both gefitinib and cetuximab treatments (164-166).    
 
MS-based approaches: targeted MRM analyses 
Current approaches in the field of mass spectrometry also allow for 
quantitation of differentially expressed proteins.  Previous studies have 
demonstrated the use of liquid chromatography-multiple reaction monitoring 
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mass spectrometry (MRM) as an invaluable tool for quantifying protein 
expression changes in complex biological systems (141, 167, 168).  MRM 
analyses using  a  triple  quadrupole  mass  spectrometer  (Figure I-7) involves  
 
 
 
 
Figure I-7. Quantifying using MRM on a triple quadrupole mass 
spectrometer.  Peptides unique to the protein of interest are selected in Q1, 
fragmented in Q2 and multiple fragment ion transitions are monitored for each 
peptide in Q3.  Peak areas for each individual transition are summed and 
normalized to transition peak areas summed for a reference standard. 
 
 
 
selecting an ion of interest (precursor) with the first mass filter Q1 and induces 
fragmentation in Q2 by collisional excitation with a neutral gas in a pressurized 
collision cell.  The resulting 'product ions' (i.e., the fragmentation products of the 
selected precursor) are mass analyzed using the third quadrupole (Q3) (169, 
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170).  This approach provides a selective method for measuring specific peptides 
and their corresponding protein.  Targeted MS analysis using MRM enhances the 
lower detection limit for peptides by up to 100-fold by allowing rapid and 
continuous monitoring exclusively for the specific ions of interest (170).  Modern 
triple quadrupole mass spectrometers are especially well suited to this type of 
analysis taking only 10–30 ms to survey each precursor-product transition, 
enabling large numbers of such transitions to be monitored during 
chromatographic elution into the mass spectrometer, with consequent high 
multiplexing capability. 
 Target peptides selected for MRM analysis should be unique (proteotypic) 
peptide sequences (typically 7-23 amino acids) and possess features that 
enhance chemical stability (170, 171).  Peptide selection is often based upon 
results obtained during LC-MS/MS shotgun experiments (172); however, in silico 
methods of protein digestion and peptide selection are also available (173).     
Contrary to antibody-based quantitation methods where antibody 
availability and specificity are often limiting, an LC-MRM-MS approach facilitates 
configuration of an assay for essentially any protein.  Quantitation by these 
methods is typically achieved using stable isotope dilution (SID), in which labeled 
peptides are spiked into samples as internal standards for the corresponding 
endogenous peptide (168, 174).  Application of this approach has proven 
sensitive enough to broach challenging quantitation problems including protein 
quantification at single-digit copy numbers in cells (172) and near ng/ml 
concentration in plasma (174, 175).  Moreover, LC-MRM-MS in concert with 
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antibody-based enrichment techniques can achieve even greater levels of 
sensitivity (176, 177).  
SID methods allow for the absolute quantitation of targeted peptides, but 
large-scale experiments are often costly ($500-$1000 per peptide) owing to the 
need for multiple isotopically labeled reagents (172, 178, 179}.    However, recent 
studies reporting “label free” methods demonstrate quantitative data comparable 
to SID-based measurements and provide alternative means for quantifying 
protein expression changes without the need for costly labeled peptides for each 
target (168, 171).  The LRP approach described by Zhang et al.—while not 
providing absolute quantitation—uses a single isotopically labeled peptide as a 
reference for all target analytes, and the data suggests the LRP method as a 
suitable approach for use in preclinical studies to rapidly screen large numbers of 
protein candidates at a fraction of the cost of configuring SID-LC-MRM-MS 
assays.   
 
Research Objectives and Approach 
 
Question and objectives 
My research addresses the broad question of how to analyze responses to 
EGFR-modulating drugs.  The major hypothesis to be tested is can changes in 
global protein expression levels produce distinct protein signatures indicative of a 
cellular response to EGFR-targeted drugs.  Chapters II and III describes the mass 
spectrometry-based approach for identifying and quantifying global protein 
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changes resulting from EGFR stimulation and inhibition.  The major objectives of 
this dissertation research were: 
 
1.  Establish a model system of EGFR activation and inhibition in human 
cancer cells using clinically relevant EGFR-targeting inhibitors 
2.  Apply global proteomic profiling to identify protein inventories for each 
treatment condition in the model system (proliferating, EGF-stimulated, 
gefitinib- or cetuximab- treated) 
3.  Develop a candidate signature of differentially expressed proteins 
indicative of a specific response to EGFR modulation and validate with 
targeted analysis 
4.  Test the candidate signature in multiple cell and tissue models to 
assess applications of this approach for future studies 
 
A secondary goal of this research is to apply a new method to quantify 
protein modification changes to EGFR.  The major focus of this work was to 
assess the performance of a newly developed MS-based quantitation method to 
detect phosphorylation changes on EGFR.  Chapter IV compares the 
performance characteristics of two quantitative mass spectrometry approaches 
(internal reference peptide (IRP) and stable isotope dilution (SID)) at quantifying 
changes in EGFR phosphorylation.  Initial studies are presented along with 
suggestions for future studies using overall findings in this dissertation. 
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Approach  
To test the hypothesis that changes in global protein expression levels 
produce distinct protein signatures indicative of a cellular response to EGFR-
targeted drugs, shotgun proteomic analysis were first employed to generate 
protein inventories for differentially treated A431 cells.  Proteomic datasets were 
compared and protein differences were identified between treatment conditions.  
These protein differences constitute potential stimulation and inhibition signatures 
in response to EGFR modulation.  A set of proteins whose expression was 
changed by EGF and reversed by both gefitinib and cetuximab comprised a 
candidate “EGFR inhibition signature”, which was further verified by multiple 
reaction monitoring (MRM) analyses.  This EGFR inhibition signature was then 
tested in 3 other models: 1) a comparison of DiFi (EGFR inhibitor-sensitive) and 
HCT116 (EGFR-resistant) cell lines, 2) in formalin-fixed, paraffin-embedded 
(FFPE) mouse xenograft DiFi and HCT116 tumors, and 3) in frozen tissue 
biopsies from a patient with the gastric hyperproliferative disorder Ménétrier’s 
disease, who was treated with cetuximab.  The results validated a multiprotein 
EGFR inhibition signature in all three models and illustrate the utility of protein 
expression changes as surrogate measures of signaling network activation and 
inhibition.   
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  CHAPTER II 
 
 CELL MODELS FOR EGFR ACTIVATION AND INHIBITION AND INITIAL 
EVALUATION OF GLOBAL PROTEIN EXPRESSION CHANGES 
 
Introduction 
 
The overarching question asked in this project is whether differences in 
global protein expression levels could indicate cellular responses to EGFR 
modulation.  This project required a model system in which activation and 
inhibition of EGFR could be established according to well-defined criteria in the 
field.  Subsequent proteomic analyses of activated and inhibited states would 
enable a test of the hypothesis that protein expression patterns indicate the 
activation state of the system.  I chose two well-established cell models for EGFR 
biochemistry and cell biology.  DiFi and A431 cells were treated with epidermal 
growth factor (EGF) and two clinically-available EGFR inhibitors, gefitinib and 
cetuximab, to manipulate the EGFR signaling axis.  Initial studies established 
culture and treatment conditions, extraction methods and verification of EGFR 
activation by western blotting to detect EGFR autophosphorylation and activation 
of downstream targets. 
Once the A431 model was established, an initial global proteome analysis 
was performed with a shotgun proteomics platform that combines polyacrylamide 
gel electrophoresis and reverse phase LC-MS/MS.  Comparison of these datasets 
indicated proteins that differed significantly in expression between treatment 
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conditions.  Protein expression differentials were further verified by multiple 
reaction monitoring (MRM) mass spectrometry analyses.  Results demonstrate 
proof-of-concept for the implementation of this platform to identify and verify 
global protein changes resulting from different responses to drug treatments. 
However, analysis of the data also suggested that longer exposure duration and 
modifications to the proteomic analysis platform would yield a more useful 
response signature.  The second phase of this work is described in Chapter III. 
 
Experimental Procedures 
 
Materials and reagents 
Iodoacetamide, ammonium bicarbonate, sodium molybdate, β-
glycerophosphate, sodium molybdate, sodium orthovanadate, 4-(2-
aminoethyl)benzenesulfonyl fluoride, aprotinin, leupeptin, betastatin, pepstatin A, 
dimethyl sulfoxoide, and sodium dodecyl sulfate (SDS) (all >99.0% purity) were 
purchased from Sigma (St. Louis, MO).  Dithiothreitol was from Bio-Rad 
(Hercules, CA).  2,2,2-Trifluoroethanol (TFE) was from Acros (Geel, Belgium).  
C-Terminal isotopically labeled β-actin peptide (GYSFTTTAE*R) containing U-
13C6, U-
15N4-arginine was obtained from New England Peptide at 99% isotopic 
purity and 95% chemical purity.    Fetal bovine serum (FBS) was from Atlas 
Biologicals (Fort Collins, CO).  Mass spectrometry grade trypsin (Trypsin Gold) 
was purchased from Promega (Madison, WI).  HPLC grade water and acetonitrile 
(ACN) were from Mallinckrodt Baker (Phillipsburg, NJ).  Phosphate buffered 
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saline, Dulbecco’s modified eagle medium (DMEM), improved minimal essential 
medium (IMEM), McCoy’s 5A medium, NuPAGE® MOPS and MES SDS running 
buffer, NuPAGE® LDS sample buffer,  NuPAGE® 10% Bis-tris gels and 
polyvinylidene difluoride membrane were from Invitrogen (Carlsbad, CA).  
Epidermal growth factor (EGF), transforming growth factor-alpha (TGF-α), EGFR, 
pY1173, pY998, SHC, pSHC (Y317), HER2, pHER2 (Y1248), HER3 and pHER3 
(Y1289) antibodies (#8916LF,  4267s, 4407s, 2432, 2431s, 2242, 2247s, 4754 
and 4791s, respectively) were purchased from Cell Signaling Technologies 
(Danvers, MA).  β-Actin antibody (#ab8224) was from AbCam (Cambridge, MA).  
4G10 antibody (#05-1050X) was from Milipore (Billerica, MA).  AlexaFluor® 680-
conjugated fluorescent secondary antibodies were obtained from Molecular 
Probes (Eugene, OR).  Trifluoroacetic acid (TFA), formic acid (FA), urea and tris-
carboxyethylphosphine (TCEP) were purchased from Thermo Fisher Scientific.  
Gefitinib and cetuximab were gifts from Dr. Carlos Arteaga and Dr. Robert 
Coffey, respectively, both at Vanderbilt University.   
 
Cell culture  
A431 human epithelial carcinoma cells were provided by Dr. Carlos 
Arteaga at Vanderbilt University (Nashville, TN) or were purchased from ATCC 
(Manassas, VA).  A431 cells were maintained in IMEM supplemented with 10% 
FBS.  DiFi human colorectal carcinoma cells were provided by Dr. Robert Coffey 
at Vanderbilt University and were maintained in DMEM and supplemented with 
10% FBS.  All cell lines were cultured at 37°C in 5% CO2.  After treatment, all 
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cells were harvested on ice using cold magnesium and calcium free phosphate 
buffered saline supplemented with a phosphatase inhibitor cocktail (1.0 mM 
sodium orthovanadate, 1.0 mM sodium molybdate, 1.0 mM sodium fluoride, and 
10 mM of β-glycerophosphate).  Cells were pelleted at 1,000 rpm at 4°C and 
pellets were flash frozen in liquid nitrogen.   
Proliferating cells were grown to 70-75% confluency before collection, while 
serum-starved cells were grown to ~60-65% confluency before incubation 
overnight in serum-free media before subsequent treatment.  Cells co-treated with 
EGF and either cetuximab or gefitinib were preincubated with the indicated 
concentrations of the inhibitor for 30 minutes prior to EGF stimulation.  Pellets 
were resuspended and lysed in either modified RIPA buffer (50 mM Tris-HCl, 150 
mM NaCl, 1% Igepal, 0.5% sodium deoxycholate, and 0.1% sodium dodecyl 
sulfate, 50 mM DTT), NETN buffer (0.5% Igepal, 20 mM Tris-HCl, 100 mM NaCl, 
and 50 mM DTT), or Laemelli buffer (2% SDS, 125 mM Tris-HCl, and 5% glycerol) 
supplemented with 50 mM DTT, phosphatase inhibitor cocktail (see above) and 
protease inhibitor cocktail (0.5 µM AEBSF, 10 mM aprotinin, 1.0 mM leupeptin, 
5.0 µM bestatin and 1.0 µM pepstatin).  Lysates were kept for 20 minutes on ice 
before sonication with five one-second pulses at 30 watts and 20% output.  The 
lysate was centrifuged at 13,000 x g and the total protein concentration of the 
supernatant was determined using a bicinchoninic acid assay from Pierce with 
bovine serum albumin used as protein standard.   
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Western blot analysis 
Equivalent sample loads were normalized for total protein concentration 
before reducing with dithiothreitol and adding NuPAGE® LDS sample buffer.  The 
samples were then boiled for 7 minutes at 90°C.   All denatured samples then 
were resolved on NuPAGE® 10% Bis-Tris gels at 160 V for ~65 minutes in either 
MOPS or MES SDS running buffer (Invitrogen).  Proteins were electrophoretically 
transferred from the gel to a polyvinylidene difluoride membrane for 3 h at 35 V in 
a cold room.  Membranes were probed overnight at 4°C using indicated primary 
antibody.  AlexaFluor® 680-labeled goat anti-rabbit and goat anti-mouse 
secondary antibodies were used to detect the corresponding primary antibodies.  
Immunoreactive proteins were visualized using the Odyssey™ Infrared IYmaging 
System and Odyssey software as described by the manufacturer (Li-Cor, Lincoln, 
NE).  
 
In-gel digestion and MS sample preparation 
Cell pellets were lysed in RIPA buffer and resolved on NuPAGE® 10% Bis-
Tris gels as described in previous section.  Gels were stained with Colloidal 
Coomassie Blue (Invitrogen).  Fifteen fractions from the top of gel to the bottom 
were excised and chopped into 1-mm cubes and placed in 0.5-mL Eppendorf 
tubes containing 100 µL of 100 mM ammonium bicarbonate, pH 8.0.  Samples 
were reduced with 10 µl of 45 mM dithiothreitol for 20 min at 55 °C and alkylated 
with 10 µL of 100 mM iodoacetamide for 20 min at room temperature in the dark.  
Samples were destained with two washes of 100 µL of 50% acetonitrile and 50 
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mM ammonium bicarbonate.  The gel pieces were then dehydrated with 100% 
acetonitrile and digested with Trypsin Gold from Promega (25 µl of 0.01 µg/µL 
Trypsin Gold) in 25 mM ammonium bicarbonate) overnight at 37 °C.  The peptides 
for each fraction were extracted with two portions of 60% acetonitrile in water and 
0.1% trifluoroacetic acid.  Samples were evaporated in vacuo and reconstituted 
with 0.1% formic acid in water.  
 
Cell preparation for LC-MRM MS analyses 
A431 cell pellets were resuspended and lysed in 100 µL of ammonium 
bicarbonate (100 mM, pH 8.0) and 100 µL of TFE and then incubated with mixing 
at 60°C for 60 min and at 1000 rpm on an Eppendorf Thermomixer before 
sonicating at 30 watts and 20% output for 10 one-second pulses.  Protein 
concentration was measured with the bicinchoninic acid assay and equivalent 
sample aliquots were reduced with 40 mM TCEP and 100 mM DTT with mixing at 
60°C for 30 min at 1000 rpm on the Eppendorf Thermomixer and then were 
incubated at ambient temperature in the dark with 200 mM iodoacetamide.  
Samples were diluted with 50 mM ammonium bicarbonate, pH 8.0 (to 10% TFE) 
before adding Trypsin Gold at a 1:50 (w/w) ratio and incubating overnight at 37ºC 
with shaking.  Aliquots of digested samples corresponding to 200 µg protein were 
lyophilized.  Samples were resuspended in 1 mL water, vortex-mixed vigorously, 
and desalted with Sep-Pak® 100 mg, C-18 columns (Waters) on a vacuum 
manifold.  After washing the columns with water, peptides were eluted with 80% 
ACN and the solution was evaporated to dryness in vacuo.   Samples were 
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reconstituted in 0.1% (v/v) aqueous formic acid to a final concentration of 0.5 
µg/µL and the isotopically labeled β-actin peptide reference standard was spiked 
in at a concentration of 20 fmol/µL.    
 
Reverse phase LC-MS/MS  
LC-MS/MS analyses were performed on an LTQ-XL mass spectrometer 
from Thermo Fisher Scientific (Waltham, MA) equipped with an Eksigent nanoLC 
1D plus pump and Eksigent autosampler (Dublin, CA).  Peptides were resolved on 
100 µm × 11 cm fused-silica capillary column (Polymicro Technologies, LLC 
Phoenix, AZ) packed with 5 µm, 300 Å Jupiter C-18 resin (Phenomenex, 
Torrance, CA) with an in-line solid-phase extraction column (pre-column, 100 µm 
× 6 cm) packed with the same C-18 resin (using a frit generated with liquid silicate 
Kasil similar to that previously described (1).  LC was carried out at ambient 
temperature over 85 min using a gradient mixture of 0.1% (v/v) FA in water 
(solvent A) and 0.1% (v/v) FA in ACN (solvent B).  A 10 min load period using 
100% solvent A at 1 µL/min was followed by an elution gradient (600 nL/min) from 
2-25% solvent B in 30 min, 25-90% solvent B over 15 min, and held at 90% 
solvent B for 17 min before returning to 2% solvent B to equilibrate column.  
Peptides eluting from the capillary tip were introduced into the LTQ source in 
micro-electrospray mode with a capillary voltage of ∼2 kV.  A full scan was 
obtained for eluting peptides in the range of 400–2000 amu followed by four data-
dependent MS/MS scans of the most intense ions. MS/MS spectra were recorded 
using dynamic exclusion of previously analyzed precursors for 60 s with a repeat 
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of 1 and a repeat duration of 1.  MS/MS spectra were generated by collision-
induced dissociation of the peptide ions at normalized collision energy of 35% to 
generate a series of b- and y-ions as major fragments.   
 
Liquid chromatography-multiple reaction monitoring (MRM)-MS  
 
MRM analyses were performed on a TSQ Vantage triple quadrupole mass 
spectrometer from Thermo-Fisher Scientific (Waltham MA) equipped with an 
Eksigent NanoLC-ultra 1D Plus pump (Dublin CA) and a capillary column and pre-
column similar to that described above.  The mobile phase consisted of the 
gradient mixture of solvent A and solvent B used for LC-MS/MS analysis.  Sample 
solution (2 µL) containing 0.5 ng/µL peptide mixture (based on protein 
concentration) were loaded for 15 min onto the column using 100% solvent A at 1 
µL/min followed by a gradient elution (400 nL/min) from 3–20% solvent B over 7 
min, 20–60% solvent B over 35 min, 60–95% solvent B in 6 min and held at 95% 
for 11 min before returning to 3% solvent B.  MRM analyses of target peptides 
and β-actin peptides (isotope labeled and endogenous) were performed using a 
1300 V electrospray voltage, 210 °C capillary temperature, and −5 V skimmer 
offset.  Both Q1 and Q3 were set at unit resolution FWHM 0.7 Da and collision 
gas (He) pressure in Q2 was held at 1.5 mTorr. Scan width was 0.004 m/z and 
scan time was 10 ms for all analyses.  Collision energy for each peptide was 
calculated using the open source software Skyline (2).  Instrument quality control 
assessment was done as described previously (3).   
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Quantitative analyses were done by the method described recently (3) 
using U-13C6, U-
15N4-arginine β-actin (BA) peptide (GYSFTTTAE*R) as the 
reference standard.  At least four MRM transitions were monitored for target 
peptides and the standard.  Signature peptides for each protein measured were 
required to be between 7-25 amino acids long and were selected based on 
uniqueness and chemical stability.  Although priority was given to peptides that 
were previously identified in the shotgun data set with high MS/MS spectral 
quality, additional peptides were selected by in silico analysis of the target protein 
sequences.  Peptides containing cysteine or methionine residues were not 
excluded and cysteines were present as carboxyamidomethylated derivatives 
following treatment with iodoacetamide during sample work-up.  Peptide 
uniqueness was confirmed by BLAST searching sequences against the UniProt 
database.  Skyline software was used to extract and integrate transition peak 
areas for each target peptide (2).   Summed peak areas for target peptide 
transitions were divided by the summed peak area for the reference standard 
peptide transitions to give normalized peak area (NPA) and coefficient of 
variations (CVs) were calculated across replicates for each treatment.  For MRM 
analyses in cell culture experiments, three replicate cell cultures were analyzed 
for each cell culture and treatment. 
  
Data analysis 
 The “ScanSifter” algorithm v1.0.5 read MS/MS spectra stored as 
centroided peak lists from Thermo RAW files and transcoded them to mzData files 
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(4).  Only MS/MS scans were written to the mzData files; MS scans were 
excluded. If 90% of the intensity of a MS/MS spectrum appeared at a lower m/z 
than that of the precursor ion, a single precursor charge was assumed; otherwise 
the spectrum was processed under both double and triple precursor charge 
assumptions. MS/MS spectra were assigned to peptides from the IPI Human 
database version 3.33 (September 7, 2007; 67837 sequence entries) by the 
MyriMatch algorithm, version 1.1.0 (5). The sequence database was doubled to 
contain each sequence in both normal and reversed orientations, enabling false 
discovery rate (FDR) estimation.  MyriMatch was configured to expect all 
cysteines to bear carboxamidomethyl modifications and to allow for the possibility 
of oxidation of methionines.  Candidate peptides were required to feature trypsin 
cleavages or protein termini at both ends, though any number of missed 
cleavages was permitted.  A precursor error of 1.25 m/z was allowed, but 
fragment ions were required to match within 0.5 m/z.  The IDPicker algorithm 
v1.6.1 (6) filtered the identifications for each reverse phase liquid chromatography 
run to include the largest set for which a 5% peptide-level identification FDR could 
be maintained, as described by Qian et al. (7). Indistinguishable proteins were 
recognized and grouped, and parsimony rules were applied to generate a minimal 
list of proteins (Protein groups) that explained all of the peptides that passed our 
entry criteria (6).  This approach uses bipartite graph analysis to derive a minimal 
list of protein identifications with shared clusters of peptides. These identifications 
were pooled for each gel sample set (15 fractions).  Proteins were required to 
have at least two different peptide sequences observed within a gel sample set.  
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FDR for peptide identifications were computed by the formula (8): FDR = (2 × 
reverse)/(forward + reverse).  The algorithm reported the number of spectra and 
number of distinct sequences observed for each protein and protein group in each 
sample set.  
 
Statistical analyses 
Comparisons of protein abundance from shotgun datasets were made with 
spectral count data (9) using QuasiTel, a statistical software modeling package 
(10).  QuasiTel uses a quasi-likelihood method based on Poisson distribution—
commonly used for count data (11)—and applies a regression model to compare 
spectral count data.  This statistical model was used to perform pair-wise 
comparisons between two treatment conditions (4 replicates per condition) which 
generated a single combined inventory of protein identifications (Comparison 
dataset).  The model also uses F-tests to compute p-values and the FDR method 
to correct for multiple hypothesis comparisons of identified proteins (12).  
Thresholds were set for p-values (≤0.05), total spectral counts (7), and spectral 
count log2 rate ratios (fold changes, ≥ 1.5) generated by this model and were used 
as criteria to filter comparison datasets.  Significance of measured differences for 
target proteins of MRM analytes was determined with two-tailed unpaired t test 
using Prism 5.0 (GraphPad Software, San Diego, CA).  
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Results 
 
Evaluation of cell lysis buffers 
Initial studies established optimal conditions for preparation and analysis of 
EGFR activation status in cell models.  The DiFi human colorectal cancer cell line 
was derived from a colon cancer patient harboring an adenomatous polyposis coli 
gene (APC) mutation—frequently found in hereditary colorectal cancers—and 
demonstrates both gene amplification and protein overexpression of the EGF 
receptor (13, 14).    Figure II-1 shows western blot analysis of DiFi cells lysed 
under three different conditions with RIPA, NETN, and Laemmli buffers.  Cells 
were  cultured  in  media  containing  no  serum  for  approximately  18  h  before  
 
   
Figure II-1.  Lysis buffer evaluation.   DiFi cells were serum-starved overnight 
before incubation with media plus 10% FBS for indicated times.  RIPA, NETN and 
Laemmli buffers (left to right) were used to lyse treated samples.  Immunoblots 
were performed for total EGFR, EGFR phosphorylation at pY1173, total and 
phosphorylated SHC.  β-Actin was used as a loading control. 
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pSHC
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addition of media plus 10% serum for indicated times.   Total EGFR and EGFR 
phosphorylation status as well as expression of an effector protein SHC (p52 
isoform) and its Y317 phosphorylated form were assessed in equally loaded (50 
µg/lane) samples for each buffer condition.  
For each lysis condition, total EGFR and SHC were detected at relatively 
unchanging levels across treatments with an exception noted in the Laemmli 
conditions for EGFR at the 30 minute time-point.    Using RIPA and NETN buffers, 
both the phosphorylated form of EGFR (p1173) and SHC (pSHC) showed an 
increase in signal with increasing incubation time with media plus serum with a 
maximum signal detected for both phosphoproteins at the 30 minute time-point.  
Phosphorylation signals detected from Laemmli lysed cells were weak relative to 
RIPA- and NETN-lysed samples and did not show dramatic changes with 
increasing serum incubation time noted for the other two buffers; however, 
maximal phosphorylation signal detection for both p1173 and pSHC was still 
observed at the 30 minute time-point.  RIPA lysis resulted in stronger signals for 
both total and phospho signals relative to NETN and Laemmli buffers and, based 
on these results, was selected as the lysis buffer for the remainder of the western 
blotting and LC MS/MS experiments. 
  
Activation of EGFR in DiFi cells 
As stated in Chapter I, there are several ligands that bind to and stimulate 
the EGFR influencing receptor activation.  Using the two EGFR-specific ligands 
epidermal growth factor (EGF) and transforming growth factor-α (TGF-α), DiFi 
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cells were treated with 10 nM concentrations of each ligand to assess the extent 
of receptor and effector activation at varying time-points (Figure II-2).  All treated 
cells were serum-starved overnight prior to treatment with ligand for the indicated 
times, while proliferating cells were cultured and collected in media containing 
10% FBS.   
 
               
Figure II-2.  EGFR stimulation in DiFi cells (10 nM).   Treated DiFi cells were 
serum-starved overnight before being treated with (A) 10 nM EGF or (B) 10 nM 
TGF-α for indicated times.  Proliferating cells (P) were not serum starved and 
serve as a reference control for basal level signaling.  Immunoblots were 
performed for total EGFR, EGFR phosphorylation at pY1173, total SHC and 
pSHC.  β-Actin was used as a loading control. 
 
 
 
Over the course of 60 min, total EGFR, SHC and β-actin levels remained 
largely unchanged during both EGF and TGF-α treatments, while the 
phosphorylated forms (p1173 and pSHC) showed signal increases with increasing 
ligand incubation time (Figure II-2A and B).  Cells treated with EGF displayed a 
time-dependent increase of phosphorylation signal detected for p1173, with 
maximal signal occurring between 30 and 60 minutes while pSHC signals peaked 
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pSHC
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around the 10 and 30 minute timepoints before tapering off at 60 min (Figure II-
2A).  Although TGF-α treatment increased phosphoprotein signals detected in 
DiFi cells, these samples did not demonstrate changes as extreme as those noted 
for EGF-treated DiFi cells (Figure II-2.B).  Analogous experiments performed with 
30 nM concentrations of EGF and TGF-α can be seen in Figure II-3.   Similar 
trends were observed using the increased ligand concentrations; however, larger 
differences were noted for p1173 and pSHC between proliferating and 30 nM 
stimulated conditions when compared to 10 nM treatments.    
         
Figure II-3.  EGFR stimulation in DiFi cells (30 nM).   Treated DiFi cells were 
serum-starved overnight before being treated with (A) 30 nM EGF or (B) 30 nM 
TGF-α 30 nM EGF for indicated times.  Proliferating cells (P) were not serum 
starved and serve as a reference control for basal level signaling.  Immunoblots 
were performed for total EGFR, sites of EGFR phosphorylation at pY1173, total 
SHC and pY998 SHC phosphorylation.  β-Actin was used as a loading control. 
 
 
 
Both Figures II-2 and II-3 illustrate a greater increase in receptor 
activation—monitored via phosphorylation of Y1173 and SHC—in cells treated 
with EGF than those treated with TGF-α.    Reports that DiFi cells not only secrete 
measurable levels of TGF-α, but also up-regulate TGF-α gene expression in 
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response to exogenous TGF-α (15) could indicate a cellular dependency on TGF-
α, which might explain the lesser extent of activation compared to EGF 
treatments.  Having noted that the 30 minute time-point typically displayed 
maximal phosphorylated protein signals and that the 30 nM treatments resulted in 
increased receptor activation, subsequent experiments were stimulated using 
these conditions.  
   
Modulation of EGFR signaling in DiFi and A431 cell lines 
 Having developed a reproducible system for EGFR stimulation, the next 
experiments focused on the application of clinically used EGFR-targeted inhibitors 
gefitinib and cetuximab to inhibit receptor activation and subsequent downstream 
signaling.   Figure II-4 shows western blot analysis of DiFi cells treated with 
increasing concentrations of cetuximab (Figure II-4A) and gefitinib (Figure II-4B).  
All treated cells were serum starved overnight prior to EGF or inhibitor plus EGF 
co-treatment.  After treatment with 30 nM EGF for 30 minutes, EGFR 
phosphorylation at residues Y998 and Y1173 increased dramatically over 
proliferating cell levels, as did global phosphotyrosine levels detected using the 
anti-phosphotyrosine antibody 4G10.  Increasing concentrations of both 
cetuximab and gefitinib lead to a decrease of EGFR phosphorylation at Y1173 
and Y998 relative to EGF-only stimulated cells.  At the concentrations used, the 
tyrosine  kinase  inhibitor gefitinib   produced a   more profound inhibition of EGFR  
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Figure II-4.  EGFR modulation in DiFi cells.   Proliferating cells (P) were not 
serum-starved and serve as a reference control for basal level signaling.  EGF 
stimulated (E) and EGF plus (A) cetuximab (10 µg/mL) or (B) gefitinib (500 nM) 
for indicated times.  DiFi cells were serum-starved overnight before indicated 
treatement for 30 min.  Immunoblots were performed for total EGFR, sites of 
EGFR phosphorylation at pY1173 and pY998, and total tyrosine phosphorylation 
(4G10).  β-Actin was used as a loading control. 
 
 
phosphorylation than did the ligand binding domain inhibitor cetuximab.  The 
highest concentration of cetuximab (20 µg/mL) reduced EGFR phosphorylation to 
approximately basal levels (Figure II-4.A) whereas gefitinib at 250 nM abolished 
both Y1173 and Y998 phosphorylation signals almost completely (Figure II-4.B).  
Similarly, total tyrosine phosphorylation was diminished well below EGF 
stimulated levels upon addition of both inhibitors, although not quite to basal level.  
The dark bands at the top of the 4G10 western blots migrate at approximately 175 
kDa and likely represent detection of phosphorylated EGFR as well as 
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phosphorylated Her2, Her3 and Her4, thus explaining the relative lack of decrease 
upon addition of increasing concentrations of both gefitinib and cetuximab. 
A431 cells are epidermoid carcinoma cells, which are characterized by 
EGFR gene amplification and protein overexpression—similar to DiFi cells—in 
addition to harboring a p53 mutation.   A431 cells were treated as described 
above for DiFi cells and the western blot analysis can be seen in Figure II-5.  
Results for EGFR, p1173 and 4G10 were analogous to those observed for DiFi 
cell experiments; however, DiFi cells appeared to have a higher level of basal 
phosphorylation relative to A431 cells when equal protein loads were used.   
 
 
Figure II-5.  EGFR modulation in A431 cells.   Proliferating cells (P) were not 
serum starved and serve as a reference control for basal level signaling.  EGF 
stimulated (E) and EGF plus plus (A) cetuximab (10 µg/mL) or (B) gefitinib (500 
nM) for indicated times.  A431 cells were serum-starved overnight before 
indicated treatment for 30 min.  Immunoblots were performed for total EGFR, 
EGFR phosphorylation at pY1173 and total tyrosine phosphorylation (4G10).  β-
Actin was used as a loading control. 
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These results are in agreement with another report that EGFR in DiFi cells 
displays higher basal levels of tyrosine phosphorylation relative to other cell lines 
(16).  Figures A1 and A2 (Appendix A) show control experiments for each cell line 
for both cetuximab and gefitinib inhibitors respectively.   DMSO vehicle control 
showed no effect on treated samples, and—contrary to a report  that cetuximab 
causes autophosphorylation of residue Y1173 of EGFR (17)—these experiments 
illustrate no increase of 1173 phosphorylation in response to cetuximab treatment.   
 
Monitoring other ErbB receptors 
 As discussed in Chapter I, EGFR can dimerize with multiple ErbB family 
members such as human epidermal growth factor receptors 2 and 3 (HER2 and 
HER3 respectively).  Figure II-6 shows western blot analysis assessing total 
HER2 and HER3 expression as well as phosphorylation status (pY1248 and 
pY1289 respectively) in response to EGFR stimulation and inhibition.   Both cell 
lines express detectable levels of HER2 and HER3 that demonstrate increased 
phosphorylated upon addition of EGF ligand.  However, the pHER2 signal 
increase appears to be less drastic in DiFi cells.  Treatment with either cetuximab 
or gefitinib diminished pHER2 and pHER3 signals to basal (proliferating) levels in 
both cell lines.    
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Figure II-6.  ErbB expression in A431 and DiFi cells.  Proliferating (P), EGF 
stimulated (E), EGF plus gefitinib (500 nM) co-treatment (G), EGF plus cetuximab 
(10 µg/mL) co-treatment (C).  All treated (A) A431 and (B) DiFi cells were serum-
starved for 18 h before 30 minute incubation with indicated treatment.  
Immunoblots were performed for total EGFR, Her2, and Her3 as well as 
phosphorylated forms of each receptor and total tyrosine phosphorylation (4G10).  
β-Actin was used as a loading control. 
 
 
 
The combined results illustrate a larger differential between EGF stimulated 
and inhibited EGFR—as well as the adapter protein SHC—in A431 cells than in 
DiFi cells.  These data, taken together with reports that DiFi cells secrete TGF-α 
and demonstrate increased basal levels of signaling relative to other cell lines (15, 
16), support the use of A431 cells as a model system of EGFR perturbation for 
further proteomic analysis.  
 
GeLC-MS analysis of A431 cells 
Shotgun proteome analyses were performed on each of the four A431 
treatment conditions described above: proliferating cells, EGF treated (30 nM), 
p1173
Her2
pHer2
β-actin
Her3
pHer3
A        A431
EGFR
B       DiFi
P     E     G    C P     E     G    C
 67
EGF and gefitinib treated or EGF and cetuximab treated.  A schematic of the 
experimental work-flow is shown in Figure II-7.  This analysis platform combines 
SDS-PAGE gel separation with LC-MS/MS analysis of peptides from the  
 
  
 
Figure II-7.  Schematic of experimental work flow.  P=proliferating. All treated 
cells were serum-starved for 18 h before incubation for 30 min with EGF (E=30 
nM) or gefitinib (G=500 nM) plus EGF, or cetuximab (C=10 µg/mL) plus EGF.  
Equal protein loads were resolved on a polyacrylamide gel and fractionated 
samples (15) were trypsin digested, reduced and alkylated before reconstitution 
for reverse-phase liquid chromatography tandem mass spectrometry analysis.  
 
fractionated proteins and is thus termed “GeLC-MS”.  In-gel trypsin digests were 
performed and peptides extracted from gel fractions were analyzed by data-
dependent  LC-MS/MS.   A  summary  of  the  global protein analysis is shown in 
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Table II-1.  Values displayed are averaged data from 3 separate cultures per 
treatment condition.  Confident spectral IDs (numbers of spectra matched to 
database sequences at 5% FDR) and similar values for protein groups (numbers 
of indistinguishable protein identifications supported by the identified peptides)  
 
Table II-1 Summary of proteomic shotgun analysis.  The table lists confident 
identifications (spectra successfully matched to database sequences at 5% FDR), 
protein groups (indistinguishable protein identifications supported by the identified 
peptides), and %CV of replicate analysis for each of the four treatment conditions 
(proliferating, 30 nM EGF, 30 nM EGF plus 500 nM gefitinib and 30 nM EGF plus 
10 µg/mL cetuximab,).  Protein group numbers are averages of three separate 
cultures per treatment.  A 5% peptide-level FDR and minimum two distinct 
peptides were required for confident protein identification. *A protein group is 
defined by a set of proteins that cannot be distinguished based on the peptide 
identifications.  A single protein is chosen to represent each protein group.   
 
 
Proliferating 
EGF 
Stimulated 
Gefitinib + 
EGF 
Cetuximab + 
EGF 
Confident 
spectral IDs 
40267 46945 54882 48867 
Protein 
groups 
3377 3486 3697 3564 
Protein 
group CV(%) 
16.8 12.8 13.3 16.2 
 
 
and protein group CVs under 17% illustrate reasonable variation across biological 
replicates.   Figure A3 (Appendix A) shows the distribution of peptides identified 
across all fractions for each of the treatment conditions with fractions 3-8 typically 
displaying the highest number of confident identifications.  Of note from the A431 
cell proteomic datasets were confident protein identifications for EGFR, HER2 and 
HER4, although no peptides unique to HER3 were identified. 
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Dataset comparisons, data filtering and identification of significant differences in 
protein expression 
 
Next, protein expression datasets from the four A431 cell conditions were 
compared to identify proteins whose levels were different between EGF- 
stimulated conditions and either proliferating or EGFR-inhibited conditions.  
Protein expression was compared on the basis of spectral counts using QuasiTel, 
a quasi-likelihood modeling software package (10).  QuasiTel performed pair-wise 
comparison between two treatment conditions based on protein spectral counts 
and variance across replicate analyses and computed p-values and rate ratios 
(fold changes) for detected proteins.   
Pair-wise comparisons were made between 1) proliferating and EGF 
stimulated cells, 2) EGF-stimulated and gefitinib plus EGF-treated cells and 3) 
EGF stimulated and cetuximab plus EGF-treated cells (Table II-2).  To control the  
 
Table II-2.  Protein identifications and protein FDR of comparison datasets.  
Pair-wise comparison of the proteomic datasets for EGF (30 nM) versus 
proliferating, EGF versus gefitinib (500 nM) plus EGF and EGF versus cetuximab 
(10 µg/mL) plus EGF were generated using QuasiTel.  The three resulting 
comparison datasets were filtered to require ≥6 spectra for each protein per 
replicate.    
 
Comparison 
EGF-stimulated 
vs. 
Proliferating 
EGF-stimulated 
vs. 
Gefitinib + EGF 
EGF-stimulated 
vs. 
Cetucimab + EGF 
Proteins 2298 2488 2393 
Protein FDR (%) 2.2 1.7 1.7 
 
 
 
protein-level   FDR,   comparisons were limited to proteins with ≥6 spectral counts 
per protein across replicates.   The three comparison datasets were further filtered 
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to contain only proteins with quasi p-values  ≤ 0.05 and fold changes ≥ 1.5.  This 
resulted in 42, 60 and 31 differential protein identifications for EGF vs. 
Proliferating, EGF vs. Gefitinib/EGF and EGF vs. cetuximab/EGF comparisons 
respectively.  Figures A4-A6 (Appendix A) list the HUGO names of proteins up 
regulated (red) and down-regulated (green)—with respect to EGF treatment—at 
selected cut-offs in each comparison dataset.    
 
MRM verification of protein expression differences in A431 cells 
Changes in protein expression were verified via MRM analyses using the 
labeled reference peptide (LRP) method described recently (3).  Expression was 
quantified by normalizing target peptide signals to a labeled β-actin peptide 
standard.  A431 cells were treated as described for western blot analysis and 
global proteomic experiments; however, cell lysis and sample preparations were 
modified to account for the lack of polyacrilamide gel fractionation (see 
experimental section).  The targeted MS data generated by MRM analyses for 11 
selected proteins are displayed in Figure II-8.  MRM data were from analyses of 3 
separate cultures for each treatment and the normalized peak area (NPA) for a 
single, proteotypic peptide is shown for each protein.   CVs calculated (across 
replicate analysis for each treatment condition) from NPA values were below 30% 
for all monitored peptides with the majority of CV values falling below 17%.   The 
peptide sequences, HUGO name, normalized peak areas, and CVs for the MRM 
data in Figure II-8 can be found in Table A1 in Appendix A.    
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Figure II-8.  MRM analysis of differential proteins.   MRM data shows normalized peak area (NPA) quantified from one 
unique peptide for each target protein across three separate cultures. Pro = proliferating cells, EGF=EGF-stimulated (30 
nM) for 30 min, GEF=gefitinib (500 nM) and EGF-treated for 30 min, CET=cetuximab (10 ug/mL) and EGF-treated for 30 
min.  ACO2 = aconitase 2, MCM3A=minichromosome maintenance complex component 3, PACN2=protein kinase C and 
casein kinase substrate in neurons 2, PGM1=phosphoglucomutyase 1, CUL2=cullin 2, PYGB=glycogen phosphorylase 
(brain), EGFR=epidermal growth factor receptor, IDH2=isocitrate dehydrogenase 2, ME1=malic enzyme 1, 
RPS6=ribosomal protein S6, and SDHB=succinate dehydrogenase subunit beta. (*) Denotes significant difference 
between EGF-treated A431 cells as determined by Student’s two-tailed, unpaired t-test.    
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In agreement with spectral count data, signals for both cullin 2 (CUL2) and 
ribosomal protein S6 (RPS6) displayed an EGF-induced increase relative to 
proliferating cells.   However, when treated with gefitinib or cetuximab, only RPS6 
signals were significantly decreased below levels observed in EGF only 
stimulated samples.  Minichromosomal maintenance complex associated protein 
3 (MCM3A), in concordance with spectra count comparison, was detected at 
higher levels in cetuximab-treated samples than in EGF-treated samples.   
Moreover, peptide signals detected for MCM3A were significantly lower in 
proliferating samples than in EGF-stimulated cells.   Also in agreement with 
findings from spectral count comparisons, was a significantly higher signal in 
proliferating cells compared to EGF-treated cells for isocitrate dehydrogenase 2 
(IDH2) and protein kinase C and casein kinase substrate  2 (PACSN2).   MRM 
analyses detected no significant differences between EGF only and EGF plus 
inhibitor treatments for EGFR (in agreement with western blots), aconitase 2 
(ACO2), phosphoglucomutase 1 (PGM1), glycogen phosphorylase B (PYGB), 
malic enzyme (ME1) and succinate dehydrogenase beta (SDHB) peptide signals.    
Since several proteins identified as significantly different in the shotgun datasets 
(e.g., phosphoglucomutase, succinate dehydrogenase, malic enzyme, isocitrate 
dehydrogenase and glycogen phosphorylase) participate in a variety of metabolic 
pathways, I hypothesized that other proteins involved in these metabolic 
processes might be differentially expressed as well.  Figures A7, A8, and A9 in 
Appendix A show expanded panels of targeted assays designed to monitor other 
proteins involved in three metabolic pathways including glycolysis, tricarboxylic 
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acid (TCA) cycle and pentose phosphate pathway (PPP) respectively.  Tables A2-
4 list the targeted peptide sequences, precursor m/z,  NPA, standard deviation 
and CV for greater than 30 proteins involved in glycolysis, the TCA cycle and PPP 
respectively.  While not all of these proteins were identified in the global LC-
MS/MS studies, MRM analysis identified significant differences between 
treatments for 12 of the 32 targeted proteins.   Of the 12 differentially expressed 
proteins, nine of these were identified in initial shotgun experiments (DERA, 
G6PD, TKT, PGD, CS, MDH2, PCK2 and PC); and six of those 12 (PGD, G6PD, 
CS, MDH2, PCK2 and PC) only narrowly failed to meet the applied filtering 
criteria.   
 
Discussion 
 
Direct analysis of phosphorylated receptor proteins and their downstream 
effectors is the most commonly employed method to assess signaling networks.  
This approach is complicated by the transient nature of protein post-translational 
modifications, their low abundance relative to unmodified proteins and potential 
artifacts due to uncontrolled preanalytical variables.   The described studies ask 
whether changes in protein expression could indicate changes in the status of a 
signaling network.  A test of this hypothesis requires an experimental model in 
which EGFR activation and inhibition can be reproducibly demonstrated by widely 
accepted criteria.  These results clearly demonstrate that EGF treatment of A431 
and DiFi cells stimulate EGFR phosphorylation and activation of associated 
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substrates, as well as global tyrosine phosphorylation.  The results also 
demonstrate that cetuximab and gefitinib treatments inhibit these responses.  A 
preliminary proteomic analysis by GeLC-MS identified large proteome inventories, 
although differences in protein expression between the treatments were modest, 
yet were verified by MRM analyses.   
For the described experiments, it was important to establish a reproducible 
model system of EGFR stimulation and inhibition.  EGFR and phosphorylated 
EGFR (activated) expression was assessed in DiFi colorectal carcinoma and 
A431 squamous cell carcinoma cells in response to receptor modulation.  DiFi 
cells displayed higher basal levels of activated EGFR and decreased response to 
EGFR stimulation and inhibition relative to A431 cells.   Based on these findings 
and an extensive literature background (18-22), the A431 cell model was selected 
as the principal experimental system to study EGFR-driven signaling events.   
Whereas the goal of this work was to evaluate the feasibility of using global 
protein expression changes as indicators of response to EGFR drug treatment 
and not to define a cellular mechanism or specific protein signature, applying this 
method to mechanistic studies of signaling pathways necessitates consideration 
of the unique biology intrinsic to the model selected.  For example, detection of 
Her2, Her3, and Her4 expression by either western blotting and/or shotgun mass 
spectrometry, which is consistent with previously published reports for the 
epidermoid carcinoma cell line (23, 24), leads to questions about the overall 
contributions of these receptors in affecting the EGFR signaling pathway of 
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interest.  Moreover, A431 cells harboring mutant p53 will undoubtedly show 
different protein changes than those cell lines possessing wild-type p53.   
LC-MS/MS analysis of differentially treated A431 cells reproducibly 
generated large, proteomic datasets for each condition.  Pair-wise comparison of 
the datasets highlighted significant differences in protein expression profiles.  An 
interesting point to note from these experiments is that, although gefitinib and 
cetuximab are both inhibitors of the EGFR receptor, the majority of the differential 
proteins identified—at the selected cut-offs—were observed to have more spectral 
counts (i.e. higher protein abundance) in inhibitor-treated conditions relative to 
EGF only conditions.  This same trend holds true when comparing EGF 
stimulated and proliferating datasets.   
MRM was successfully used to quantify > 40 proteins, 10 of which were 
identified as significantly different in shotgun experiments; one of these was 
EGFR.  Of the 10 proteins targeted, 5 were verified as having significant changes 
consistent with observations from global analysis.  CVs were calculated for each 
of the four treatments per protein and only one was greater than 30%; the majority 
fell below 17% (see supplemental tables in Appendix A).  Use of the MRM 
approach to target multiple proteins in three metabolic pathways (glycolysis, TCA 
cycle and PPP) illustrates the ease and versatility of this approach to develop 
targeted assays that can elaborate on initial screening results from shotgun 
analysis.  For example, this pathway-directed approach detected significant 
changes in several proteins that were either not detected in shotgun analyses or 
did not meet the filtering requirements applied to comparison datasets.   
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Although several differential proteins were successfully confirmed using 
targeted LC-MRM MS methods, the results obtained from these studies highlights 
potential points for refinement of experimental design.  For example, statistical 
analysis of 4 replicate datasets might be approaching the limits for the statistical 
model suggesting potential benefits from the use of more replicates to strengthen 
statistical analysis.  In addition, the use of 30 minute treatment time-points—while 
adequate for detection of a few significant protein differences—may not be 
adequate to allow development of a robust protein expression signature.  This 
work was done while the shotgun analysis platforms in our laboratory were 
undergoing development and the GeLC-MS method was replaced for many 
applications by a method in which protein digests are fractionated by isoelectric 
focusing (IEF) and the fractions are analyzed by LC-MS/MS.  Application of this 
latter platform is described in Chapter III. 
The main objective for this work was to assess the feasibility of using 
global protein expression signatures to indicate a response to drug treatment.  
These studies establish proof-of-concept experiments for using shotgun (LC-
MS/MS) and targeted (LC-MRM) mass spectrometry platforms to identify global 
protein changes in EGFR modulated cells.   
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CHAPTER III  
 
PROTEIN EXPRESSION SIGNATURES FOR INHIBITION OF EPIDERMAL 
 GROWTH FACTOR RECEPTOR-MEDIATED SIGNALING 
 
Introduction 
 
The main objective of this work was to determine whether protein 
expression signatures can represent the effects of drugs on a signaling network.  
The experiments detailed in Chapter II establish a foundation for this body of 
work and provide proof-of-concept for using the described approach to test the 
proposed hypothesis that changes in global protein expression levels can 
produce distinct protein signatures indicative of a cellular response to EGFR 
modulation.   
However, the lack of a robust protein expression differential for EGFR 
activation and inhibition in the initial studies suggested the need for modifications 
in the experimental approach described in Chapter II.   Accordingly, four changes 
were made to the experimental approach:  1) the treatment period was extended 
from 30 minutes to 4 hours; 2) the number of replicate datasets used for global 
proteomic comparisons was increased from four to six; 3) the initial 
polyacrylamide gel fractionation of proteins was replaced with isoelectric focusing 
of peptides on pH gradient gel strips following tryptic digestion; and 4) initial 
starting material for each sample was increased from 100 µg to 200 µg of 
protein.   
81 
 
Proliferating
EGF
Gefitinib+EGF
Cetuximab+EGF
S
e
ru
m
-s
ta
rv
e
d
  
tr
e
a
te
d
 fo
r 
4
 h
pI = 3.5 to 4.7
lyse, digest &
desalt (C18)
IEF (15 fractions) (MS/MS) 
Shotgun 
proteomics
on LTQ
Protein
identifications
*3 separate cultures
per condition
*2 IEF gel strips
per culture
 
Figure III-1. Schematic of sample work flow.  Proliiferating, EGF treated (30 
nM) or EGFR inhibitor and EGF co-treated A431 cells (500 nM gefitinib or 10 
µg/mL cetuximab) were either serum starved and treated with 30 nM EGF or co- 
treated with EGFR inhibitors and EGF.  Trypsin digested samples were resolved 
using immobilized pH gradient gel strips (3.5-4.7) and isoelectric focusing.  Gel 
strips were cut into 15 fractions and a total of six replicates (three separate 
cultures and two gel strips per culture) were analyzed using liquid 
chromatography tandem mass spectrometry. 
 
 
 
Differentially treated A431 cells were analyzed with a standardized 
shotgun proteomics platform that combines peptide isoelectric focusing and LC-
MS/MS (1, 2).  Comparison of these A431 proteomic datasets indicated proteins 
that differed significantly in expression between treatment conditions and 
constitute potential stimulation and inhibition signatures.  A set of proteins whose 
expression was changed by EGF and reversed by both gefitinib and cetuximab 
comprised a candidate “EGFR inhibition signature”, which was further verified by 
multiple reaction monitoring (MRM) analyses.  The EGFR inhibition signature 
was then monitored in three other models: 1) a comparison of DiFi (EGFR 
inhibitor-sensitive) and HCT116 (EGFR-resistant) cell lines, 2) in formalin-fixed, 
paraffin-embedded (FFPE) mouse xenograft DiFi and HCT116 tumors, and 3) in 
82 
 
frozen tissue biopsies from a patient with the gastric hyperproliferative disorder 
Ménétrier’s disease, who was treated with cetuximab.  The results validated a 
multiprotein EGFR inhibition signature in all three models and illustrate the utility 
of protein expression changes as surrogate measures of signaling network 
activation and inhibition.   
 
Experimental Procedures 
 
Materials and reagents 
Iodoacetamide, ammonium bicarbonate, sodium molybdate, β-
glycerophosphate, sodium molybdate, sodium orthovanadate, 4-(2-
Aminoethyl)benzenesulfonyl fluoride, aprotinin, leupeptin, betastatin, pepstatin A, 
dimethyl sulfoxoide, and sodium dodecyl sulfate (all >99.0% purity) were 
purchased from Sigma (St. Louis, MO).  Dithiothreitol was from Bio-Rad 
(Hercules, CA); 2,2,2-trifluoroethanol (TFE) was from Acros (Geel, Belgium).  C-
terminal isotopically labeled β-actin (BA) peptide (GYSFTTTAE*R) containing U-
13C6, U-
15N4-arginine was obtained from New England Peptide at 95% chemical 
purity.  Fetal bovine serum (FBS) was from Atlas Biologicals (Fort Collins, CO).  
Mass spectrometry grade trypsin (Trypsin Gold) was purchased from Promega 
(Madison, WI).  HPLC grade water and acetonitrile (ACN) were from Mallinckrodt 
Baker (Phillipsburg, NJ).  Phosphate buffered saline, Dulbecco’s modified eagle 
medium (DMEM), improved minimal essential medium (IMEM), McCoy’s 5A 
medium, NuPAGE® MOPS and MES SDS running buffer, NuPAGE® LDS 
sample buffer,  NuPAGE® 10% Bis-tris gels and polyvinylidene difluoride 
83 
 
membrane were from Invitrogen (Carlsbad, CA).  Epidermal growth factor (EGF), 
EGFR, pY1173, pY998, Jagged 1, c-Jun, caspase 3 and PARP antibodies 
(#8916LF, 4267s, 4407s, 2641, 2620, 9165, 9542 and 9662 respectively) were 
purchased from Cell Signaling Technologies (Danvers, MA).  Claudin 4 and β-
actin antibody (#ab53156 and ab8224 respectively) were from AbCam 
(Cambridge, MA).  4G10 antibody (#05-1050X) was from Milipore (Billerica, MA).  
AlexaFluor® 680-conjugated fluorescent secondary antibodies were obtained 
from Molecular Probes (Eugene, OR).  Trifluoroacetic acid (TFA), formic acid 
(FA), urea and tris-carboxyethylphosphine were purchased from Thermo Fisher 
Scientific.  Gefitinib and cetuximab were gracious gifts from Dr. Carlos Arteaga 
and Dr. Robert Coffey respectively, both at Vanderbilt University.  Sub-X was 
from Surgipath (Richmond, IL).   
Frozen gastric epithelial biopsy specimens were obtained from were 
obtained from Dr. Robert Coffey at Vanderbilt University from a previous study 
(3), which was a single-arm clinical trial to explore the effectiveness of a 4-week 
course of cetuximab in patients with clinically and histologically confirmed 
Ménétrier’s disease. This prospective, open-label trial was approved by the 
Vanderbilt University Medical Center Institutional Review Board (IRB), and all 
participants provided written informed consent.  DiFi and HCT116 derived mouse 
xenograft tumor samples were a gift from Dr. Charles Manning and a previous 
study (4); tissues were obtained as archival FFPE sections.   
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Cell culture 
A431 human epithelial carcinoma cell lines were either a gift from Dr. 
Carlos Arteaga at Vanderbilt University (Nashville, TN) or purchased from ATCC 
(Manassas, VA).  A431 cells were maintained in IMEM supplemented with 10% 
FBS.  DiFi human colorectal carcinoma cells were a gift from Dr. Robert Coffey at 
Vanderbilt University and were maintained in DMEM and supplemented with 10% 
FBS.  HCT116 human colorectal carcinoma cells were from ATCC and were 
maintained in McCoy’s 5A medium also supplemented with 10% FBS.  All cell 
lines were cultured at 37°C in 5% CO2.  Proliferating cells were grown to 70-75% 
confluency before collection, while all treated cells were grown to ~60-65% 
confluency before incubation overnight in serum-free media.  These serum-
starved cells were then either treated with 30 nM EGF only for 4 h (EGF 
Stimulated), or preincubated with 500 nM gefitinib or 10 µg/mL cetuximab (unless 
otherwise noted) for 30 minutes before treatment with 30 nM EGF for 4 h in the 
presence of the inhibitors (gefitinib treated and cetuximab treated respectively), or 
pre-treated with DMSO (DMSO control) before EGF stimulation.   All cells were 
harvested on ice using cold magnesium and calcium free phosphate buffered 
saline and supplemented with a phosphatase inhibitor cocktail (1.0 mM sodium 
orthovanadate, 1.0 mM sodium molybdate, 1.0 mM sodium fluoride, and 10mM of 
β-glycerophosphate).  Cells were pelleted by centrifugation at 500 x g at 4°C and 
pellets were flash frozen in liquid nitrogen. 
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Western blot analysis 
Cell pellets were resuspended and lysed in a modified RIPA buffer (50 mM 
Tris-HCl, 150 mM NaCl, 1% Igepal, 0.5% sodium deoxycholate, and 0.1% sodium 
dodecyl sulfate) supplemented with phosphatase inhibitor cocktail (see 
concentrations in previous section) and protease inhibitor cocktail (0.5 µM 
AEBSF, 10 mM aprotinin, 1.0 mM leupeptin, 5.0 µM bestatin and 1.0 µM 
pepstatin).  Lysates sat for 20 minutes on ice before sonication with five one 
second pulses at 30 watts and 20% output.  The lysate was centrifuged at 12,000 
rpm and the total protein concentration of the supernatant was determined using a 
bicinchoninic acid assay from Pierce with bovine serum albumin used as protein 
standard.  Equivalent samples loads were normalized for total protein 
concentration before reducing with dithiothreitol and adding NuPAGE® LDS 
sample buffer.  The samples were then boiled for 7 minutes at 90°C.    
Serial tissue biopsies from a Ménétrier’s disease patient treated with 
cetuximab were provided as lysates generated using the TFE and ammonium 
bicarbonate protocol (described in the following section).  Prior to western blot 
analysis, aliquots of MD biopsy lysates were lyophilized and resuspended in 
HPLC water a total of three times in order to remove residual traces of TFE before 
resuspending tissue lysate in RIPA buffer.    All denatured samples were then 
resolved using NuPAGE® 10% Bis-Tris gels at 160 V for ~65 minutes in either 
MOPS or MES SDS running buffer (Invitrogen).  Proteins were electrophoretically 
transferred from the gel to a polyvinylidene difluoride membrane for 3 h at 35 V at 
4°C.   
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Membranes were probed using EGFR, pY1173, pY998, Jagged 1, c-Jun, 
Claudin 4, 4G10, caspase 3, PARP or β-actin primary antibodies overnight at 4°C.  
AlexaFluor® 680-labeled goat anti-rabbit and goat anti-mouse secondary 
antibodies were used to detect the corresponding primary antibodies.  
Immunoreactive proteins were visualized using the Odyssey™ Infrared IYmaging 
System and Odyssey software as described by the manufacturer (Li-Cor, Lincoln, 
NE).  
 
Cell and tissue preparation for MS analyses 
A431, DiFi, and HCT116 cell pellets were resuspended and lysed in 100 µL 
of ammonium bicarbonate (100 mM, pH 8.0) and 100 µL of TFE and incubated at 
60°C for 60 min at 1000 rpm on an Eppendorf Thermomixer before sonicating at 
30 watts and 20% output for 10 one second pulses.  Protein concentration was 
assessed using Pierce bicinchoninic acid assay and manufacturer’s protocol.  
Equivalent sample aliquots were reduced with 40 mM Tris-carboxyethylphosphine 
and 100 mM dithiothriotol at 60°C for 30 min at 1000 rpm on the Eppendorf 
Thermomixer then incubated at ambient temperature in the dark with 200 mM 
iodoacetamide.  Samples were diluted with 50 mM ammonium bicarbonate, pH 
8.0 (to 10% TFE) before adding Trypsin Gold at a 1:50 (w:w) ratio and incubating 
overnight at 37ºC with shaking (400 rpm).  200 µg aliquots of digested samples 
were frozen and dried down in vacuo.  Samples were resuspended in 1 mL HPLC 
water, vortexed vigorously, and desalted using Sep-Pak® 100 mg, C-18 columns 
from Waters and a vacuum manifold.  After washing with HPLC water, peptides 
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were eluted with 80% ACN and dried in vacuo.  Aliquots of A431 lysate for use 
with LC-MS/MS studies were also subjected to a subsequent separation method 
described in the Isoelectric focusing of peptides section.  Dried sample aliquots for 
LC-MRM-MS analysis were reconstituted in 0.1% (v:v) FA in water to obtain a 
final concentration of 0.5 µg/µL, and the isotopically labeled β-actin peptide was 
spiked in at a concentration of 20 fmol/µL.    
DiFi and HCT116 derived mouse xenograft tumor samples were a gift from 
Dr. Charles Manning at Vanderbilt University.  These xenografts are from a study 
published by Dr. Manning and colleagues in Clinical Cancer Research in 2008 
and should be referenced for experimental details (4).  All xenograft samples were 
acquired as formalin-fixed paraffin embedded tumor blocks from DiFi and HCT116 
derived xenografts.  Three 30 µm slices were cut from each tumor block and 
placed into a single 1.5 mL Eppendorf tube.  Paraffin was removed with three 
washes in 1 mL of Sub-X, and sample rehydration was achieved with three 1 mL 
washes each of 100, 85, and 70% ethanol in HPLC water.  To complete the 
antigen retrieval process, samples were heated for 1 h at 80 °C in 100 µL 
ammonium bicarbonate (100 mM).                                      
Human tissue biopsies from a patient with Ménétrier’s disease (MD) were 
obtained from Dr. Robert Coffey at Vanderbilt University.  The sample set 
originates from a single patient treated with cetuximab and consists of 3 separate 
tissue biopsies for each of the following time points: baseline (control), 1 day, 1 
week, 1 month and 4 months after initial cetuximab treatment.  The samples were 
flash-frozen and came from a patient involved in a previously published study 
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from 2009 in Science and Translational Medicine which should be referenced for 
specific details (3).   
DiFi and HCT116 derived mouse tumor xenograft samples were acquired 
as FFPE tumor blocks.  Three 30 µm slices were cut from each tumor block and 
placed into a single 1.5 mL Eppendorf tube.  These were processed as described 
previously (2).  Rehydrated mouse xenograft samples and Menetrier’s disease 
lysates were prepared for LC-MRM-MS analysis using the TFE and ammonium 
bicarbonate protocol described previously for cell lines; however, the tissue 
samples were sonicated 3 times at 30 watts and 20% output continuously for 20s 
both before and after 60 min incubation in 50mM ammonium bicarbonate with 
50% TFE.    
 
Isoelectric focusing of peptides 
A431 tryptic peptide mixtures (200µg) were resuspended in 155 µL of 6M 
urea.  Samples were loaded into sample loading wells of the ZOOM IPGRunner 
cassette.  10cm ZOOM strips with immobilized pH gradient gel from 3.5-4.7 were 
placed into cassette and allowed to incubate with samples at room temperature 
for 1 h.  Cassette was placed into a ZOOM IPGRunner cell, connected to a power 
supply and run for 15 minutes at 175 V, ramped from 175 V to 2000 V over 45 
minutes, and held at 2000 V for 105 minutes.  The gel strips were then cut into 15 
fractions (4 mm pieces), and placed in separate wells of a 96-well enzyme-linked 
immunosorbent assay (ELISA) plate.  Peptides were eluted from the strips as 
follows: 200 µL of 0.1% FA in water for 15 min; 200 µL of 50% acetonitrile 
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(ACN)/0.1% FA for 15 min; 200 µL of 100% ACN/0.1% FA for 15 min.   Extracted 
peptides for each fraction were pooled, evaporated in vacuo, resuspended in 1 ml 
of 0.1% trifluoroacetic acid (TFA) and desalted over a 96-well, C18 Oasis 
hydrophilic-lipophilic balance 30 µm (µElution) plate (Waters Corp.).  After 
washing with HPLC water and step-wise elution (200 µL of 30% ACN/0.1% TFA, 
200 µL 70% ACN/0.1% TFA, and 200 µL of 100% ACN/0.1% TFA), peptide eluate 
for each IGP strip fraction were pooled, evaporated in vacuo, resuspended in 100 
µL of 0.1% (v/v) FA in water and placed in sample vials for LC-MS/MS analysis.  
 
Reverse phase LC-MS/MS  
LC-MS/MS analyses were performed on an LTQ-XL mass spectrometer 
from Thermo-Fisher Scientific (Waltham, MA) equipped with an Eksigent nanoLC 
1D plus pump and Eksigent autosampler (Dublin, CA) analogous to those 
described in the Reverse phase LC-MS/MS section in Chapter II.  The only 
difference being that five data-dependent scans of the most intense ions were 
acquired after the initial full scan as opposed to only four collected in experiments 
described in Chapter II.      
 
MRM analyses 
Targeted MRM experiments were performed on a TSQ Vantage triple 
quadrupole mass spectrometer from Thermo-Fisher Scientific (Waltham MA) 
equipped with an Eksigent 1D Plus NanoLC pump (Dublin CA).  Studies were 
conducted as described in Liquid chromatography-multiple reaction monitoring-
mass spectrometry (LC-MRM-MS) section in Chapter II. 
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Data analysis 
 The “ScanSifter” algorithm v2.0.4 read tandem mass spectra stored as 
centroided peak lists from Thermo RAW files and transcoded them to mzData 
files. Only MS/MS scans were written to the mzData files; MS scans were 
excluded. If 90% of the intensity of a tandem mass spectrum appeared at a lower 
m/z than that of the precursor ion, a single precursor charge was assumed; 
otherwise the spectrum was processed under both double and triple precursor 
charge assumptions. Tandem mass spectra were assigned to peptides from the 
IPI Human database version 3.56 (2009-05-05 with 76591 entries) by the 
MyriMatch algorithm, version 1.6.33 (5). The sequence database was doubled to 
contain each sequence in both normal and reversed orientations, enabling false 
discovery rate estimation. MyriMatch was configured to expect all cysteines to 
bear carboxamidomethyl modifications and to allow for the possibility of oxidation 
on methionines. Candidate peptides were required to feature trypsin cleavages or 
protein termini at both ends, though any number of missed cleavages was 
permitted. A precursor error of 1.25 m/z was allowed, but fragment ions were 
required to match within 0.5 m/z. The IDPicker algorithm v2.6.1 (6) filtered the 
identifications for each reverse phase liquid chromatography run to include the 
largest set for which a 5% peptide-level identification false discovery rate could be 
maintained, as described by Qian et al. (7). Indistinguishable proteins were 
recognized and grouped, and parsimony rules were applied to generate a minimal 
list of proteins (Protein groups) that explained all of the peptides that passed the 
entry criteria (6). This approach uses bipartite graph analysis to derive a minimal 
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list of protein identifications with shared clusters of peptides. These identifications 
were pooled for each IEF sample set (15 fractions). Proteins were required to 
have at least two different peptide sequences observed within an IEF sample set. 
False discovery rates (FDR) for peptide identifications were computed by the 
formula (8): FDR = (2 × reverse)/(forward + reverse). The algorithm reported the 
number of spectra and number of distinct sequences observed for each protein 
and protein group in each sample set.  
 
Statistical analyses 
As described in the Statistical analyses section of Chapter II, comparison of 
protein spectral count data between treatments was carried out using the 
statistical modeling software package QuasiTel (9).   This statistical model was 
used to perform pair-wise comparisons between two treatment conditions (6 
replicates per condition) which generated a single combined inventory of protein 
identifications (Comparison dataset).  Comparison datasets were generated for 
the following groups: proliferating cells versus EGF stimulated cells, cetuximab 
treated cells versus EGF stimulated cells, and gefitinib treated cells versus EGF 
stimulated cells.  Thresholds were set for p-values (≤0.20), total spectral counts 
(11), and spectral count log2 rate ratios (fold changes, ≥ 2) generated by this 
model and were used as criteria to filter comparison datasets.  Significance of 
measured differences for target proteins of all MRM analytes was determined with 
two-tailed unpaired t test using Prism 5.0 (GraphPad Software, San Diego, CA).  
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Results 
 
EGFR modulation in A431 cells 
 The A431 cell model of activation and inhibition described in Chapter II was 
modified to include a longer 4 hour treatment time.  Cells proliferating in the 
presence of serum served as baseline controls, whereas serum-starved cells 
treated with EGF served as the benchmark for EGFR activation.  The 
phosphorylation status of the EGF receptor as well as global tyrosine 
phosphorylation was measured by western blot analysis (Figure III-2).  After 
treatment with 30 nM EGF for 4 h, EGFR phosphorylation at residues Y998 and 
Y1173 increased dramatically, as did global phosphotyrosine levels indicated 
activation, as measured with the antiphosphotyrosine antibody 4G10.  EGFR 
protein expression inversely varied with activation, which reflects enhanced 
receptor internalization and down-regulation upon activation (10-13).  Increasing 
concentrations of both cetuximab and gefitinib lead to a decrease of EGFR 
phosphorylation at Y1173 and Y998 compared to EGF only stimulated cells.  At 
the concentrations used, the tyrosine kinase inhibitor gefitinib produced a more 
profound inhibition of EGFR phosphorylation than did the ligand binding domain 
inhibitor  cetuximab.    The highest  concentration of  cetuximab  (20 µg/mL) only  
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A                                                                    B
Figure III-2.  Activation and inhibition of EGFR in A431 cells.  A431 cells 
were serum-starved overnight before being treated with either 30 nM EGF (E) for 
4 hrs or co- treated first with cetuximab (A) or gefitinib (B) at the indicated 
concentrations for 30 minutes prior to 4 hr treatment with EGF.  Proliferating cells 
(P) were not serum starved and serve as a reference control.  Immunoblots were 
performed for total EGFR, sites of EGFR phosphorylation at pY1173 and pY998 
and total tyrosine phosphorylation was detected with the 4G10 antibody.  β-Actin 
was used as a loading control. 
 
 
reduced EGFR phosphorylation to basal levels (Figure III-2A), whereas gefitinib at 
250 nM reduced both Y1173 and Y998 phosphorylation well below basal levels 
(Figure III-2B).  Total tyrosine phosphorylation detected in EGF-stimulated cells 
showed an increase over signals detected in proliferating cells, and while both 
inhibitors reduced detected levels of total tyrosine phosphorylation, only gefitinib 
was capable of reducing tyrosine phosphorylation below basal levels.  
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 With the exception of p998 in cetuximab-treated cells, minimal differences 
were noted between EGFR and total tyrosine phosphorylation status for the two 
highest concentrations of each inhibitor (10 and 20 µg/mL for cetuximab or 500 
and 1000 nM for gefitinib).  Based on these results, a single concentration each 
for cetuximab (10 µg/mL) and gefitinib (500 nM) was selected for subsequent 
experiments.  Although these doses produced different degrees of inhibition, both 
drugs reproducibly and significantly inhibited EGFR signaling.  At the selected 
concentrations, both inhibitors significantly and reproducibly inhibited EGFR 
signaling.  While changes in phosphorylation were noted after 4 hours, EGF 
treatment did not induce apoptosis as determined by caspase 3 and PARP 
cleavage (Figure B1, Appendix B).  A slight rounding of A431 cells in culture was 
noted for EGF- treated cells, in agreement with previous reports 14, 15, Cells co-
treated with inhibitor and EGF retained an unaltered morphology.  Neither EGF 
nor EGFR inhibitors produced significant detachment of cells from the culture 
dish.   
 
Global protein expression analyses 
Shotgun proteomic analyses were performed on the four A431 treatment 
conditions described above: proliferating cells, EGF-treated, EGF and gefitinib- 
treated or EGF and cetuximab-treated.  A schematic of the sample work-flow can 
be seen in Figure III-1.  Cells were treated, collected and lysed, tryptic digests 
were prepared and resolved by IEF, and the IEF fractions were analyzed by data-
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dependent LC-MS/MS.  A summary of the global protein analysis is shown in 
Table III-1.   Values  displayed  are  averaged  data  from 3 separate  cultures and 
 
 
Table III-1.  LC-MS/MS data summary. The table lists confident identifications 
(# of spectra successfully matched to peptides), protein groups, and %CV of 
replicate analysis for each of the treatment conditions.  Protein group numbers 
are averages of 6 replicates (three separate cultures, and two process replicates 
of each) per treatment (30 nM EGF, 10 µg/mL cetuximab, 500 nM gefitinib).  A 
5% peptide-level FDR and minimum two distinct peptides were required for 
confident protein identification. *A protein group is defined by a set of proteins 
that cannot be distinguished based on the peptide identifications.  A single 
protein is chosen to represent each protein group.   
                              
 Proliferating 
EGF 
Stimulated 
Gefitinib + 
EGF 
Cetuximab + 
EGF 
Confident 
spectral IDs 
32567 36156 34105 35322 
Protein groups 5203 5294 5347 5250 
Protein group 
CV (%) 
4.4 4.8 4.9 4.5 
 
 
two process replicates of each culture per treatment condition.  Similar values for 
confident spectral IDs (numbers of spectra matched to database sequences at 
5% FDR) and protein groups (numbers of indistinguishable protein identifications 
supported by the identified peptides) and protein group CVs under 5% 
demonstrate high reproducibility of the analyses across biological replicates.   
Figure B2 (Appendix B) shows the distribution of peptides identified across all 
IEF gel fractions for each of the treatment conditions with fractions 7-13 typically 
displaying the most confident identifications. 
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Dataset comparisons, data filtering and derivation of a candidate EGFR inhibition 
signature 
 
Next, protein expression datasets from the four A431 cell conditions were 
compared to identify proteins whose levels were changed by EGFR activation and 
for which the changes were reversed by the inhibitors.  Protein expression was 
compared on the basis of spectral counts using QuasiTel, a quasi-likelihood 
modeling software package (9).  QuasiTel performed pair-wise comparison 
between two treatment/biological conditions based on protein spectral counts and 
variance across replicate analyses and computed p-values and rate ratios (fold 
changes) for detected proteins.   
Pair-wise comparisons were made between 1) proliferating and EGF 
stimulated cells, 2) EGF stimulated and EGF/gefitinib treated cells and 3) EGF 
stimulated and EGF/cetuximab treated cells (Figure III-3, colored boxes).  To 
control the protein-level FDR, comparisons were limited to proteins with ≥11 
spectral counts per protein across replicates.  Accordingly, the three comparisons 
included   3783,   3881   and  3750 proteins, which corresponded  to  protein-level 
FDRs of 3.3, 3.1 and 3.3% respectively.  The colored circles in Figure III-3 
represent proteins differentially expressed (both up and down) between 
treatments with a fold change of ≥ 2.0 and p-values ≤ 0.20.  The blue circle (191 
proteins) represents proteins differentially expressed between EGF stimulated 
cells and non-treated, proliferating cells while the green circle (237 proteins) and 
yellow (133 proteins) circles signify proteins whose EGF-stimulated changes were 
reversed  by  gefitinib  and  cetuximab  inhibition,  respectively.    Tables  B1-B3 in 
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≥ 11 spectra per protein
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Figure III-3.  Filtering and comparison of A431 proteome datasets.  Colored 
rectangles show protein identifications from global proteomic analyses of the four 
treatment groups. Dashed rectangles show number of proteins in comparison datasets 
that were filtered to have ≥11 spectral counts per protein across replicates.  
Comparisons of protein spectral counts between treatment groups were performed by 
quasi-likelihood analysis; and a p-value and spectral count rate ratio (fold change) were 
generated.   The colored circles represent lists of proteins differentially expressed (both 
up and down) between treatments with a fold change of ≥2.0 and quasi p-values ≤ 0.20. 
The resulting protein groups represent proteins differentially expressed in response to 
EGF (blue), EGF-induced protein changes reversed by gefitinib (green) and EGF-
induced protein changes reversed by cetuximab (yellow).  The Venn diagram 
comparison indicates proteins whose expression changes are shared by the different 
experimental conditions.  The central overlap indicates the “EGFR inhibition signature”, 
which refers to EGF-stimulated protein expression changes reversed by both inhibitors.   
149
106 8715 
57
13
18
EGFR inhibition 
signature
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Appendix B provide a complete list of proteins in each of these groups.  The group 
reversed by cetuximab is only about half as large as the group reversed by 
gefitinib, which is consistent with the lesser degree of EGFR inhibition produced 
by cetuximab in the model (Figure III-2), as well as with possible off-target effects 
of gefitinib due to its inhibition of multiple kinases (16, 17).    
The Venn diagram (Figure III-3) compares these three groups of proteins to 
explore the common protein expression changes associated with EGF stimulation 
and EGFR inhibition.  The three groups comprised 445 proteins, of which 13 
proteins were shared between all three groups.  Another 90 proteins were shared 
between two groups and most (342 proteins) belonged to only a single group.  
The center overlap contained 13 proteins whose expression was significantly 
changed by EGF treatment and these changes were reversed by both inhibitors.  
This group is referred to hereafter as the “EGFR inhibition signature”.  The 13 
proteins are: coiled-coiled domain containing 50 (CCDC50), cyclin-dependent 
kinase inhibitor 1A (CDKN1A, p21), claudin 4 (CLDN4), cordon-bleu-like protein 
1(COBLL1), jagged 1 (JAG1), proto-oncogenes c-Jun and JunD (JUN and JUND 
respectively), DNA primase subunit 1 (PRIM1), RNA binding motif protein 15 
(RBM15), translocase of outer mitochondrial membrane 20 (TOMM20), trafficking 
protein particle complex 3 (TRAPPC3), and tripartite motif containing protein 32 
(TRIM 32) and glutamine-fructose-6-phosphatetransaminase 2 (GFPT2).   
The Venn diagram also indicates protein subgroups with expression 
patterns similar to those in the EGFR inhibition signature.  For example, EGF-
induced expression changes were reversed only by cetuximab for 15 proteins and 
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only by gefitinib for 57 proteins.  Another 18 proteins were reversed by both 
cetuximab and gefitinib, but these proteins were not significantly elevated by EGF 
treatment at the selected cut-offs.  The proteins found outside of any overlap 
showed significant differences between EGF stimulation and either non-treated 
(proliferating) or inhibitor treated cells; however, these protein differentials were 
unique to individual treatments and comparisons.  Table B4 in Appendix B lists 
the proteins found in each overlapping section of the Venn diagram.      
These protein groupings, including the EGFR inhibition signature, depend 
on the selected thresholds for fold change and p-values.  More lenient thresholds 
may increase detection of false-positive differences, whereas more stringent 
criteria may decrease detection of true differences.  Manipulation of thresholds for 
p-value and fold change can shift some proteins from one classification to another 
in the Venn diagram (Figure B3, Appendix B).  At all levels of filtering, both 
CDKN1A and RBM15 meet the cut-off criteria in all three comparison datasets 
and were found in the center overlap. 
 
MRM verification of EGFR inhibition signature in A431 cells 
To verify expression differences for the 13 proteins in the EGFR inhibition 
signature, MRM analyses using the labeled reference peptide (LRP) method 
described recently (18) was performed to quantitate target peptides with reference 
to a labeled β-actin peptide standard.  A431 cells were treated as described for 
global proteome comparisons, but no IEF fractionation was performed.  The data 
generated by MRM analyses is displayed together with spectral count data from 
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the shotgun analyses (Figure III-4).  MRM data (red bar) were from analyses of 
three separate cultures for each treatment and the normalized peak area (NPA) 
for a single, proteotypic peptide  is  shown  for  each protein.  The spectral count  
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Figure III-4.  Normalized MRM data and spectral count correlation of EGFR 
inhibition signature proteins.   Each panel shows both MRM data (red bar) and 
spectral count data (teal bar) for each protein of interest across four A431 cell 
treatment conditions: proliferating cells (P), EGF-treated (E), EGF and gefitinib 
(G+E) and EGF and cetuximab (C+E).   The left Y-axis is normalized peak area 
(NPA), which is the total MRM transition peak area for the target peptide divided 
by the peak area for the β-actin labeled reference peptide.  MRM data is 
representative of one unique peptide for each target protein across three 
separate cultures.  Spectral counts (SC) are the total number of spectra identified 
for each protein across replicate analyses.  (*) Denotes significant difference 
compared to EGF treated cells as determined by Student’s two-tailed, unpaired t-
test.     
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 data (Figure III-4, teal bar) displays the total number of spectra identified for the 
corresponding protein across six replicate shotgun analyses (three separate 
cultures and two process replicates of each culture).  The peptide sequences, 
peptide and normalized peak areas, and CVs for the MRM data in Figure III-4 can 
be found in Table B5 of Appendix B.   Calculated CVs for NPA values measured 
peptides across the treatment conditions for all but two of the peptides were below 
30%.  For 39 of these, CVs were less than 18%.  MRM analyses for a second, 
unique peptide for 10 of the 12 EGFR inhibition signature proteins produced 
similar results (Appendix B, Figure B4 and Table B6).  
MRM analyses detected peptide transitions corresponding to 12 of the 13 
EGFR inhibition signature proteins.  None of the peptides monitored for 
glutamine-fructose-6-phosphatetransaminase 2 (GFPT2) produced detectable 
signals.  This protein was not considered further.  For the remaining 12 proteins, 
MRM analyses verified almost all of the expression differences detected by 
shotgun analyses (Figure III-4).  EGF-induced protein expression compared to 
proliferating cells was significantly different by MRM in 8 of the 12 cells and the 
trends in the others were consistent with spectral count differences, except for 
TOMM20 and RBM15.   Significant reversal of EGF-induced expression was 
verified by MRM for both inhibitors for all 12 proteins, except for the effect of 
cetuximab on PRIM1, which fell short of statistical significance, although the trend 
was consistent with the spectral count comparison.   
 
 
 
102 
 
Confirmation of EGFR inhibition signature protein changes in DiFi and HCT-116 
cell lines 
 
The next studies analyzed changes in EGFR inhibition signature proteins in 
cells that differ in response to EGFR inhibitors.  MRM analyses was used to 
measure the 12 EGFR inhibition signature proteins in DiFi and HCT-116 
colorectal cancer cell lines.   DiFi cells demonstrate both gene amplification and 
protein overexpression of the EGFR and also harbor an adenomatous polyposis 
coli (APC) germline mutation found in familial adenomatous polyposis (FAP) (19, 
20).  DiFi cells thus would be expected to show similar responses to A431 cells.  
HCT116 cells show increased autocrine production of the EGFR-stimulating 
ligand transforming growth factor-alpha (TGF-α) and carry a mutant allele (G13D) 
of the KRAS protoncogene (21, 22).  Because KRAS mutations block clinical and 
cellular responses to EGFR inhibitors, such as cetiximab, I hypothesized that an 
EGFR inhibition signature would be minimal or absent in the HCT116 cells.  
Both cell lines were treated with EGF and inhibitors as described above 
and the 12 EGFR inhibition signature proteins were analyzed.  Peptides for 11 of 
the 12 proteins were successfully monitored in DiFi cells, whereas peptides for 
only eight of the proteins were detected in HCT116 cells (Figure III-5 and III-6 
respectively).  The COBLL1, PRIM1 and RBM15 peptides monitored in HCT116 
cells produced no detectable signals and CDKN1A peptide signals were absent in 
both cell lines.  Most of the peptide signals monitored in DiFi cells showed 
statistically significant differences between EGF only and inhibitor treated cells 
(Figure III-5) consistent with the trends noted in A431 cell experiments (Figure III- 
4). Only JUND and PRIM1 failed to show significant changes.  HCT116 cells were 
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largely resistant to changes in EGFR inhibition signature proteins, with significant 
differences  detected  only  for  CCDC50, JUND and TOMM20.   CCDC50 peptide 
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Figure III-5.  MRM data for EGFR inhibition signature proteins in DiFi cells.  
Plots represent data from analysis of three replicate cultures for each treatment 
condition.  Y-axis shows the normalized peak area (NPA), which is the total MRM 
transition peak area for the target peptide divided by the peak area for the β-actin 
labeled reference peptide.  (*) Denotes statistically significant from EGF treatment 
condition (determined by Student’s two-tailed, unpaired t-test). 
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signals were significantly upregulated in both inhibitor treated conditions when 
compared to EGF only samples—in  agreement with A431 and DiFi cell MRM 
data—whereas JUND and TOMM20 peptides showed substantial differences for 
only gefitinib or cetuximab treatments respectively (Figure III-6).  Tables B8 and 
B9 (Appendix B) list the peptide peak areas, normalized peak areas, averages 
and CVs for the EGFR inhibition signature peptides monitored in the two cell lines. 
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Figure III-6.  MRM data for EGFR inhibition signature proteins in HCT116 
cells.  Plots represent data from analysis of three replicate cultures for each 
treatment condition.  Y-axis shows the normalized peak area (NPA), which is the 
total MRM transition peak area for the target peptide divided by the peak area for 
the β-actin labeled reference peptide.  (*) Denotes statistically significant from 
EGF treatment condition (determined by Student’s two-tailed, unpaired t-test).  
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To confirm the expression of the EGFR inhibition signature in the DiFi and 
HCT116 cells, at least half of the detectable signature proteins were required to 
show expression changes consistent with changes measured in the A431 model.  
The MRM data for DiFi cells demonstrate expression changes consistent with 
those in A431 cell—11 of the 12 signature proteins were detected and 9 showed 
significant expression differences.  None of the proteins showed changes 
opposite those observed in A431 cells.  This result for DiFi cells is consistent with 
their overexpression of EGFR and responsiveness to EGFR inhibitors.  In 
contrast, the HCT116 cells display expression changes sensitive to both inhibitors 
in only one of the eight detectable signature proteins (CCDC50) and responded 
only to a single inhibitor for two others (JUND and TOMM20).  By the defined 
criteria, the HCT116 cells do not display an EGFR inhibition signature, a result 
that is consistent with the effect of the heterozygous G13D KRAS mutation, which 
blocks responses to EGFR inhibitors (22).   
 
Immunoblot confirmation of EGFR inhibition signature 
Further confirmation of protein changes in response to EGFR perturbation 
was done by immunoblotting with antibodies to p-EGFR, JAG1, JUN and CLDN4 
in the A431, DiFi and HCT116 cell lines across all treatments (Figure III-7).  In all 
cell lines, an increase was observed in p998 and p1173 signals in EGF-treated 
cells relative to proliferating.  In A431 and DiFi cells treated with gefitinib, EGFR 
p998 and p1173 both were decreased to basal (proliferating) levels, while a less 
profound, yet still detectable decrease was observed in HCT116 cells.  Cetuximab  
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Figure III-7.  Western blot analysis of EGFR inhibition signature proteins in 
treated A431, DiFi and HCT116 cells.  P=proliferating cells, E=30 nM EGF for 4 
h, G=500 nm gefitinib + 30 nM EGF for 4 h, and C= 10 µg/mL cetuximab + 30nM 
EGF for 4 h.  Each cell line was probed for total EGFR, EGFR tyrosine 
phosphorylation and three proteins (e.g. JAG1, JUN and CLDN4) from the EGFR 
inhibition signature.  β-Actin was used as a loading control.  
 
 
 
treatment (at 10 µg/mL) in all three cell  lines  partially  inhibited  EGFR  
autophosphorylation.   For EGFR p1173 in DiFi cells and p998 in HCT116 cells, 
no change in phosphotyrosine immunoblot signal was detected between EGF only 
and cetuximab-treated cells (Figure III-7).  Protein expression changes in all three 
cell lines measured by immunoblot were consistent with MRM data.  In A431 and 
DiFi cell lines, JAG1, JUN and CLDN4 were increased in EGF treated compared 
to proliferating cells.  In both A431 and DiFi cells, gefitinib decreased JAG1, JUN 
and CLDN4 expression, whereas cetuximab produced partial reversal of EGF 
stimulation for these proteins.  In HCT116 cells, EGF elevated JAG1, but the 
inhibitors did not reverse this effect.    
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Confirmation of EGFR inhibition signature protein changes in mouse xenograft 
tumors 
 
  To further confirm protein changes in the EGFR inhibition signature in 
tissue specimens, mouse xenograft tumors derived from DiFi and HCT116 cell 
lines were analyzed.   These xenograft samples come from a previous study, in 
which novel optical imaging probes were used to study therapeutic responses to 
cetuximab in vivo (4).  DiFi and HCT116 xenografts were grown in athymic nude 
mice.  Tumor bearing mice were then treated with 40 mg/kg cetuximab or saline 
vehicle intraperitoneally every three days for one week (three total injections).  
Image analysis demonstrated a significant decrease in EGF-probe uptake in DiFi 
xenografts and increased apoptosis in cetuximab-treated mice, whereas HCT116 
xenografts showed neither effect.  Gefitinib was not employed in this study.     
 FFPE sections from the xenograft tumors were analyzed by MRM to 
measure the 12 EGFR inhibition signature proteins.  Analyses of xenograft tumors 
from vehicle treated mice were used for reference to assess the effects of 
cetuximab treatment.  MRM analyses detected eight of the 12 EGFR inhibition 
signature proteins in each xenograft type (Figure III-8 and III-9).  DiFi derived 
tumors from cetuximab-treated mice showed decreased expression of CLDN4, 
JAG1, JUN, and TRIM32 and an increase in TRAPPC3 when compared to tumors 
from vehicle treated mice.  These differences are similar to those between EGF-
treated and only to cetuximab/EGF-treated DiFi cells, although the xenograft 
analyses yielded no statistically significant differences for CCDC50, COBLL1, or 
RBM15 (Figure III-8).     
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Figure III-8.  MRM data for EGFR inhibition signature proteins in mouse 
xenografts derived from DiFi cells.  Plots represent 4 biological replicates and 
show the average normalized peak area with standard deviation (COBLL1 
peptide signal was not detected in one replicate).  Y-axis shows the normalized 
peak area (NPA), which is the total MRM transition peak area for the target 
peptide divided by the peak area for the β-actin labeled reference peptide.  (*) 
Denotes statistically significant from EGF treatment condition (determined by 
Student’s two-tailed, unpaired t-test).  
 
 
 
HCT116 xenografts from cetuximab-treated mice showed a significant 
increase in TRAPPC3 and RBM15 compared to vehicle treated tumors, but the 
other proteins in the EGFR inhibition signature were either unchanged or were not 
detected (Figure III-9).  Of note are the differences between the EGFR inhibition 
signatures for the treated HCT116 cells and the HCT116 mouse tumors. In 
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HCT116 cells,  cetuximab  increased  CCDC50  and  TOMM20,  but  not  in  the  
HCT116 xenografts. The lack  of  consistent  inhibitor-induced  protein  expression  
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Figure III-9.  MRM data for EGFR inhibition signature proteins in mouse 
xenografts derived from HCT-116 cells.  Plots represent five biological 
replicates and show the average normalized peak area with standard deviation.  
Y-axis shows the normalized peak area (NPA), which is the total MRM transition 
peak area for the target peptide divided by the peak area for the β-actin labeled 
reference peptide.  (*) Denotes statistically significant from EGF treatment 
condition (determined by Student’s two-tailed, unpaired t-test).  
 
 
 
differences in the HCT116 xenograft samples is consistent with the lack of 
response to cetuximab in vivo (4).  MRM data for the DiFi and HCT xenograft 
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samples are provided in Tables B10 and B11 respectively.  An important aspect of 
this study is the analysis of the EGFR inhibition signature in archival FFPE tissue 
specimens.  Although a few of the measured peptides yielded CVs around 40%, 
most yielded CVs < 30%.   
Confirmation of the EGFR inhibition signature was assessed by the criteria 
described above—changes concordant with the A431 model in at least 50% of the 
measurable signature proteins.  The signature was confirmed in DiFi xenografts 
(five concordant changes in eight detectable signature proteins), but not in 
HCT116 xenografts (two concordant changes in eight detectable signature 
proteins).  A summary of the MRM data for all cell lines and both xenograft 
models can be seen in Figure III-10. 
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Figure III-10.  Summary of expression changes for EGFR inhibition signature 
proteins in cell lines and mouse xenograft models.  Symbol colors indicate 
decreased expression (green); increased expression (red); detected, but no 
significant change (black) compared to EGF treatment in cells (c) or compared to 
vehicle control in xenografts (x); and not detected (white).  Only cetuximab 
treatment was used in xenograft experiments. 
 
 
 
Use of the EGFR inhibition signature to assess therapeutic response to cetuximab 
in Ménétrier’s disease  
 
A potential use of the EGFR inhibition signature is to assess response to 
drug treatment.  To test the applicability of the EGFR inhibition signature to 
assess clinical response to EGFR inhibition, serial biopsies were analyzed from a 
single Ménétrier’s disease patient treated with cetuximab, as described in a recent 
study (3).  Ménétrier’s disease is a rare hypertrophic gastropathy characterized at 
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the molecular level by high expression of transforming growth factor-α (TGFA) 
and constitutively activated EGFR signaling (23, 24).  Symptoms of Ménétrier’s 
disease are highly responsive to cetuximab therapy, which rapidly and 
dramatically reverses most effects of the disease (3, 25).   
 One patient from a recent study (3) showed improved symptoms and a 
histologically normal stomach after the initial one month trial.  Baseline (no 
treatment) specimens as well as serial biopsies from one day and one week post-
initial cetuximab treatment were analyzed in triplicate (three separate analyes of 
pooled biopsies from several sites in the stomach) from this patient.  MRM 
analyses detected peptides from nine of the 12 EGFR inhibition signature proteins 
(Figure III-11).  The MRM data are presented in expanded form in Table B12.  
Because the cell model for EGFR inhibition reflected an acute response to EGF 
and inhibitors, I focused on protein expression changes after one day and one 
week of cetuximab treatment (biopsies were also collected at one and four 
months of continued treatment).  CLDN4, JAG1, and JUN all were significantly 
decreased relative to baseline after 1 day. JUND and TRIM32 appeared 
decreased, although the effect was not significant.  These changes all are 
consistent with the effects of cetuximab treatment in the A431 and DiFi cell 
models.   In contrast, CCD50, COBBL1, TOMM20 all were decreased by 1 day of 
cetuximab treatment, in contrast to the increases in these proteins produced by 
cetuximab in the A431 and DiFi models.  At 1 week cetuximab treatment, CLDN4, 
JAG1 and JUN were still decreased relative to pretreatment, consistent with 
responses to cetuximab  
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Figure III-11.   MRM analyses of EGFR inhibition signature proteins in tissue 
biopsies from a Ménétrier’s disease patient treated with cetuximab.  Gastric 
tissue biopsies were collected from three separate locations prior to treatment 
(baseline control) and at 1 day and 1 week after treatment with cetuximab.  
Normalized peak area (NPA), which is the total MRM transition peak area for the 
target peptide divided by the peak area for the β-actin labeled reference peptide.  
Data points are representative of three separate biopsies taken from a single 
patient with mean and standard deviation shown.  (*) Denotes significant 
difference between baseline and time post initial treatment as determined by 
Student’s two-tailed t-test.       
 
 
 
treatment in A431 cells, DiFi cells and the DiFi xenograft model.  Expression of 
JAG1, JUN and CLDN4 expression was also measured by immunoblotting (Figure 
III-12).  Consistent with MRM data, JAG1 and CLDN4 were significantly 
decreased from the baseline sample at one day and one week post-treatment.  
JUN expression measured by immunoblotting did not change with cetuximab 
treatment.   
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Figure III-12.  Western blot analysis of tissue biopsies from a patient with 
Menetrier’s disease.  Tissue lysates from a mixture from three individual gastric 
biopsies taken before treatment (B) and after 1 day and 1 week of treatment with 
cetuximab.  Equal amounts of protein were loaded and analyzed by 
immunoblotting for total EGFR, JAG1, JUN and CLDN4 proteins.  β-Actin was 
used as a loading control.   
 
 
 
By the criteria described above, these results do not confirm the EGFR 
inhibition signature.  Three of the signature proteins (CCD50, COBBL1, TOMM20) 
showed changes opposite those in the A431 model.  Nevertheless, the three 
proteins (CLDN4, JUN and JAG1) showing changes concordant with the A431 
model, were most consistently responsive to EGFR inhibition in all experiments.  
  
Discussion 
 
Direct analysis of phosphorylated receptor proteins and their downstream 
effectors is the most commonly employed method to assess signaling networks.  
This approach is complicated by the transient nature of protein post-translational 
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modifications, their low abundance relative to unmodified proteins and potential 
artifacts due to uncontrolled pre-analytical variables.   I asked whether analysis of 
changes in protein expression could indicate changes in the status of a signaling 
network.  The rationale for this concept is two-fold.  First, protein expression is 
easier to measure and is less labile than phosphorylation or other post-
translational modifications.  Second, signaling pathways ultimately drive gene and 
protein expression changes, which are most directly linked to phenotypes.  A 
protein expression-based analysis could be routinely applied to clinical 
specimens, including archival FFPE tissues, where direct measurements of 
phosphorylated intermediates may be neither practical nor valid.  Here the 
hypothesis that manipulation of the EGFR signaling axis with clinically-used drugs 
generates characteristic protein expression changes was tested.  These results 
confirm the hypothesis and demonstrate a prototypical approach to derive and 
test protein expression signatures for drug action on signaling networks.   
Based on an extensive literature background (26-30) and results described 
in Chapter II, the A431 cell model was selected as reproducible system to study 
EGFR-driven signaling events.  Four treatment conditions were selected for 
comparisons: normal proliferating cells, cells stimulated with EGF and cells pre-
incubated with either gefitinib or cetuximab and then treated with EGF in the 
presence of the inhibitors.  The initial immunoblot analyses (Figure III-2) 
confirmed EGFR activation and inhibition.  All treated A431 cells were serum-
starved overnight to synchronize the cells and to limit potential interference by 
alternate EGFR ligands, which could complicate results.  Serum starving the cells 
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nevertheless introduced an inherent experimental difference between the 
proliferating (non-treated) cells harvested in the presence of 10% fetal bovine 
serum and the EGF treated A431 cells incubated in serum-free media.   Shotgun 
and MRM analyses (Figure B5, Table B7, Appendix B) verified elevation of two 
proteins (HMGCR and HMCS1) and a decrease of one protein (A2MG) reported 
to be induced by serum starvation.  These proteins were expressed at similar 
levels in all EGF-treated A431 cells (even in the presence of the inhibitors) 
compared to proliferating cells.  This example illustrates the potential for 
experimental artifacts and underscores the importance of understanding the 
underlying biology of the discovery model.   
Shotgun proteomic analyses of treated and non-treated A431 cells yielded 
highly reproducible proteomic inventories—CVs for numbers of protein 
identifications were less than 5% across three separate cultures for each 
treatment condition (Table I).  The combined inventories comprised nearly 4,300 
proteins identified at a protein-level FDR of 4.7%.  Quasi-likelihood analyses 
generated three pairwise comparisons (EGF versus proliferating, EGF versus 
gefitinib, and EGF versus cetuximab) based on shotgun spectral count data.  
These datasets were then filtered on the basis of spectral counts (≥ 11), fold-
change (≥ 2), and p-value (≤ 0.20) to generate the three protein groups 
representing EGF-simulated proteins, cetuximab-sensitive proteins and gefitinib-
sensitive proteins (Figure III-3).  A Venn diagram comparison of these generated 
the EGFR inhibition signature proteins.   
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Three important points should be emphasized about the comparison 
process.  First, the application of a minimum spectral count threshold (here ≥11 
across all analysis runs in each dataset comparison) is required to control protein-
level FDR.  Without the threshold, protein FDR exceeded 30%, whereas with the 
threshold, protein FDR was approximately 3%.  Second, an important 
consideration in dataset comparisons is the stringency of the cut-off criteria 
applied.  A relatively loose p-value threshold (≤0.2) was employed to maximize 
detection of differences in protein group comparisons.  The rationale is that 
subsequent MRM analyses would identify false positive differences and confirm 
true positives that might not have been detected in the spectral count 
comparisons at higher stringency.  A 2-fold expression cut-off was employed for 
the same comparisons.  I experimented with different p-value and fold-change 
thresholds (Figure B3, Appendix B) and ultimately settled on criteria that yielded 
an EGFR inhibition signature compatible in number of proteins with the capacity to 
perform subsequent MRM studies.  Third, the interplay between p-value and fold-
change threshold variation also affected the number and distribution of proteins in 
the overlap categories in Venn diagram analysis.  For example, at thresholds of p 
≤0.2 and a 2-fold difference, the central overlap (EGFR inhibition signature) in the 
Venn diagram contained 13 proteins, but at p ≤0.1, the central overlap contained 
only 4 proteins (JUN, JUND, CDKN1A, and RBM15) (Figure B3, bottom row 
middle Venn diagram ).     
Despite the relatively loose criteria used to derive the EGFR expression 
signature, 11 of the 13 proteins were verified by MRM with expression changes 
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similar to those observed from shotgun data (Figure 4).  One protein (GFPT2) 
proved difficult to monitor selectively by MRM and was not further studied and 
another (PRIM1) did not show significant reversal of EGF-induced change by 
cetuximab.   Although these MRM analyses targeted a single peptide for each of 
the proteins, a parallel set of analyses targeting a second unique peptide for 10 of 
the EGFR inhibition signature proteins similarly verified the results of the spectral 
count comparisons.       
Although the shotgun analyses represented an empirical approach to 
discover a candidate signature, the component proteins have interesting and 
biologically plausible relations to EGFR signaling.  A core group of proteins (e.g. 
JAG1, JUN, and CLDN4) displayed the most robust responses to EGFR inhibition.  
JAG1 (Jagged1) is a Notch1 receptor ligand with reported links to EGFR 
expression (31, 32); moreover, up-regulation of JAG1 expression and Notch1 
signaling has been noted in human colon adenocarcinomas and intestinal tumors 
(33-35) and associated with poor prognosis in breast cancer (36).  An increase in 
JUN detection in EGF-treated samples is consistent with literature reports that 
indicate an increase in mRNA levels for the transcription factor upon EGF 
stimulation (37-39).  Overexpression of JUN has also been linked with increased 
invasiveness and hormone resistance in breast cancer cells (40).   Increased 
expression of the tight junction protein CLDN4 upon EGF treatment (41) is in 
agreement with the data.  JUN and CLDN4 also are linked to EGF via the 
transcription factor Sp1 (42, 43).  EGFR manipulation dramatically affected 
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CDKN1A, a TP53-regulated cyclin dependent kinase inhibitor (44), but only in 
A431 cells, which lack a functional TP53 protein.   
Once a candidate EGFR expression signature was established, I asked 
whether this set of protein expression changes can consistently represent the 
output of the EGFR signaling network in cells and tissues that differ in 
responsiveness to inhibitors.  The EGFR inhibition signature in the DiFi cells was 
nearly identical to that in the A431 model (Figure -10), which is consistent with the 
high EGFR expression and responsiveness to inhibitors for both lines.  In 
contrast, the HCT116 cells displayed only one consistent change (increase in 
CCDC50 by both inhibitors) observed in the A431 cells (Figure III-10).  This result 
is consistent with the impact of the KRAS mutant status of these cells, which 
blocks response to EGFR inhibition (22).   
Analyses of DiFi and HCT116 derived mouse xenograft models extended 
confirmation of the EGFR inhibition signature to tissue specimens.  Although 
fewer targeted EGFR inhibition signature proteins were detected overall (eight of 
12 for each xenograft type), there was again a clear difference in response of the 
signature proteins.  Five of eight detected signature proteins displayed the 
expected expression changes in DiFi xenografts, whereas only two did in HCT116 
xenografts (Figure III-10).  An important aspect of the xenograft studies is that 
they demonstrate the potential to analyze protein expression signatures in FFPE 
specimens.  Although it has been previously demonstrated that shotgun proteome 
inventories of frozen and FFPE tissues are equivalent (2), yield of proteins may be 
decreased.  Indeed, comparison of the cell line and xenograft data also suggests 
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a “loss of signal”, in that fewer of the signature proteins were quantifiable in the 
xenografts.   
The EGFR inhibition signature was evaluated in Ménétrier’s disease 
because of the dramatic response of this syndrome to cetuximab therapy (3).  The 
results indicate that the three most consistent elements of the signature (JUN, 
JAG1 and CLDN4) respond to cetuximab treatment in Ménétrier’s disease.  
However, CCDC50, COBBL1 and TOMM20 expression changes were opposite to 
those in the A431 model.  This discrepancy could reflect that fact that Ménétrier’s 
disease is a hyperproliferative disorder, but not a cancer, and thus may differ in 
other ways from the biology of the A431 discovery model and the DiFi and 
HCT116 models, which are all cancer cell lines.  This point underscores the 
importance of matching the discovery model as closely as possible to the clinical 
application of an expression signature. 
While the described model of EGFR activation developed in A431 cells 
might not be representative of all models, the confirmation of several protein 
changes in various EGFR sensitive models supports the assertion that protein 
expression changes can represent the effect of drugs on a signaling network.  
One possible problem with comparing cell models and tissue samples is that 
endogenous levels of EGF and exposure cannot be controlled in tissues.  
Moreover, other factors in vivo inherent to tissue samples may influence the 
expression of candidate signature proteins.  These reasons could contribute to a 
lack of complete agreement between cell and in vivo models.   However, some of 
most dramatic changes observed (JUN, JAG1 and CLDN4) show consistent 
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expression patterns in all EGFR inhibitor sensitive systems studied.  This 
suggests the most dramatic changes maybe the most robust across the system.  
Despite this possible complication, the results support the hypothesis that 
significant EGFR-driven changes in cell models can be detected in tissue 
systems. 
The main objective in this work was to determine whether protein 
expression signatures can represent the effects of drugs on a signaling network, 
rather than to develop and refine a clinically useful EGFR inhibition signature.  
This latter objective would entail a more elaborate process that includes 1) 
multiple discovery systems to generate a more broadly-based candidate 
signature, 2) integration of quantitative measurements with a valid statistical 
model to establish score thresholds and account for variability and 3) systematic 
validation in a carefully selected, valid patient cohort.  Nevertheless, some of the 
proteins identified in this study would appear likely to contribute to a clinically 
useful EGFR inhibition protein profile.  These results establish proof of concept for 
this approach by demonstrating that protein expression signatures detect 
activation and inhibition of dynamic signaling networks.  Clinically useful response 
signatures developed through this approach could have broad impact in the field 
of cancer therapeutics. 
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CHAPTER IV 
 
SITE-SPECIFIC, QUANTITATIVE COMPARISON OF EGFR 
PHOSPHORYLATION CHANGES INDUCED BY EGF AND INHIBITOR S 
 
Introduction 
 
Whereas Chapters II and III dealt with identifying global protein expression 
differences in response to drug treatments, the experiments detailed in Chapter IV 
describe a mass spectrometry-based approach for quantitation of changes in 
post-translationally modified proteins.  As referenced in the previous chapters, 
posttranslational protein modifications (PTM), such as phosphorylation, are 
difficult to quantify because they are highly dynamic and present at low levels.  
Nevertheless, quantitative analysis of PTMs has been achieved using liquid 
chromatography tandem mass spectrometry methods (LC-MS/MS) (1-4).  Global 
quantification of phosphorylation or other PTMs typically employs costly isotope 
labeling methods such as chemical derivatization (e.g., iTRAQ) or metabolic 
incorporation of stable isotope-labeled amino acids in cell culture (SILAC) (5-8).  
For targeted quantitation of site-specific phosphorylations, stable isotope dilution 
has demonstrated the highest precision of quantitation (7-9), but this approach 
requires costly labeled standards for each peptide of interest.   
Additional approaches deemed “Label-free” quantitation methods have 
been adopted as viable alternatives to stable isotope dilution.  These methods fall 
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broadly into two groups, spectral counting and integrating MS1 peak areas.  
Although the spectral counting method compares favorably to stable isotope 
labeling in both precision and accuracy for quantifying proteins in shotgun 
proteomics analyses (10, 11), the sampling of individual modified peptide spectra 
by “data-dependent MS/MS” is insufficient in capturing enough spectra to use this 
method for quantification at the peptide level.  Quantification by integrated MS1 
signals for specific peptide ions is performed by extraction of selected ion 
chromatograms from LC-MS datasets.  However, the MS1 signal will not 
distinguish between sites if differentially modified peptides cannot be resolved 
chromatographically.   
In many cases, analysis of PTM is performed on purified proteins or simple 
mixtures, such as immunoprecipitates, expressed proteins, or proteins purified by 
chromatography or electrophoresis.  In such cases, the need to quantify a 
stoichiometric change in a modification frequently follows the initial identification of 
modified forms.  Since the modified form has been identified, the MS/MS spectral 
characteristics of the modified peptides of interest are known.  In this context, the 
goal is targeted quantitation of changes to specific proteins, rather than a 
quantitative global survey.  Here, the validation of a label-free approach to 
measure quantitative changes in modifications to specific proteins is described.  
The approach uses targeted LC-MS/MS analysis with extracted selected reaction 
monitoring (pseudo-SRM or pSRM) using a linear ion trap mass spectrometer to 
enable selective detection and further quantification of modified peptides.  
Normalizing pSRM signals for the target peptides to signals from unmodified 
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reference peptides within the same protein, termed the internal reference peptide 
(IRP) method, corrects for run-to-run variations in signal intensities.  Although 
other reports  have described similar quantification methods previously (12-20), 
the studies described herein—based on proof-of-concept experiments performed 
by Dr. Amy-Joan Ham—allowed for validation of the IRP method by defining its 
performance characteristics and comparing them to stable isotope dilution; a 
method accepted as the  “gold standard” for MRM/SRM-based quantitation.  The 
performance of pSRM was further assessed using both MS/MS and MS3 data for 
quantification.  The studies described in Chapter IV represent a team project I did 
with Drs. Stacy D. Sherrod and Dr. Amy-Joan Ham in our laboratory.  This project 
was the development of the IRP method and its application to analyze 
phosphorylated forms of epidermal growth factor receptor (EGFR) in response to 
anticancer drugs.  My role in this team project was in establishing the EGFR 
activation and inhibition model described in the previous chapters and in 
performing analyses to map and quantify differential EGFR phosphorylation.  The 
data demonstrate the utility of the IRP method to quantify site-specific changes in 
EGFR phosphorylation in response to modulation by EGF and the two tyrosine 
kinase inhibitors, cetuximab and gefitinib.    
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Experimental Procedures 
 
Materials and reagents  
Acetonitrile and HPLC grade water were from Mallinckrodt Baker 
(Phillipsburg, NJ) and 98% pure formic acid was from EMD (Darmstadt, 
Germany).  Trypsin gold was purchased from Promega (Madison, WI), 
dithiothreitol (DTT) from Pierce (Rockford, IL), and iodacetamide was from Sigma 
(St. Louis, MO).  The A431 cell line was obtained from ATCC (Manassas, VA), 
improved MEM media and PBS were purchased from Invitrogen-GIBCO 
(Auckland, NZ).  Media supplement, fetal bovine serum, was from Atlas 
Biologicals (Fort Collins, CO).  For Western blotting, primary antibodies for 
phosphotyrosine site 1173 phosphotyrosine site 998 and EGFR were purchased 
from Cell Signaling Technology (Danvers, MA).  Primary antibodies were detected 
using anti-rabbit and anti-mouse secondary antibodies conjugated with 
Fluorophore 680 from Invitrogen (Carlsbad, CA) and imaged using the LI-COR 
Odyssey Imager system with 3.0 application software (Lincoln, NE).  All gels 
(NuPAGE), western blot membranes and gel reagents (LDS, PVDF membrane, 
and SimplyBlue SafeStain) were purchased from Invitrogen (Carlsbad, CA).  
Individual components of the NETN lysis buffer, protease inhibitor cocktail and 
phosphatase inhibitor cocktail (see below) were purchased from Sigma (St. Louis, 
MO).  Beads from immunoprecipitations, Protein A and Protein G were purchased 
from ThermoScientific (Rockford, IL) and Roche (Indianapolis, IN), respectively.   
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Synthetic phosphorylated peptides, DRVpYIHPF and IKNLQpSLDPSH, 
were purchased as part of the Phosphopeptide Standard I from Protea 
Biosciences (Morgantown, WV).  Bovine serum albumin (BSA) was purchased 
from ThermoScientific (Rockford, IL).  Four C-terminal isotopically labeled 
phosphotyrosine peptides containing U-13C6, U-
15N4-arginine or U-
13C6, U-
15N2-
lysine from EGFR (Y998 − MHLPSPTDSNFpYR, Y1110 − 
RPAGSVQNPVpYHNQPLNPAPSR, Y1173 − GSHQISLDNPDpYQQDFFPK and 
Y1197 − GSTAENAEpYLR) were purchased from New England Peptide, LLC 
(Gardner, MA) at ≥95% chemical purity based on amino acid analysis.  EGFR 
antibody and cetuximab were a gift from Dr. Robert Coffey; gefitinib was a gift 
from Dr. Carlos Arteaga, both from Vanderbilt-Ingram Cancer Center (Nashville, 
TN).   
 
Phosphopeptide/BSA spike experiments  
The following studies in this section were performed by Dr. Amy-Joan Ham 
as proof-of-concept experiments for development of the IRP method.  Synthetic 
phosphopeptide mixture (DRVpYIHPF and IKNLQpSLDPSH) was resuspended in 
0.1% formic acid to a concentration of 500 pmol/mL and peptides were spiked into 
100 µL of 6.0 µg/mL (6 ng of BSA) tryptic digest of BSA at concentrations ranging 
from 0.01-2.0 fmol/ng BSA (which corresponds to 0.064-12.8 fmol/µL) in 0.1% 
formic acid.  The BSA tryptic digest was performed on 200 µg of 2 mg/mL BSA. 
The sample was diluted in ammonium bicarbonate, reduced in 45 mM DTT at 
55°C for 20 min, alkylated in the dark at room temperature for 20 min using 100 
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mM iodoacetamide and digested with 4 µg of trypsin overnight at 37°C.  An 
aliquot of this digest was diluted with 0.1% formic acid to a final concentration of 
6.0 µg/mL.   
 
Cell culture  
A human epithelial carcinoma cell line (A431) was cultured in 150 mm 
culture dishes in improved MEM supplemented with 10% fetal bovine serum at 
37°C in 5% CO2.  A431 cells were grown to ~60-70% confluency prior to 
harvesting (control or treatment).  All treated cells were serum-starved (18 hrs), 
followed by treatment with 30 nmol epidermal growth factor (EGF) for 20 min or 
incubated with either 10 µg/mL cetuximab) or 500 nmol gefitinib) for 30 min 
followed by subsequent stimulation with EGF for 20 min.  Cells were harvested on 
ice with Mg and Cl-free PBS supplemented with a phosphatase inhibitor cocktail 
(1 mM sodium fluoride, 10 mM β-glycerophosphate, 1 mM sodium molybdate, and 
1 mM activated sodium orthovanadate), pelleted by centrifugation at ~250 x g, 
flash-frozen and stored at -80°C.   
 
Immunoprecipitation, western blot, and sample preparation  
Cell pellets were lysed by resuspension in NETN lysis buffer (50 mM Tris-
HCl, pH 7.5, 150 mM NaCl, 1% Igepal, and 5% glycerol) containing protease 
inhibitors (0.5 mM 4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride, 10 
mM aprotinin, 1 mM leupeptin, 1.5 µM E-64, 5µM betastatin and 1 µM pepstatin 
A) and the phosphatase inhibitor cocktail, and incubated on ice for 25 min prior to 
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mechanical lysis by sonication.  After cell lysis, suspensions were cleared by 
centrifugation at 9,400 x g for 5 min.  The bicinchoninic acid assay (protein 
standard was bovine serum albumin) was used to measure the protein 
concentration of the cell lysate.  A 100 µg aliquot of total cell lysate was collected 
as input control and combined with 4X LDS buffer and DTT for a final 
concentration of 1X and 50 mM, respectively.  A 3 mg portion of the remaining 
cleared lysate was incubated at 4°C for 1.5 hours with cetuximab at a ratio of 5 µg 
of cetuximab for every 1 mg of cell lysate.  A 30 µl portion of pre-equilibrated 
Protein A and Protein G resin (1:1 v:v) were added to the suspension and 
incubated with the lysate for 45 min at 4°C.  The suspension was then centrifuged 
at ~200 x g for 2 min at 4°C.  The supernatant was removed and the resin washed 
three times with NETN lysis buffer.  Protein(s) were eluted by treating beads for 5 
min at 85°C in 2X LDS buffer and 50 mM DTT.  Samples were fractionated in 
NuPAGE 10% Bis-Tris SDS-PAGE gels using MOPS buffer.  Gels were either 
prepared for western blot by transferring proteins to PVDF membrane or stained 
(for 1 hour) using Simply Blue Safe Stain followed by destaining in deionized 
water overnight.   
Targeted MS analysis was performed on the digested EGFR gel regions.  
Briefly, the EGFR protein bands were excised and rinsed with 100 mM ammonium 
bicarbonate (pH 8.0).  Gel pieces were reduced with 50 mM DTT at 60°C for 30 
min, followed by alkylation with 100 mM iodoacetamide in the dark at ambient 
temperature for 20 min, and digested with 200 ng trypsin overnight at 37°C.  
Peptides were extracted from the gel three times with 60% acetonitrile/ 0.1% 
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formic acid (v/v).  Peptides were evaporated in vacuo (SpeedVac concentrator, 
Thermo-Fisher, Waltham, WA) and reconstituted in 30 µL of 5% acetonitrile, 0.1% 
formic acid with 12.5 fmol/µL of isotopically-labeled peptides spiked in for LC-
pSRM-MS analysis.   
 
Mass spectrometry and data analyses  
LC-pSRM-MS and MS3 analyses were performed on a LTQ Velos from 
ThermoFisher Scientific (San Jose, CA) mass spectrometer equipped with an 
Eksigent Nano-1D Plus HPLC and AS-1 autosampler (Dublin, CA).  Peptides 
were separated on a 100 µm × 11 cm fused silica capillary column (Polymicro 
Technologies, LLC., Phoenix, AZ) and 100 µm x 6 cm fused silica capillary pre-
column packed with 5 µm, 300 Å Jupiter C18 (Phenomenex, Torrance, CA).  Liquid 
chromatography was performed using a 95 min gradient at a flow rate of either 
400 or 600 nL/min using a gradient mixture of 0.1% (v/v) formic acid in water 
(solvent A) and 0.1% (v/v) formic acid in acetonitrile (solvent B).  Briefly, a 15 min 
wash period (100% solvent A) was performed followed by a gradient to 98% A at 
15 min (1.2 µl/min) and eluent was diverted to waste prior to the analytical column 
using a vented column set up similar to that previously described (21).  Following 
removal of residual salts, the flow was redirected to flow through the analytical 
column and solvent B increased to 75% over 35 minutes and up to 90% in 65 
minutes.  The column was re-equilibrated to 98% solvent A for 10 minutes after 
each run.  All peptides were analyzed using targeted analysis of doubly and/or 
triply charged ions to acquire the complete MS/MS spectrum.  MS3 analysis was 
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performed on the neutral loss of phosphoric acid for phosphopeptides 
IKNLQpSLDPSH (Protea peptide), MHLPpSPTDSNYR and 
GSHQIpSLDNPDYQQDFFPK (both EGFR phosphopeptides) in addition to 
MS/MS analysis.  Typical targeted parameters include an isolation width of 2 
bracketed around the m/z of interest, a fragmentation time of 10 ms, normalized 
collision energy of 35.0, spray voltage of 1.8 kV and capillary temperature at 200 
ºC.   
Data was analyzed using either Xcalibur software (ThermoFisher, San 
Jose, CA) to determine extracted ion current peak area for 3-5 transitions for each 
targeted peptide or the full scan MS/MS filtering feature in Skyline 0.7 software 
(22).  Each phosphopeptide was normalized by dividing the individual 
phosphopeptide (sum of three or four ion transitions/peptide) by either the 
individual reference peptides (sum of three or four ion transitions/peptide) or to the 
sum of all the reference (unmodified internal peptides from BSA or EGFR) 
peptides.   
 
Skyline implementation   
Full support for pSRM using chromatograms extracted from targeted 
MS/MS spectra for peak area calculations was implemented in the Skyline 
software tool, as shown in Figures C1-2 (Appendix C), and released in version 
1.1.  These new features included method export for ThermoFisher LTQ 
instruments as well as chromatogram extraction from MS/MS spectra at targeted 
product ion mass-to-charge ratios, making available for pSRM many existing 
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Skyline features proven in SRM experiments with triple quadrupole mass 
spectrometers. 
 
Statistical methods  
The relationship between response and concentration were modeled by 
applying a weighted least square with the robust linear model using Tukey's bi-
weight to down-weight potential outliers.  This model (23) assumes that 
measurement standard deviation increases linearly with concentration.  The 
model also accounts for non-linear behavior at low concentrations by 
incorporating change-points.  Selection of change points is based on Akaike’s 
information criterion (AIC), where the optimal model is the one with the minimum 
AIC.  The fitted model provided three summary statistics: correlation coefficient 
(r2), slope and coefficient of variation (CV).  The details of the methods have been 
described previously (8, 23).   
 
Results 
 
Overview of analytical approach  
This work describes quantitative analysis of post-translationally-modified 
peptides by pSRM together with either stable isotope dilution (SID) or a new IRP 
method.  The pSRM experiments are targeted MS/MS analyses performed by 
producing a full MS/MS spectrum for each precursor m/z in a target list using a 
linear ion trap mass spectrometer (LTQ Velos).  Transitions are extracted from the 
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full MS/MS or MS3 spectrum and peak areas for transitions are summed and 
normalized to areas for a reference standard.  For stable-isotope dilution (SID), 
the summed peak area is normalized to summed peak areas for transitions from a 
stable isotope labeled peptide standard.  In the IRP method, one or more 
unmodified proteotypic peptides from the target protein serve as the reference 
standard for the modified peptides in the analysis.  Because the target modified 
peptides and the reference standard are present in the same protein, the IRP 
method corrects for variations in recovery of the protein in the analysis.  
Normalized signals increase or decrease with a corresponding increase or 
decrease in the stoichiometry of the modification.  
Experiments performed by Dr. Amy Ham establish a proof-of-concept for 
the IRP method to detect differences in modification stoichiometry.  These 
experiments analyzed synthetic phosphopeptides spiked into a BSA digest 
background.  The peptides, DRVpYIHPF (angiotensin II) and IKNLQpSLDPSH 
(cholecystokinin 10-20), were spiked into the BSA digest at concentrations were 
chosen to mimic the low abundance phosphorylation events that occur in 
biological systems (14) represented a 0.12-14% stoichiometry relative to BSA.   
Concentration response curves generated on an LTQ Velos linear ion trap 
using pSRM for modification specific transitions with strong transition signals.  
These experiments also assess the use of MS3 measurements for quantification 
of protein modifications, in which fragmentations from the neutral loss of 
phosphoric acid from the target phosphopeptide were measured.   
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These analyses demonstrated that the pSRM method generated 
measurements that were comparable in linearity and precision to data generated 
by stable isotope dilution.  CV values ranged from 7.3-15.7% (median 10%) and 
similar values for r2, slope and CV were obtained for both MS/MS and MS3 
measurements.  Although the analyses were done on a linear ion trap with 
automatic gain control (AGC), which limits filling of the trap at higher ion currents 
the IRP-normalized signals appeared linear over a 200-fold concentration range, 
which suggests that AGC has little impact on response under the conditions of our 
analyses.  Dr. Ham’s work thus established essential proof-of-concept for the 
method we applied to quantify site-specific changes in EGFR phosphorylation. 
 
Analysis of six EGFR phosphopeptides in A431 cells 
To assess the performance of the IRP method to perform relative 
quantification of specific phosphorylation sites, the changes in phosphorylation 
levels of EGFR at four phosphotyrosine sites and two phosphoserine sites were 
examined.  Cell culture experiments using A431 cells and 20 minute treatments 
similar to those described in Chapter II (e.g., proliferating cells, EGF stimulated, 
gefitinib treated or cetuximab treated) were performed.  Post-treatment, EGFR 
was immunoprecipitated with cetuximab in the presence of protease and 
phosphatase inhibitors, resolved on an SDS-PAGE gel, and the EGFR-containing 
band was excised and digested in-gel with trypsin (Figure IV-1A and B).  Modified 
peptides corresponding to phosphorylation at sites Y998 (MHLPSPTDSNFpYR), 
Y1110 (RPAGSVQNPVpYHNQPLNPAPSR), Y1173 
 141
(GSHQISLDNPDpYQQDFFPK), Y1197 (GSTAENAEpYLR), S991 
(MHLPpSPTDSNFYR) and S1166 (GSHQIpSLDNPDYQQDFFPK) within EGFR 
were targeted for quantification using pSRM.  Phosphoserine sites (S991 and 
S1166) were also monitored using MS3 of the 98 Da neutral loss ion 
corresponding to the loss of phosphoric acid.  Stable-isotope labeled peptides 
corresponding to sites Y998, Y1110, Y1173 and Y1197 were spiked in prior to 
pSRM analysis to enable comparison of the stable-isotope dilution and IRP 
methods.   
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Figure IV-1 Sample work flow and IRP methodology.  (A) Illustrates the immunoprecipitation (IP) method for EGFR and 
treatment groups utilized in these experiments. After IP, EGFR corresponding band on SDS PAGE gel was excised and 
targeted analysis performed on an LTQ Velos mass spectrometer.  (B) Represents analytical approach for normalizing six 
EGFR phosphorylated peptides to internal reference peptides (IRPs).  IRPs are unmodified peptides within the protein of 
interest, in these experiments EGFR.   
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In addition to the six phosphopeptides, five unmodified peptides from 
EGFR were selected as internal reference (normalization) peptides.  The location 
and domain position in EGFR (extracellular, juxtamembrane, tyrosine kinase or 
cytoplasmic) of each reference and phosphorylated peptide are presented in 
Figure IV-2.  Internal reference peptides were selected based on high signal 
stability, as well as a range of elution times spanning the chromatographic 
separation (Figure IV-3). For each targeted peptide (phosphorylated and 
reference), extracted ion current we selected 3-5 transitions that indicate 
modification specificity and/or generate strong pSRM transition signals. The 
peptide sequences, precursor m/z and specific transitions were extracted and 
listed in Table C1 in Appendix C.  The sum of transitions (peak areas) for 
phosphopeptides was divided by the sum of transitions for each individual internal 
reference peptides from EGFR or its stable-isotope labeled counterpart. Three 
biological replicates were performed for each treatment group and three technical 
LC-pSRM-MS injections for each sample. 
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Figure IV-2. Human epidermal growth factor receptor (hEGFR) amino acid 
sequence. Normalizing and phosphorylated peptides are highlighted in different 
colors. The nonphosphorylated peptides that were chosen to be used as 
normalizing peptides are located in the extracellular (IPLENLQIIR, 
NLQEILHGAVR and EISDGDVIISGNK), juxtamembrane (GLWIPEGEK) and 
tyrosine kinase domains (ITDFGLAK). Two phosphopeptides that we monitored 
are located in the tyrosine kinase domain (MHLPpSPTDSNFYR and 
MHLPSPTDSNFpYR).  The other four phosphopeptides (pY and pS) that were 
monitored are located in the cytoplasmic domain 
(RPAGSVQNPVpYHNQPLNPAPSR, GSHQIpSLDNPDYQQDFFPK, 
GSHQISLDNPDpYQQDFFPK and GSTAENAEpYLR). 
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Figure IV-3.  The retention time for normalizing peptides ranged across the 
peptide elution retention time.  Retention time plots for all internal 
nonphosphorylated reference peptides (top) and stable-isotope labeled pY 
peptides, Y998 – MHLPSPTDSNFpYR, Y1110 – 
RPAGSVQNPVpYHNQPLNPAPSR, Y1172 – GSHQISLDNPDpYQQDFFPK, and 
Y1197 –GSTAENAEpYLR) (bottom). Retention time plots were generated from 
biological replicate three, technical replicate three.  The underlined amino acid 
indicates which amino acid was stable isotope labeled. 
 
 
35 40 45 50 55
0
25
50
75
100
Retention time (min.)
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
 (
%
)
35 40 45 50 55
0
25
50
75
100
Retention time (min.)
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
 (
%
)
pY1172pY1110
pY1197
pY998
ITDFGLAK
EISDGDVIISGNK
NLQEILHGAVR
GLWIPEGEK
IPLENLQIIR
 148
Western blot analysis of EGFR IP 
Immunoblot analysis were performed pre- and post IP for each treatment 
group (proliferating, EGF stimulated, co-treated cetuximab and EGF and co-
treated gefitinib and EGF) for total EGFR, and specific pY sites Y998 and Y1173.  
The amount of receptor phosphorylation at sites Y998 and Y1173 in A431 cells 
analyzed (Figure IV-4)  varied  substantially  with  treatment  group.   EGF treated  
 
 
Figure IV-4.  EGFR IP in A431 cells.  A431 cells not treated, modulated with 
EGF, or co-treated with inhibitor (cetuximab or gefitinib) followed by EGF exhibit 
different EGFR activation statuses. Immunoblot showing EGFR activation prior to 
and after treatment(s) (phosphorylation at Y998 and Y1173).  Both 
phosphorylated forms of the receptor were targeted in the pSRM-MS method.  
Input lane is 5% of total protein load, and IP lane is post- immunoprecipitation.  
Control lanes show the IP performed using mouse IgG.  All treated cells were 
serum-starved overnight prior to any treatment.   
 
 
 
samples had the highest detected signal for EGFR phosphorylation at both 
pY998 and pY1173 sites.  Consistent with data reported in Chapters II and III, 
gefitinib at 500 nM for 20 min decreased phosphorylation at both EGFR tyrosine 
sites near or below basal levels (proliferation), while 10 µg/mL cetuximab 
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treatment for 20 min was less potent at inhibiting EGFR activation.  Thus, EGFR 
phosphorylation detected for 10 µg/mL cetuximab treatments show signals 
significantly less than for EGF treatment, but more than basal levels for both pY 
sites. 
 
 
Comparison of IRP and SID-based quantitation of site-specific phosphorylation in 
EGFR 
 
After generating data for three biological replicates and three technical LC-
pSRM-MS injections for each sample, median %CV plots were generated for each 
internal reference peptide and stable isotope labeled peptide.  The median %CV 
plots were calculated using the three technical replicate analyses performed for 
each treatment, biological replicate and internal reference or stable isotope 
labeled peptide.  Representative data for peptide 
RPAGSVQNPVpYHNQPLNPAPSR can be seen in Figure IV-5.  Each panel 
represents summed peak area signals for one targeted peptide normalized to five 
individual, internal reference peptides and one SID counterpart.  See Appendix C 
Figures C1-5 (A, B and C) for additional CV plots of technical replicate analysis 
from each of three separate cultures.  Median CV values varied considerably for 
IRP measurements with different normalization peptides.   Normalization to the 
EGFR peptide IPLENLQIIR yielded the lowest global CV (median 22%), whereas 
the other normalization peptides NLQEILHGAVR (median 27%), 
EISDGDVIISGNK (median 27%), GLWIPEGEK (median 26%) and ITDFGLAK 
(median 32%) displayed modestly greater variation.  CV values differed between 
distinct biological replicate experiments.  In these studies, biological replicate 
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experiments one and two displayed lower variability, with median CVs from 
different IRP peptides averaging approximately 30%, whereas biological replicate 
experiment three yielded more variation (≥ 50%).  This higher variation was the 
result of individual technical replicate runs, some of which produced low signal 
across the chromatogram.--------------------------------------------------------------------------   
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Figure IV-5. Median CV plots for peptide RPAGSVQNPVpYHNQPLNPAPSR.  The CV’s were calculated by the 
technical replicate analysis on a per treatment basis for each internal reference or stable isotope labeled peptide. (A-C) All 
data (three technical replicates for each treatment) was used to calculate median CV’s for biological replicate one (A), two 
(B) and three (C). The black dashed line represents 15% CV, and the red dashed line represents 30% CV. 
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Because these pSRM analyses were employed ion trap analyzers, ion 
injection times could be compared for low-signal versus high-signal runs.   Figure 
IV-6 shows ion injection time plots for all five IRPs and one SID peptide for all 
technical replicates of biological replicate three only.  These time plots should be 
relatively stable because they represent three technical replicates of the same 
sample; however, technical replicate one shows a substantial difference (typically 
at least one order of magnitude longer) compared to technical replicates two and 
three.  Longer ion injection times reflect reduced ion input, typically because of 
lower sample amounts; Figure IV-6 shows similar differences were obtained for 
the extracted ion current (XIC) (time vs. relative abundance (%) of the same 
peptides, i.e., relative abundance (%) was typically ≤10% of technical replicates 
two and three (Figure IV-6); these XICs should be relatively stable between 
technical replicates.  In comparing Figures IV-6 and 7 to Figures IV-8 and 9, 
which display ion injection times and XIC plots were stable and similar for 
samples that did not generate high median CVs.  The ion injection time and XIC 
plots are both performance metrics described in (24), indicate that technical 
replicate one of biological replicate three was a poor MS analysis. This failed MS 
analysis is responsible for the overall high median CVs in biological replicate 3.  
In all of the experiments, the SID method yielded significantly greater 
measurement precision, with a global median CV of 15%.   
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Figure IV-6. Time vs. ion injection time for EGF treated samples (biological replicate 3).  Data is shown for five 
internal reference peptides and a stable isotope labeled peptide (GSTAENAEpYLR).  The maximum allowable ion 
injection time in these experiments is 100 ms. These data show the ion injection time for technical replicate one (red) was 
drastically different than both technical replicates two and three, i.e., technical replicate one always required a longer ion 
injection time for the same sample, suggesting the instrument was behaving differently during the EGF-treated technical 
replicate one run. These data indicate the reason why large CV values for EGF treated biological replicate three was 
observed. 
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Figure IV-7. Extracted ion chromatograms (time vs. relative abundance (%)) for EGF treated samples (biological 
replicate 3). Data is shown for five internal reference peptides and a stable isotope labeled peptide (GSTAENAEpYLR).  
These data show that the relative abundance (%) for technical replicate one is drastically different than both technical 
replicates two and three, i.e., technical replicate 1 has a low intensity for the same sample, suggesting the instrument was 
behaving significantly different during the EGF treated biological replicate three (technical replicate one run). These data 
indicate the reason why large CV values for EGF-treated biological replicate three were observed. 
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Figure IV-8. Time vs. ion injection time for proliferating samples (biological replicate 3).  Data is shown for five 
internal reference peptides and a stable isotope labeled peptide (GSTAENAEpYLR).  The maximum allowable ion 
injection time in these experiments is 100ms. These data show the ion injection time for technical replicate one was 
similar to both technical replicates two and three, unlike Figure IV-6.  
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Figure IV-9.  Extracted ion chromatograms (time vs. relative abundance (%)) for proliferating samples (biological 
replicate 3).  Data is shown for five internal reference peptides and a stable isotope labeled peptide (GSTAENAEpYLR). 
These data show that the relative abundance (%) for technical replicate one was similar to both technical replicates two 
and three, unlike technical replicate one in Figure IV-7. 
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The data generated by analyses of immunoprecipitated EGFR from 
biological experiment 1 using the IRP and SID methods are shown in Figure IV-
10.  Both methods yielded similar measures of phosphorylation at Y1173 
(GSHQISLDNPDpYQQDFFPK), its stimulation by EGF and inhibition by 
cetuximab and gefitinib (Figure IV-10A and B).  The IRP method displayed nearly 
identical results to SID for all four phosphotyrosine sites (Y998, Y1110, Y1173 
and Y1197) (Figure IV-10C and Figures C6-C9).  These results also are 
consistent with the immunoblot analysis for Y1173 shown in Figure IV-3.  EGF-
treated stimulation produced the highest normalized pSRM signal, whereas 
samples co-treated with 500 nM gefitinib showed profound decreases in Y1173 
phosphorylation to below basal (proliferating) levels.  Co-treatment with 
cetuximab produced less dramatic decreases in Y1173 phosphorylation to near 
basal levels. Figure IV-10C represents the degree of site-specific 
phosphorylation relative to that for EGF stimulation by a phosphorylation index, 
which was calculated as the ratio of the proliferating (P), gefitinib (G+E) or 
cetuximab (C+E) normalized pSRM signal to the EGF-stimulated normalized 
pSRM signal (Eq. 1).   
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Both IRP and SID approaches yielded similar results and consistently detected 
similar phosphorylation status differences between the four treatment groups.   
 
 
  
(Eq. 1) 
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Figure IV-10.  Comparison of IRP and SID approaches for 
(GSHQISLDNPDpYQQDFFPK).    Treatment groups show the same trends when 
pY peptides are normalized to an internal reference peptide or its stable isotope 
labeled counterpart.  EGFR peptide pY1172 (GSHQISLDNPDpYQQDFFPK) 
normalized to an (A) internal reference peptide (IPLENLQIIR) and (B) its pY SID 
peptide standard.  (C) Phosphorylation index for each EGFR pY peptide and cell 
treatment group. Similar trends are observed for each pY targeted peptide after 
normalization to an IRP (red) or its stable isotope labeled counterpart (purple).  
The phosphorylation index is normalized to EGF-stimulated cells(100%).  These 
data represent three technical LC-pSRM-MS injections of biological replicate one.  
ND, not detected in LC-pSRM-MS experiments. The underlined amino acid 
indicates which amino acid was stable isotope-labeled.   
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Analysis of using MS3 measurements for quantification of EGFR phosphoserine 
modifications  
 
For pS and pT peptides MS/MS spectra are dominated by neutral loss of 
H3PO4, measurements based on MS
3 fragmentation of the neutral loss ion offer    
higher   confidence sequence-specific detection.   MS3 measurements for relative 
quantification of phosphoserine modifications were performed on peptides for 
EGFR sites S991 (MHLPpSPTDSNFYR) [M+2H-H3PO4]
2+ and S1166 
(GSHQIpSLDNPDYQQDFFPK) [M+3H-H3PO4]
3+.  Peak areas from MS3 
measurements were normalized to MS/MS-derived peak areas for the 5 EGFR 
IRP sequences described above, as well as to the MS/MS-derived peak areas for 
the isotope-labeled pY peptide standards used for SID analyses of the pY forms 
of these sequences (see above).  Median CV plots for IRP measurements of 
S991 and S1166 phosphopeptides (Figures C4 and C5) indicate that 
normalization to the IPLENLQIIR peptide produced the smallest measurement 
variation overall, which was comparable to that achieved with normalization to the 
synthetic pY SID peptide sequence analogs.  Both analysis methods yielded 
nearly identical estimates of phosphorylation changes induced by EGF and the 
effects of cetuximab and gefitinib (Figure IV-11 and Figures C10 and C11).   
Phosphorylation levels for S991 display a pattern similar to that for the 
four phosphotyrosines described above.  Phosphorylation at S991 increased 
after EGF treatment compared to basal (proliferating) levels and were reversed, 
although not completely, by both inhibitors.  This result differs slightly from those 
seen in Figure IV-10A and B where gefitinib treatment diminished 
phosphotyrosine   signals   below   basal   level.       Similar   results   for   S991  
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Figure IV-11.  MS3 trend plots for two phosphoserine modified peptides 
based on treatment group.  Phosphopeptide pS991 (MHLPpSPTDSNFYR) 
normalized to an (A) IRP or (B) pY SID peptide standard (MHLPSPTDSNFpYR) 
show similar trends.  These data are similar to trends observed for pY peptide 
MHLPSPTDSNFpYR.  Phosphopeptide pS1166 (GSHQIpSLDNPDYQQDFFPK) 
normalized to an (C) IRP or (D) pY SID peptide standard 
(GSHQISLDNPDpYQQDFFPK) show similar trends.  These data show that MS3 
measurements can be used for quantification of protein modifications.  These data 
represent three technical injects of biological replicate two. The underlined amino 
acid indicates which amino acid was stable-isotope labeled. 
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phosphorylation were reported by Stover et al. (25), who used mass spectrometry 
analyses to detect S991 phosphorylation induced by EGF stimulation and 
inhibited by the EGFR inhibitor PK166.    
In contrast, similar analyses of phosphorylation at S1166 
(GSHQIpSLDNPDYQQDFFPK) using both methods indicated a very different 
pattern. EGF treatment produced little or no S1166 phosphorylation, although 
gefitinib further decreased phosphorylation at this site.  The lack of significant 
EGF-induced phosphorylation at S1166 is consistent with a previous study that 
employed a mass spectrometry method (12).  On the other hand, combined 
cetuximab and EGF produced the highest amount of phosphorylation at S1166. 
 
Discussion 
 
The major goal of this work was to evaluate the IRP method for quantifying 
changes in protein PTMs.   Although previous work has reported use of variations 
of this approach (19, 20), these studies detail performance characteristics of the 
method in comparison to SID.  Furthermore, this work describes the 
implementation of MS/MS and MS3-based pSRM measurements on an LTQ Velos 
ion trap instrument.  The pSRM transitions can be extracted from MS/MS and MS3 
data, normalized to peak areas from reference peptides within the same protein, 
thus affording relative quantification of protein modifications.  Unlike MRM, pSRM 
records a full MS/MS spectrum for each monitored peptide, which allows for 
spectrum verification by visual inspection as well as the ability to choose different 
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ions to extract based on PTM site (e.g., pS, pT vs. pY).  As with other MS-based 
methods, IRP analyses can measure multiple site specific phosphorylation sites in 
parallel without the need for site specific antibodies and without potential concerns 
for antibody cross-reactivity or lack of phospho–site specificity.  The method does 
not provide the analytical precision of SID; however, the lack of requirement for 
labeled internal standards, the ease of implementation and the suitability for 
typical quantitative comparisons—as illustrated with the analyses of EGFR 
phosphorylation—all make this method suitable for broad application in protein 
biochemistry.   
Previous label-free quantitation approaches have utilized estimated 
stoichiometry (ES), flyability ratios, the native reference peptide (NRP) method or 
the selected ion tracing method to quantify post-translational modifications (12-
18).  In all of these methods, XICs (ion currents) at the MS level are generated for 
each site specific modification as well as its unmodified peptide complement or an 
unmodified reference peptide.  These methods calculate the stoichiometry (or site 
abundance) of individual post-translationally modified sites by taking the modified 
peptide peak area and normalizing to the sum of modified and unmodified peak 
area (18), to an unmodified reference peptide peak area (15-17) or to the sum of 
unmodified peak area plus the peak area of any other possible sites of 
modification on the target peptide (12).  A key difference between our approach 
and previous methods is the use of MS/MS extracted ion chromatograms rather 
than MS1 data for each modified and reference peptide. Unlike the ES method 
and other MS1-based methods, the pSRM utilizes MS/MS and MS3 data to obtain 
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peptide sequence and site specific localization data, thus allowing quantitation 
even when peptide peaks cannot be resolved by liquid chromatography.   
In the EGFR phosphorylation studies, internal reference peptides were 
chosen such that 1) they were not known to be modified, 2) eluted across the 
chromatogram, 3) displayed consistent signal stability, 4) were observed in 
previous data dependent LC-MS/MS data, and 5) contained between 7 and 20 
amino acids and lacked methionine and cysteine residues.  Phosphopeptides 
were normalized individually to the each of the five internal reference peptides 
(ITDFGLAK, IPLENLQIIR, GLWIPEGEK, NLQEILHGAVR and EISDGDVIISGNK).  
Individual analyses of the internal reference peptides indicated that some internal 
reference peptides showed large differences in the range and median CV plots 
(Figures C1-C5).  The results show that multiple IRPs should be evaluated to 
optimize the performance of the IRP method.  Ultimately, we chose the internal 
reference peptide with the lowest median CV in the dataset.   
We studied biological variations of EGFR phosphorylation in A431 cells 
under 4 treatment conditions.  IRP analyses with all of the internal reference 
peptides except GLWIPEGEK detected the same differences between treatments 
as did SID analyses, which demonstrate that moderate differences in 
measurement variation do not significantly impact the biological conclusions 
drawn from these studies.  In our SID analysis of 4 analyzed phosphotyrosine 
sites in EGFR, median CVs ranged from 5-15%, whereas IRP analyses (using 
reference peptide IPLENLQIIR) of the same 4 sites had median CVs around 20% 
(Figures C1-C5).  Although the median CV for the IRP method was greater than 
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the SID method, the interpretation of phosphorylation differences with both 
methods is identical.  The phosphorylation sites Y998 and Y1173 were also 
monitored with commercially available antibodies and these analyses confirmed 
the mass spectrometry results (Figure IV-4).  By all 3 methods (immunoblot, SID 
and IRP), gefitinib was a more potent inhibitor of EGFR than cetuximab at 
indicated concentrations—immunoblot analyses for Y998 and Y1173 are barely 
above background and both SID and IRP methods for sites Y998, Y1110, Y1173, 
and Y1197 were calculated to have a phosphorylation index <10% when 
compared to EGF-treated cells.   
MS3 analyses for two pS containing peptides in EGFR, 
MHLPpSPTDSNFYR (S991) and GSHQIpSLDNPDYQQDFFPK (S1166), yielded 
results consistent with previous literature reports (12, 25).  Phosphoserine peptide 
S991 follows the same overall changes as the four EGFR pY sites (Y998, Y1110, 
Y1173 and Y1197); with the exception that gefitinib was not a more potent 
inhibitor than cetuximab.  Trends across the different treatment groups were 
consistent whether the MS3 pS peptides were normalized to the isotope-labeled 
pY SID peptide standard or to the internal reference peptide with the lowest 
median CV (IPLENLQIIR).  The effect of EGFR inhibitors on phosphorylation at 
site S1166 and site S991 has not previously been reported.   
In these experiments, the SID and IRP methods were analyzed on a linear 
ion trap mass spectrometer (LTQ Velos), which monitors ≤ 20 peptides in a single 
LC-pSRM-MS experiment.  While pSRM measurements do not provide the same 
throughput as triple quadrupole based MRM analyses (> 30 peptides can be 
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measured with 4 transitions in a single, unscheduled LC-triple quadrupole MRM 
analysis), the added benefit of the peptide sequence confirmation from the full 
MS/MS spectrum and the ability to acquire higher order tandem MS data are 
significant advantages.  The pSRM approach also allows selection of the 
transition after MS/MS analysis and enables quantitative extension of modification 
mapping experiments without transferring methods to another platform.  Our 
results suggest several precautions that can improve the reliability of pSRM 
analyses.  First, multiple technical replicate injections enable assessment of 
instrument performance-based variation due to chromatography, detectors, ion 
injection times, and signal intensity.  Second, an IRP method should incorporate 
multiple internal reference peptides to provide confirmatory results, to identify 
peptides with the lowest variation and to minimize error due to ion suppression 
effects, and co-eluting interferences.  In our studies, we observed a consistently 
poor performing internal reference peptide, GLWIPEGEK, which generated large 
variations in both CV normalized pSRM signal (Figures C1-C5) and which 
generated EGF- and inhibitor-related phosphorylation differences inconsistent 
with analyses using the other internal reference peptides.  Arbitrary selection of a 
single reference peptide would not have detected this effect.   
We employ IRP analyses for analyses of modifications on individual 
proteins in relatively simple samples, such as immunoprecipitated proteins or 
proteins isolated from SDS-PAGE gel bands.  We have not considered and do not 
recommend the IRP approach for global analyses of modified proteins in complex 
proteomes.  In the appropriate context, the IRP method is intended to estimate 
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differences in protein modifications between similar samples.  The data are 
comparable in measurement variation to immunoblot analyses (CVs up to 40%).  
MS-based analyses by both the IRP and SID methods are able to selectively 
measure many site-specific changes for which reliable antibody reagents are 
unavailable.  IRP analyses display lower precision than SID analyses, but are 
useful in many applications where high precision is not required.  IRP-based 
methods also do not labeled peptide standards, which add significantly to analysis 
costs.  In the context of targeted biochemical analyses, the IRP method accounts 
for variations in immunoprecipitation or affinity capture efficiency, gel fractionation 
and protein digestion.  The IRP method also accounts for variability in both 
biological and technical replicates.  These features make the IRP method a 
flexible, general approach for comparative analysis of protein modifications which 
can find widespread application in biochemical analyses.   
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CHAPTER V 
 
PERSPECTIVE 
  
Contributions and General considerations 
 
Summary 
The hypothesis underlying this work was that differences in global protein 
expression levels can produce distinct protein changes indicative of a cellular 
response to EGFR signaling modulation.  The studies detailed in Chapters II and 
III prove the hypothesis and present a robust approach to identify differential 
protein signatures as indicators of anti-EGFR therapy.  In addition, Chapter IV 
defines the performance characteristics of a new quantitative approach for 
detecting phosphorylated peptides.  Together, these approaches represent 
powerful tools for studying molecular signaling events of EGFR activation and 
inhibition.  
  
Current practices and limitations 
Protein and phosphoprotein analyses in tumor tissues by reverse phase 
protein array methods have identified putative signatures for EGFR inhibitor 
responses (1-4).  These approaches can be very powerful but require availability 
of high-quality antibodies for detection and assay development generally lags 
behind identification of putative targets.   Moreover, immunoassays can be 
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affected by non-specific reactions and can fail if a relevant epitope has been 
removed by conformational changes, proteolysis, or posttranslational 
modifications.   
Studies in cell models using global phosphoproteomics and targeted 
analysis of EGF pathway phosphoprotein intermediates have provided the most 
comprehensive analyses of EGFR-driven signaling networks (5-8).  However, 
phosphoproteomic analysis of tissue specimens is complicated by sample 
heterogeneity, limiting amounts of available tissue, and low abundance of 
modified peptides (analyses typically require affinity enrichment of 
phosphorylated proteins) (5, 9-11).  In addition, the transient nature of 
phosphorylation modifications also presents the challenge of preserving 
phosphorylation status during sample preparation.  Acquisition practices for 
biopsies and surgical resections do not permit rigorous control of preanalytical 
variables, such as ischemic time and temperature, which trigger stress 
responses that may obscure the status of network intermediates in vivo (12-14).  
Despite the rapid growth of information about EGFR signaling networks, 
identification of robust molecular markers linking network status and therapeutic 
response remains a challenge.   
 
A new approach 
Given above limitations in current practices, more robust approaches to 
measure signaling networks are needed to overcome the shortcomings of direct 
phosphoproteome and antibody-based analyses.  In this research, a core group 
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of proteins including Jagged, JUN and CLDN4 shared responses in all of the 
EGFR inhibitor-sensitive models including mouse xenograft (FFPE blocks) and 
tissue biopsies from a MD patient.  While data for these proteins were in 
agreement in models, further validation is required to develop a clinically relevant 
assay.  The main objective of this work was to determine whether protein 
expression signatures can represent the effects of drugs on a signaling network, 
rather than to develop and refine a clinically useful signature of EGFR sensitivity.  
The combine results of Chapters II and III illustrate the utility of this approach to 
identify and verify proteins differences between treatment conditions and across 
multiple biological systems and illuminate this platform as a viable option to 
investigate other signaling pathways in a similar systematic approach.  A key 
benefit of using the LRP method to quantitate target peptides is the ease and 
speed of assay development (i.e., leads identified today can translate into 
targeted assays tomorrow).  
Further investigations specific to this experimental approach should be 
considered as well.  For example, cetuximab and gefitinib inhibit EGFR via two 
different modes (15-17).  Thus, differential proteins found exclusively in one 
signature or the other could represent the distinctly different molecular events 
underlying each mechanism of inhibition.  In the global shotgun data, clusterin 
was found to be two fold higher in gefitinib-treated cells than in EGF-treated cells 
while cetuximab had no effect on expression of clusterin.  This is intriguing, as 
clusterin has been reportedly involved in regulation of cell proliferation and as a 
pro-survival factor (18, 19).   
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In addition, further MRM studies of the proposed EGFR inhibition signature 
should be pursued at a variety of time points in both EGFR-sensitive and EGFR- 
resistant cell models to better understand the temporal characteristics of the 
responding proteins.  The model presented in this dissertation research 
represents early signaling responses to acute treatment of a system with EGFR-
targeted drugs; however, analyses of the protein signature in longer treatment 
settings would provide a more complete picture of the underlying biology.  
It is unarguable that cultured cells and intact tissues present clear 
differences that may affect response to EGF and inhibitors.  Indeed, a systematic 
assessment of factors affecting cell versus tissue responses to EGFR modulation 
is certainly beyond the scope of this work although necessary to illuminate the 
distinct mechanisms in each system.  Global shotgun analysis of the DiFi and 
HCT-116 cells compared to corresponding xenograft tissue analyses could 
provide insight into the molecular differences between in vitro and in vivo models 
of signaling modulation; however, uncontrollable variables in vivo such as 
endogenous expression of ligands at various concentrations and exposures 
complicate a direct comparison between models.  Furthermore, sample storage 
must be accounted for in this analysis since the xenograft samples are FFPE 
while the cell culture samples are flash frozen (20).   
 
Pre-clinical application and companion diagnostics 
Perhaps a more far-reaching application of the described platform is as a 
tool for identifying “companion biomarkers”.  The term "companion biomarker" 
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means that a particular diagnostic test is specifically linked to a therapeutic drug 
either in drug development or in the clinic. Companion biomarkers assist in the 
stratification and sub-classification of patient disease types in an effort to 
optimize therapy (21, 22).  For example, an IHC-based test for Her2 (23) is used 
to determine the suitability of patients for anti-Her2 therapy.  However, the ability 
of Her2 expression status to predict the benefit of trastuzumab is a subject of 
much debate, as it seems to be modest at best with a positive predictive value 
(PPV) usually in the region of 25–40% (24).  IHC has numerous limitations—
technical and interpretative—that impact reproducibility and accuracy as 
demonstrated by poor correlation between Her2 testing and predicting (25).  
Furthermore, KRAS mutation was found, in retrospective analyses, to be 
correlated with absence of response to anti-EGFR therapies (26).  Indeed, KRAS 
is considered a predictive drug-response-specific biomarker and anti-EGFR 
therapies are no longer recommended for patients harboring KRAS mutation 
(27). 
The combined global identification and LRP verification platform is well-
suited to help fill the gap between cell culture and clinic.  The LRP method is a 
cost-effective approach in the discovery phase when new targets are being 
identified through in vitro models, in a preclinical setting when large numbers of 
putative candidates are being screened, or in retrospective analyses of archival 
FFPE tissues.  Challenges remain in validating and translating initial markers or 
signatures generated using defined in vitro models to in vivo systems.  
Systematic development of protein signatures for clinical use entails 1) multiple 
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discovery systems to generate a more broadly-based candidate signature, 2) 
integration of quantitative measurements with a valid statistical model to 
establish score thresholds and account for variability and 3) validation in a 
carefully selected, valid patient cohort.   
Indeed more investigations are required for the clinical validation of a 
specific signature of EGFR inhibitor response.  Nevertheless, some of the 
proteins identified in this study would appear likely to contribute to a clinically 
useful EGFR inhibition protein profile.  This research establishes proof-of-
concept for this approach by demonstrating that protein expression signatures 
detect activation and inhibition of dynamic signaling networks.  Clinically useful 
response signatures developed through this approach could have broad impact 
in the field of cancer therapeutics. Although the path of translating protein 
differentials identified in vitro to clinically useful biomarkers presents a gauntlet of 
obstacles prior to candidate validation, this research provides data illustrating the 
described approach as a progressive step in the rigorous process of identifying 
companion biomarkers.   
 
Conclusion 
In summary, the LRP method was employed to validate protein differences 
observed from shotgun analyses in EGFR drug treated A431 cells.  An EGFR 
inhibition signature targeted assay developed in a model system was applied 
across several biological contexts including additional cell models, mouse 
xenograft models, and human tissues samples.  The data show the success of the 
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approach in detecting differential responses to EGFR stimulation and inhibition 
and suggest a wide range of applications to investigate other signaling networks 
as well as a potential use in clinical samples to characterize patient response to 
drug treatment.   
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APPENDIX A 
 
Data to Chapter II: 
 
CELL MODELS FOR EGFR ACTIVATION AND INHIBITION AND INITIAL 
EVALUATION OF GLOBAL PROTEIN EXPRESSION CHANGES 
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Figure A1.  No effect from gefitinib DMSO control.   Proliferating cells (P), 
EGF-stimulated (E), Gefitinib (500 nM) plus EGF (G) Cetuximab (10 µg/mL) plus 
EGF (C), and DMSO plus EGF control (D).  Treated A431 and DiFi cells were 
serum-starved overnight before being treated with either 30 nM EGF alone or co-
treated with inhibitor and EGF for 4 h.  Proliferating cells were not serum starved 
and serve as a reference control for basal level signaling.  Immunoblots were 
performed for total EGFR and phosphorylation at Y1173 (Cell signaling #4267s, 
4407s ).  β-actin was used as a loading control. 
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Figure A3.  Peptide identification distribution.   Treated A431 cells were serum-starved overnight before being treated for 30 min 
with 30 nM EGF or gefitinib (500 nM) plus EGF or cetuximab (10 µg/mL) plus EGF.  Proliferating cells were not serum-starved.  
Graphs show number of peptides identified per gel fraction.  Each bar is representative of a single MS analysis. 
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Figure A4.  Proteins up- and down-regulated in EGF versus proliferating conditions.   Up (red) and down (green) 
regulated proteins (relative to EGF) with ≥6 spectra per protein, ≥1.5 fold change and quasi p-value ≤ 0.05 identified from 
EGF versus proliferating comparison datasets. 
Comparison
EGF Stimulated
vs
Proliferating
EGF stimulated
vs
Gefitinib+EGF
EGF stimulated
vs
Cetuximab+EGF
Proteins 2298 2488 2393
FDR(%) 2.2 1.7 1.7
Proteins 42 33 65
Proteins  filtered for a Quasi p-value ≤ 0.05 
& ≥ 1.5 Fold Change
ATP6V0D1 ATPase, H+ transporting, lysosomal 38kDa, V0 subunit d1 
ATP6V1B2 ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit B2
CD47 CD47 molecule
COL12A1 collagen, type XII, alpha 1
CUL2 cullin 2
EIF2S1 eukaryotic translation initiation factor 2, subunit 1 alpha, 35kDa
FARSA phenylalanyl-tRNA synthetase, alpha subunit
LPCAT1 lysophosphatidylcholine acyltransferase 1
MSH2 mutS homolog 2, colon cancer, nonpolyposis type 1 (E. coli)
NOC3L nucleolar complex associated 3 homolog (S. cerevisiae)
NT5DC1 5'-nucleotidase domain containing 1
PSMC1 proteasome (prosome, macropain) 26S subunit, ATPase, 1
PSMD7 proteasome (prosome, macropain) 26S subunit, non-ATPase, 7
RAB21 RAB21, member RAS oncogene family
REEP5 receptor accessory protein 5
RPS26 Ribosomal protein S26
SARNP SAP domain containing ribonucleoprotein
UGP2 UDP-glucose pyrophosphorylase 2
HYOU1 hypoxia up-regulated 1
ATP1A2 ATPase, Na+/K+ transporting, alpha 2 (+) polypeptide
L2HGDH L-2-hydroxyglutarate dehydrogenase
PACSN2 protein kinase C and casein kinase substrate in neurons 2
ACAT1 acetyl-Coenzyme A acetyltransferase 1
RPS23 ribosomal protein S23
SH3GLB1 SH3-domain GRB2-like endophilin B1
LTF Lactotransferrin
PLIN3 perilipin 3
CHP calcium binding protein P22
SUCLG2 succinate-CoA ligase, GDP-forming, beta subunit
OGFR opioid growth factor receptor
ARPC1B actin related protein 2/3 complex, subunit 1B, 41kDa
NDUFV1 NADH dehydrogenase (ubiquinone) flavoprotein 1, 51kDa
ACO2 aconitase 2, mitochondrial
CYB5B cytochrome b5 type B (outer mitochondrial membrane)
HIBCH 3-hydroxyisobutyryl-Coenzyme A hydrolase
IDH2 isocitrate dehydrogenase 2 (NADP+), mitochondrial
SPCS3 signal peptidase complex subunit 3 homolog (S. cerevisiae)
SR140 U2-associated SR140 protein
MRPL47 mitochondrial ribosomal protein L47
SEC23IP SEC23 interacting protein 
CAPR1 Carpin-1 Isoform 2 
RRFM Ribosome recyling factor 
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Figure A5.  Proteins up- and down-regulated in EGF versus cetuximab-treated conditions.   Up (red) and down 
(green) regulated proteins (relative to EGF) with ≥6 spectra per protein, ≥1.5 fold change and quasi p-value ≤0.05 identified 
from EGF versus cetuximab comparison datasets. 
  
Comparison
EGF Stimulated
vs
Proliferating
EGF stimulated
vs
Gefitinib+EGF
EGF stimulated
vs
Cetuximab+EGF
Proteins 2298 2488 2393
FDR(%) 2.2 1.7 1.7
Proteins 43 60 31
Proteins  filtered for a Quasi p-value ≤ 0.05 
& ≥ 1.5 Fold Change
CHD3 Chromodomain-helicase DNA binding protein
HIST1H1A histone cluster 1, H1a
MACF1 microtubule-actin crosslinking factor 1 
MAT2B methionine adenosyltransferase II, beta
NOSIP nitric oxide synthase interacting protein
NT5DC1 5'-nucleotidase domain containing 1
RPS26 Ribosomal protein S26
RPS6 ribosomal protein S6
ACSL4 acyl-CoA synthetase long-chain family member 4
BRIX1 BRX1, biogenesis of ribosomes, homolog (S. cerevisiae)
CYB5B cytochrome b5 type B (outer mitochondrial membrane)
DDX23 DEAD (Asp-Glu-Ala-Asp) box polypeptide 23
FUS fusion (involved in t(12;16) in malignant liposarcoma)
H2AFY2 H2A histone family, member Y2
HYOU1 hypoxia up-regulated 1
MCM3 minichromosome maintenance complex component 3
ME1 malic enzyme 1, NADP(+)-dependent, cytosolic
NLRP2 NLR family, pyrin domain containing 2
NOLC1 nucleolar and coiled-body phosphoprotein 1
PGM1 phosphoglucomutase 1
PSMD2 proteasome (prosome, macropain) 26S subunit, non-ATPase, 2
PYGB phosphorylase, glycogen; brain
SFRS9 splicing factor, arginine/serine-rich 9
Stat3 Signal transducer and activator of transcription 3
STIP1 stress-induced-phosphoprotein 1
TBL1XR1 transducin (beta)-like 1 X-linked receptor 1
TIAL1 TIA1 cytotoxic granule-associated RNA binding protein-like 1
USP10 ubiquitin specific peptidase 10
USP5 ubiquitin specific peptidase 5 (isopeptidase T)
VPS29 vacuolar protein sorting 29 homolog (S. cerevisiae) 
WDR77 WD repeat domain 77
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Figure A6.  Proteins up- and down-regulated in EGF versus gefitinib-treated conditions.   Up (red) and down (green) 
regulated proteins (relative to EGF) with ≥6 spectra per protein, ≥1.5 fold change and quasi p-value ≤0.05 identified from 
EGF versus gefitinib comparison datasets. 
Comparison
EGF Stimulated
vs
Proliferating
EGF stimulated
vs
Gefitinib+EGF
EGF stimulated
vs
Cetuximab+EGF
Proteins 2298 2488 2393
FDR(%) 2.2 1.7 1.7
Proteins 20 60 31Proteins  filtered for a Quasi p-value ≤ 0.05 
& ≥ 1.5 Fold Change
ARPC4 actin related protein 2/3 complex, subunit 4, 20kDa
BTAF1
BTAF1 RNA polymerase II, B-TFIID transcription factor-
associated, 
DNM2 dynamin 2
DNM3 dynamin 3
EIF2S3 eukaryotic translation initiation factor 2, subunit 3 gamma, 52kD
EVPL envoplakin
KRAS v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog
MAP4 microtubule-associated protein 4
MYH14 myosin, heavy chain 14
PAFAH1B3 platelet-activating factor acetylhydrolase, isoform Ib, subunit 3 
PPP1R12A protein phosphatase 1, regulatory (inhibitor) subunit 12A 
ABCD3 ATP-binding cassette, D (ALD), member 3 
AGK acylglycerol kinase
AP2M1 adaptor-related protein complex 2, mu 1 
BRIX1 BRX1, biogenesis of ribosomes, 
COASY Coenzyme A synthase
CSNK2A2 casein kinase 2, alpha prime polypeptide
CTBL1 Beta-catinin protein like-1
DAK dihydroxyacetone kinase 2
EPCAM epithelial cell adhesion molecule
ETF1 eukaryotic translation termination factor 1
HIBCH 3-hydroxyisobutyryl-Coenzyme A hydrolase
HSDL2 hydroxysteroid dehydrogenase like 2
LSR lipolysis stimulated lipoprotein receptor
LYZ lysozyme (renal amyloidosis)
MAPK3 mitogen-activated protein kinase 3
MRPL47 mitochondrial ribosomal protein L47
NDUFV1 NADH dehydrogenase flavoprotein 1,
NLRP2 NLR family, pyrin domain containing 2
NPEPPS aminopeptidase puromycin sensitive
OGFR opioid growth factor receptor
P4HA1 prolyl 4-hydroxylase, alpha polypeptide I
PGM1 phosphoglucomutase 1
PIGT phosphatidylinositol glycan anchor, class T
PLRG1 pleiotropic regulator 1 (PRL1)
POLR2H polymerase (RNA) II polypeptide H
PPP1R1
0 protein phosphatase 1, regulatory subunit 10
PSB5 Proteosome subunit bet S5
PSIP1 PC4 and SFRS1 interacting protein 1
PSMD2 Proteasome 26S subunit, non-ATPase, 2
PSMD4 Proteasome 26S subunit, non-ATPase, 4
PYGB phosphorylase, glycogen; brain
RCN1 reticulocalbin 1, EF-hand calcium binding domain
ROA3 Nuclear Riboprotein A3
RPL23A ribosomal protein L23a
SAR1A SAR1 homolog A (S. cerevisiae)
SCARB1 scavenger receptor class B, member 1
SCP2 sterol carrier protein 2
SDHB
succinate dehydrogenase, subunit B, iron 
sulfur (Ip)
SLC25A10
solute carrier family 25 dicarboxylate
transporter-10)
SPTBN2 spectrin, beta, non-erythrocytic 2
SRP72 signal recognition particle 72kDa
SRPRB signal recognition particle receptor, B subunit
STIP1 stress-induced-phosphoprotein 1
TIAL1 TIA1 cytotoxic granule-associated RBP-like 1
TNPO1 transportin 1
TTLL12 tubulin tyrosine ligase-like family, member 12
UCHL5 ubiquitin carboxyl-terminal hydrolase L5
USP5 ubiquitin specific peptidase 5 (isopeptidase T)
WDR18 WD repeat domain 18
Proteins  filtered for a Quasi p-value ≤ 0.05 
& ≥ 1.5 Fold Change
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Table A1.  MRM data for LC-MRM targeted proteins depicted in Figure II- 8.  Pre. m/z = precursor mass to charge 
ratio, Protein = HUGO name, NPA = normalized peak area, Std. Dev. = standard deviation, CV = coefficient of variation.  
Pro = proliferating cells, EGF = EGF-stimulated (30 nM for 30 min), GEF = gefitinib (500 nM) and EGF treated, CET = 
cetuximab (10 µg/mL) and EGF-treated.  Data is representative of three separate cultures.   All precursor m/z have a 
charge of 2+ unless otherwise noted. 
               
PeptideSequence Pre. m/z Protein NPA 
Std. 
Dev. 
CV 
(%) 
NPA 
Std. 
Dev. 
CV 
(%) 
NPA 
Std. 
Dev. 
CV 
(%) 
NPA 
Std. 
Dev. 
CV 
(%) 
   
PRO PRO PRO EGF EGF EGF GEF GEF GEF CET CET CET 
FNPETDYLTGTDGK 926.9832 ACO2 0.0547 0.0051 9.38 0.0632 0.0088 13.90 0.0537 0.0072 13.44 0.0621 0.0032 5.17 
ALAPSAECPIAEENLAR 906.4515 MCM3A 0.0836 0.0045 5.38 0.1511 0.0347 22.95 0.1491 0.0225 15.11 0.2576 0.0675 26.20 
AIYHDLEQSIR 672.8490 PACN2 0.1133 0.0133 11.74 0.0886 0.0014 1.59 0.1201 0.0226 18.84 0.0925 0.0233 25.16 
VDLGVLGK 400.7475 PGM1 0.1959 0.0075 3.84 0.1840 0.0521 28.30 0.1855 0.0191 10.28 0.1925 0.0019 1.00 
HNALIQEVISQSR 747.9048 CUL2 0.2267 0.0125 5.49 0.3254 0.0472 14.50 0.3949 0.0369 9.34 0.3409 0.0380 11.14 
DFYELEPEK 585.2717 PYGB 0.3135 0.0042 1.33 0.3170 0.0849 26.78 0.3424 0.0481 14.05 0.3747 0.0607 16.19 
TDLHAFENLEIIR 524.2790 EGFR  0.5447 0.0375 6.89 0.5360 0.0388 7.23 0.5509 0.0942 17.10 0.5869 0.0227 3.87 
YFDLGLPNR 547.785 IDH2 0.550 0.035 6.34 0.437 0.013 3.01 0.452 0.016 3.56 0.422 0.049 11.70 
GIFASGSPFK 505.7689 ME1 0.7881 0.0559 7.09 0.9736 0.1578 16.20 0.9597 0.0539 5.62 0.9371 0.1074 11.46 
MATEVAADALGEEWK 810.8823 RPS6 0.8953 0.0108 1.20 2.2385 0.0465 2.08 1.5933 0.2071 13.00 1.3998 0.1400 10.00 
CGPMVLDALIK 608.8251 SDHB 1.1818 0.0401 3.39 1.3417 0.1479 11.02 1.2692 0.1166 9.18 1.4737 0.1117 7.58 
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Figure A7.  MRM data for analysis of glycolysis pathway-associated proteins.   Shows normalized peak area (NPA) 
quantified from one unique peptide for each target protein across three separate cultures. Pro=proliferating cells, 
EGF=EGF stimulated (30 nM) for 30 min, GEF=gefitinib (500 nM) and EGF-treated for 30 min, CET=cetuximab (10 µg/mL) 
and EGF-treated for 30 min.  LDHB=lactate dehydrogenase B, HK2=hexokinase 2, SLC2A12=solute carrier family 2 
member 12, HK3=hexokinase 3, SLC5A1=solute carrier family 5 member 1, PKM2=pyru8vate kinase (muscle), 
GAPDH=glyceraldehyde-3-phosphate dehydrogenase.  (*) Denotes significant difference between EGF-treated A431 cells 
as determined by Student’s two-tailed, unpaired t-test.------------------------------------------------------------------------------------------                
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Table A2.   MRM data for glycolysis pathway-associated proteins depicted in Figure A7.  Pre. m/z = precursor mass 
to charge ratio, Protein = HUGO name, NPA = normalized peak area, Std. Dev. = standard deviation, CV = coefficient of 
variation.  Pro = proliferating cells, EGF = EGF-stimulated (30 nM for 30 min), GEF = gefitinib (500 nM) and EGF treated, 
CET = cetuximab (10 µg/mL) and EGF-treated.  Data is representative of three separate cultures.  All precursor m/z have a 
charge of 2+ unless otherwise noted. 
 
PeptideSequence Pre. m/z Protein NPA 
Std. 
Dev. 
CV 
(%) 
NPA 
Std. 
Dev. 
CV 
(%) 
NPA 
Std. 
Dev. 
CV 
(%) 
NPA 
Std. 
Dev. 
CV 
(%) 
   
Pro Pro Pro EGF EGF EGF GEF GEF GEF CET CET CET 
DYSVTANSK 492.735 LDHB 0.0822 0.0105 12.72 0.0762 0.0120 15.69 0.0775 0.0212 27.39 0.0671 0.0042 6.26 
NVELVEGEEGR 615.802 HK2 0.1246 0.0072 5.78 0.1528 0.0285 18.64 0.1285 0.0344 26.75 0.1455 0.0086 5.89 
ALSDTTEELTVIK 710.382 SLC2A12 0.2697 0.0377 13.97 0.3676 0.0877 23.86 0.3380 0.0510 15.09 0.3284 0.0509 15.51 
ATPDGSER 416.693 HK3 0.3108 0.0183 5.90 0.4160 0.0596 14.34 0.3790 0.0309 8.15 0.4302 0.0483 11.22 
GTVGGFFLAGR 541.293 SLC5A1 0.4119 0.0535 12.98 0.4503 0.0967 21.47 0.4133 0.0596 14.42 0.4178 0.0463 11.08 
EAEAAIYHLQLFEELR 644.667 PKM2 0.8823 0.1197 13.57 0.9597 0.1386 14.45 0.9094 0.0878 9.65 0.8979 0.1148 12.79 
AAFNSGK 347.680 GAPDH 9.5663 0.9951 10.40 11.9845 1.1479 9.58 9.9483 0.7025 7.06 10.3648 0.4264 4.11 
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Figure A8.  MRM data for analysis of tricarboxylic acid cycle-associated proteins.   Shows normalized peak area 
(NPA) quantified from one unique peptide for each target protein across three separate cultures. Pro = proliferating cells, 
EGF = EGF-stimulated (30 nM) for 30 min, GEF = gefitinib (500 nM) and EGF-treated for 30 min, CET = cetuximab (10 
µg/mL) and EGF-treated for 30 min.  DLD=dihydrolipoamide dehydrogenase, ACO1=aconitase 1, IDH3A=isocitrate 
dehydrogenase 3A, PC=pyruvate carboxylase, IDH3G=isocitrate dehydrogenase 3 (NAD+) gamma 
PCK2=phosphoenolpyruvate carboxykinase 2, DLAT=dihydrolipoamide S-acetyltransferase, SUCLG2=succinate-CoA 
ligase, GDP-forming, beta subunit, MDH1=malate dehydrogenase 1, ACLY=ATP citrate lyase, IDH1=isocitrate 
dehydrogenase 1, PDHB=pyruvate dehydrogenase beta, PDHA1=pyruvate dehydrogenase alpha 1, CS=citrate synthase 
and MDH2=malate dehydrogenase 1.  (*) Denotes significant difference between EGF treated A431 cells as determined by 
Student’s two-tailed, unpaired t-test.    
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Table A3.   MRM data for tricarboxylic acid cycle-associated proteins depicted in Figure A8. Pre. m/z = precursor 
mass to charge ratio, Protein = HUGO name, NPA = normalized peak area, Std. Dev. = standard deviation, CV = 
coefficient of variation.  Pro = proliferating cells, EGF = EGF-stimulated (30 nM for 30 min), GEF = gefitinib (500 nM) and 
EGF-treated, CET = cetuximab (10 µg/mL) and EGF-treated.  Data is representative of three separate cultures. All 
precursor m/z have a charge of 2+ unless otherwise noted.    
 
               
PeptideSequence Pre. m/z Protein NPA 
Std. 
Dev. 
CV 
(%) 
NPA 
Std. 
Dev. 
CV 
(%) 
NPA 
Std. 
Dev. 
CV 
(%) 
NPA 
Std. 
Dev. 
CV 
(%) 
   
PRO PRO PRO EGF EGF EGF GEF GEF GEF CET CET CET 
ADGGTQVIDTK 552.780 DLD 0.0500 0.0006 1.28 0.0577 0.0097 16.85 0.0469 0.0062 13.29 0.0656 0.0068 10.31 
FVEFFGPGVAQLSIADR926.983 ACO1 0.0547 0.0051 9.38 0.0663 0.0088 13.26 0.0537 0.0072 13.44 0.0621 0.0032 5.17 
NVTAIQGPGGK 521.288 IDH3A 0.1183 0.0214 18.08 0.1217 0.0210 17.22 0.1189 0.0084 7.04 0.1342 0.0177 13.17 
DFTATFGPLDSLNTR 827.907 PC 0.1303 0.0049 3.76 0.1829 0.0161 8.79 0.1353 0.0109 8.02 0.1641 0.0143 8.74 
LGDGLFLQCCR 669.818 IDH3G 0.2441 0.0362 14.84 0.2876 0.0777 27.02 0.3088 0.0046 1.50 0.2612 0.0059 2.27 
EVLAELEALER 636.346 PCK2 0.2522 0.0244 9.68 0.4270 0.0279 6.52 0.3161 0.0229 7.23 0.3684 0.0197 5.36 
GVETIANDVVSLATK 758.914 DLAT 0.5712 0.0578 10.12 0.6084 0.0248 4.08 0.6180 0.0967 15.65 0.5904 0.0188 3.19 
EQIDIFEGIK 596.316 SUCLG2 0.4621 0.0911 19.71 0.5258 0.0434 8.26 0.5421 0.0302 5.56 0.5068 0.0297 5.86 
GEFVTTVQQR 582.804 MDH1 0.8579 0.0276 3.22 0.9482 0.0619 6.52 0.9192 0.0495 5.39 0.8649 0.0364 4.21 
FGGALDAAAK 460.745 ACLY 0.8922 0.0390 4.38 0.8374 0.0770 9.20 0.8301 0.0458 5.51 0.9162 0.0255 2.78 
DIFQEIYDK 585.788 IDH1 1.0673 0.1500 14.05 1.2144 0.1035 8.52 1.2435 0.1895 15.24 1.1705 0.0956 8.17 
DFLIPIGK 451.771 PDHB 1.3994 0.1392 9.94 1.6418 0.6547 39.88 1.9155 0.3073 16.04 1.8533 0.1351 7.29 
EILAELTGR 501.285 PDHA1 1.8516 0.1383 7.47 2.4620 0.1940 7.88 2.0650 0.0666 3.22 2.1777 0.0509 2.34 
FVEGLPINDFSR 697.359 MDH1 2.3160 0.2803 12.10 0.3200 0.0355 11.11 0.2454 0.0117 4.75 2.9115 0.2677 9.19 
GLVYETSVLDPDEGIR 881.947 CS 4.5215 0.5809 12.85 5.1485 0.5491 10.67 4.1054 0.3759 9.16 4.2636 0.2184 5.12 
GYLGPEQLPDCLK 745.371 MDH2 6.3996 0.4287 6.70 8.4708 1.0878 12.84 6.8216 0.3710 5.44 7.6578 0.4968 6.49 
               
               
               
194 
 
 
Figure A9.   MRM data for analysis of pentose phosphate pathway-associated proteins.   Shows normalized peak 
area (NPA) quantified from one unique peptide for each target protein across three separate cultures. Pro = proliferating 
cells, EGF = EGF-stimulated (30 nM) for 30 min, GEF = gefitinib (500 nM) and EGF treated for 30 min, CET = cetuximab 
(10 µg/mL) and EGF-treated for 30 min.  GSR=glutathione reductase, H6PD=hexose-6-phosphate dehydrogenase, 
DERA=deoxyribose-phosphate aldolase, PGLS=6-phosphogluconolactonase, PGD=phosphogluconate dehydrogenase, 
G6PD=glucose-6-phosphate dehydrogenase, TKT=transketolase, TALDO1=transaldolase 1, ALDOA=aldolase A, fructose-
bisphosphate and PKLR=pyruvate kinase, liver and RBC.  (*) Denotes significant difference between EGF-treated A431 
cells as determined by Student’s two-tailed, unpaired t-test.------------------------------------------------------------------------------------   
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Table A4.   MRM data for pentose phosphate pathway-associated proteins depicted in Figure A9. Pre. m/z = 
precursor mass to charge ratio, Protein = HUGO name, NPA = normalized peak area, Std. Dev. = standard deviation, CV 
= coefficient of variation.  Pro = proliferating cells, EGF = EGF-stimulated (30 nM for 30 min), GEF = gefitinib (500 nM) and 
EGF-treated, CET = cetuximab (10 µg/mL) and EGF-treated.  Data is representative of three separate cultures.  All 
precursor m/z have a charge of 2+ unless otherwise noted. 
               
Peptide Sequence Pre. m/z Protein NPA 
Std. 
Dev. 
CV 
(%) 
NPA 
Std. 
Dev. 
CV 
(%) 
NPA 
Std. 
Dev. 
CV 
(%) 
NPA 
Std. 
Dev. 
CV 
(%) 
   
Pro Pro Pro EGF EGF EGF GEF GEF GEF CET CET CET 
YGIENVK 411.721 GSR 0.0509 0.0025 4.96 0.0701 0.0131 18.69 0.0754 0.0106 14.06 0.0685 0.0060 8.82 
LLDFEFSSGR 585.793 H6PD 0.1248 0.0132 10.61 0.1731 0.0254 14.66 0.1522 0.0172 11.32 0.1660 0.0071 4.26 
IGASTLLSDIER 637.851 DERA 0.2113 0.0344 16.29 0.2885 0.0355 12.31 0.2481 0.0321 12.94 0.2426 0.0106 4.38 
TVIFVATGEGK 561.314 PGLS 0.3583 0.0203 5.67 0.4956 0.0706 14.24 0.4742 0.0472 9.96 0.4584 0.0169 3.68 
NPELQNLLLDDFFK 853.443 PGD 0.7246 0.0186 2.56 0.9382 0.0854 9.10 0.7062 0.0803 11.37 0.8297 0.0121 1.45 
DGLLPENTFIVGYAR 832.936 G6PD 1.1034 0.0457 4.14 1.3762 0.1442 10.48 1.3590 0.0381 2.80 1.2679 0.0538 4.25 
AVELAANTK 458.759 TKT 1.1682 0.0438 3.75 1.4472 0.0697 4.82 1.2164 0.1099 9.03 1.3416 0.0842 6.28 
AAQASDLEK 466.738 TALDO1 3.0914 0.2649 8.57 3.7777 0.4124 10.92 3.3789 0.1936 5.73 3.4561 0.1287 3.72 
ELSDIAHR 470.746 ALDOA 4.7904 0.1443 3.01 5.7731 0.8979 15.55 5.4072 0.5647 10.44 4.9287 0.1521 3.09 
GDLGIEIPAEK 571.309 PKLR 8.4288 0.5006 5.94 10.1709 1.4182 13.94 8.9897 0.7784 8.66 8.9241 0.4471 5.01 
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APPENDIX B 
 
Data to Chapter III: 
 
PROTEIN EXPRESSION SIGNATURES FOR INHIBITION OF EPIDERMAL 
GROWTH FACTOR RECEPTOR-MEDIATED SIGNALING 
 
  
197 
 
 
 
Figure B1.  Western blot analysis of caspase 3 and PARP cleavage in 
treated A431, DiFi and HCT116 cells.  P=proliferating cells, E=30nM EGF for 4 
h, G=500 nm gefitinib + 30nM EGF for 4 h, and C= 10 µg/mL cetuximab + 30nM 
EGF for 4 h.  Each cell line was probed with antibodies for full length caspase 3 
(32 kDa), cleaved caspase 3 (19 kDa) and an antibody that recognizes both full 
length PARP (116kDa) and cleaved PARP (89 kDa). β-Actin was used as a 
loading control.   
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Figure B2.  Peptide identification distribution.   Treated A431 were serum-starved overnight before being treated with 
30 nM EGF or gefitinib (500 nM) plus EGF or cetuximab (10 µg/mL) plus EGF.  Proliferating cells were not serum-starved.  
Graphs show number of peptides identified per each IEF gel fraction.  Each bar is representative of a MS single analysis. 
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Figure B3.  Varying the thresholds for filtering comparison datasets.  The colored circles represent lists of proteins 
differentially expressed (both up and down) at varying criteria between differently treated A431 cells.  The resulting protein 
groups represent proteins differentially expressed in response to EGF (blue), EGF-induced protein changes reversed by 
gefitinib (green) and EGF-induced protein changes reversed by cetuximab (yellow).  Fold changes were kept static at 
either 1.5 or 2.0 while p-values were varied from 0.05 – 0.20.   
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Table B1.  Stimulation signature.  Accession numbers, HUGO names, % 
coverage, spectral counts, fold-change and p-values for proteins identified from 
QuasiTel comparison of EGF-stimulated and proliferating A431 cell proteomes.  
Results were filtered to have at least 11 spectra across all analysis (12), a fold 
change ≥ 2 (base 2 log rate ratio of 1.0) and a p-value ≤ 0.20.  rev_ prefix 
indicates reverse database hit.  Protein-level FDR = 11.9%.    
Protein HUGO Coverage 
EGF 
counts 
Pro 
counts 
Fold 
Change 
Quasi  
p-value 
Total 
Counts 
rev_IPI00940099.1 11 1 16 17.763 0.001 17 
rev_IPI00845353.2 4 3 9 3.331 0.044 12 
rev_IPI00477426.3 4 3 8 2.961 0.021 11 
rev_IPI00247295.4 2 6 11 2.035 0.121 17 
rev_IPI00385267.4 2 6 11 2.035 0.079 17 
rev_IPI00027180.1 4 70 29 2.174 0.065 99 
rev_IPI00741537.5 2 20 7 2.574 0.074 27 
rev_IPI00293200.3 2 9 3 2.702 0.076 12 
rev_IPI00642259.2 2 9 3 2.702 0.129 12 
rev_IPI00010903.2 2 15 5 2.702 0.024 20 
rev_IPI00645369.2 3 9 3 2.702 0.184 12 
rev_IPI00302270.3 1 10 1 9.007 0.025 11 
rev_IPI00023868.1 1 12 1 10.809 0.013 13 
IPI00478003.1 A2M 2 4 43 11.935 0.000 47 
IPI00217272.7 AACS 9 11 4 2.477 0.110 15 
IPI00413730.4 ACSS2 7 24 7 3.088 0.006 31 
IPI00019901.1 ADD1 11 7 13 2.062 0.035 20 
IPI00022431.2 AHSG 4 14 30 2.379 0.010 44 
IPI00413641.7 AKR1B1 4 4 8 2.220 0.152 12 
IPI00296183.7 ALDH3A1 18 26 9 2.602 0.038 35 
IPI00032516.5 AP1M1 11 9 4 2.027 0.159 13 
IPI00337741.4 APEH 13 12 22 2.035 0.016 34 
IPI00022229.1 APOB 1 2 11 6.106 0.039 13 
IPI00013988.2 ARHGAP5 5 3 9 3.331 0.033 12 
IPI00472160.5 ARHGEF2 9 10 4 2.252 0.041 14 
IPI00014232.1 ARL6IP1 8 19 6 2.852 0.071 25 
IPI00170548.1 ATAD2 21 29 53 2.029 0.025 82 
IPI00059139.1 ATP6V1E2 18 10 4 2.252 0.080 14 
IPI00296191.1 ATP6V1H 21 12 3 3.603 0.130 15 
IPI00396074.2 ATP8B2 4 6 11 2.035 0.108 17 
IPI00180154.4 ATXN2 6 3 8 2.961 0.026 11 
IPI00514611.1 BCAP29 10 5 11 2.442 0.118 16 
IPI00294158.1 BLVRA 7 3 8 2.961 0.139 11 
IPI00218054.2 C11orf31 25 3 15 5.551 0.001 18 
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IPI00782974.1 C17orf85 8 3 9 3.331 0.009 12 
IPI00027898.3 C21orf70 16 5 11 2.442 0.025 16 
IPI00014516.1 CALD1 13 20 9 2.002 0.009 29 
IPI00060148.3 CCDC127 6 4 12 3.331 0.092 16 
IPI00217059.5 CCDC50 16 3 10 3.701 0.029 13 
IPI00657752.1 CD81 11 3 9 3.331 0.052 12 
IPI00005822.2 CDC23 14 5 12 2.664 0.017 17 
IPI00303099.2 CDCA8 9 3 11 4.071 0.004 14 
IPI00645518.1 CDIPT 14 8 17 2.359 0.040 25 
IPI00015713.4 CDKAL1 7 4 11 3.053 0.045 15 
IPI00009384.5 CDKN1A 18 14 0 4.369 0.000 14 
IPI00101532.5 CEP55 15 6 13 2.405 0.034 19 
IPI00238469.6 CEP97 6 3 8 2.961 0.178 11 
IPI00398992.6 CHD8 4 11 3 3.303 0.040 14 
IPI00021944.1 CLDN4 12 12 3 3.603 0.072 15 
IPI00000692.2 CLIC3 23 28 11 2.293 0.001 39 
IPI00006615.3 CLPB 9 10 22 2.442 0.002 32 
IPI00291262.3 CLU 26 17 6 2.552 0.085 23 
IPI00216682.5 CNN3 17 24 9 2.402 0.094 33 
IPI00807339.2 COBLL1 8 3 11 4.071 0.024 14 
IPI00010133.3 CORO1A 10 4 9 2.498 0.107 13 
IPI00419731.4 CRELD2 12 6 13 2.405 0.021 19 
IPI00295387.5 CRLF3 20 2 12 6.661 0.001 14 
IPI00647073.1 CUL2 13 6 15 2.776 0.032 21 
IPI00013892.1 CYTH3 8 8 3 2.402 0.200 11 
IPI00071483.1 DDX4 4 21 9 2.102 0.022 30 
IPI00015799.2 DGAT1 10 3 12 4.441 0.007 15 
IPI00006433.6 DNAJC16 8 10 3 3.002 0.082 13 
IPI00830108.1 DNAJC2 21 25 9 2.502 0.006 34 
IPI00257508.4 DPYSL2 22 26 6 3.903 0.006 32 
IPI00293251.5 DST 6 12 23 2.128 0.028 35 
IPI00185038.3 DUOX1 10 16 7 2.059 0.020 23 
IPI00096972.5 EHMT2 4 3 8 2.961 0.049 11 
IPI00003921.2 EPB41 11 7 13 2.062 0.043 20 
IPI00384975.4 EPB41L1 8 16 7 2.059 0.077 23 
IPI00010338.1 F3 26 41 16 2.308 0.021 57 
IPI00031670.6 FAM114A1 10 4 8 2.220 0.196 12 
IPI00178750.3 FAM192A 25 5 10 2.220 0.166 15 
IPI00910530.1 FGFR2 2 8 3 2.402 0.188 11 
IPI00456630.6 FNDC3A 2 4 9 2.498 0.071 13 
IPI00009057.2 G3BP2 11 14 4 3.153 0.046 18 
IPI00552587.1 GADD45GIP1 35 13 25 2.135 0.005 38 
IPI00030229.4 GALE 15 5 10 2.220 0.128 15 
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IPI00216159.14 GFPT2 8 4 10 2.776 0.029 14 
IPI00005132.3 GNL3L 10 4 11 3.053 0.074 15 
IPI00005677.1 GNPAT 6 4 9 2.498 0.139 13 
IPI00186721.2 GOPC 10 3 11 4.071 0.014 14 
IPI00478657.4 GRSF1 21 17 7 2.188 0.080 24 
IPI00012948.3 HBEGF 10 0 14 4.648 0.000 14 
IPI00010590.2 HELLS 20 13 33 2.818 0.006 46 
IPI00029193.1 HGFAC 5 4 26 7.216 0.000 30 
IPI00021770.1 HMGCR 14 26 4 5.855 0.002 30 
IPI00008475.1 HMGCS1 28 169 57 2.671 0.000 226 
IPI00008934.1 HMGCS2 3 21 5 3.783 0.001 26 
IPI00011970.3 HSD17B7 17 12 4 2.702 0.007 16 
IPI00555915.1 HSP90AB6P 7 31 12 2.327 0.035 43 
IPI00024284.5 HSPG2 3 8 18 2.498 0.100 26 
IPI00220014.2 IDI1 28 17 5 3.063 0.006 22 
IPI00293735.2 IKBKAP 12 5 11 2.442 0.079 16 
IPI00290198.3 IL18 17 4 8 2.220 0.100 12 
IPI00759472.1 INCENP 10 5 15 3.331 0.020 20 
IPI00099650.2 JAG1 5 10 3 3.002 0.109 13 
IPI00008965.1 JUN 13 21 4 4.729 0.010 25 
IPI00289547.4 JUND 10 10 4 2.252 0.042 14 
IPI00299554.3 KIF14 9 9 19 2.344 0.008 28 
IPI00044751.5 KIF20B 12 7 24 3.806 0.001 31 
IPI00000769.2 KIF22 16 3 10 3.701 0.010 13 
IPI00001458.1 KNTC1 5 5 12 2.664 0.132 17 
IPI00016458.2 L2HGDH 6 5 10 2.220 0.052 15 
IPI00000070.1 LDLR 15 38 15 2.282 0.005 53 
IPI00937839.1 LOC100293655 19 16 31 2.151 0.006 47 
IPI00847670.1 LOC440043 20 53 21 2.273 0.061 74 
IPI00385128.3 LPCAT4 10 7 13 2.062 0.055 20 
IPI00020557.1 LRP1 6 17 38 2.482 0.001 55 
IPI00007321.2 LYPLA1 9 5 10 2.220 0.142 15 
IPI00301082.1 MAGEA1 7 13 3 3.903 0.041 16 
IPI00065350.1 MAGEB18 8 8 3 2.402 0.119 11 
IPI00297989.4 MAGEB6 5 9 3 2.702 0.162 12 
IPI00009542.1 MAGED2 19 8 16 2.220 0.043 24 
IPI00025323.7 MAP9 3 11 1 9.908 0.051 12 
IPI00185037.9 MARK1 6 5 10 2.220 0.103 15 
IPI00064797.1 MARK4 5 3 9 3.331 0.048 12 
IPI00029275.1 MFI2 9 14 26 2.062 0.052 40 
IPI00024266.3 MGST3 22 8 3 2.402 0.107 11 
IPI00418290.1 MRPL14 21 10 4 2.252 0.043 14 
IPI00010278.6 MRPS30 7 8 3 2.402 0.052 11 
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IPI00030273.1 MST1R 6 3 10 3.701 0.023 13 
IPI00022498.1 MT2A 61 21 7 2.702 0.059 28 
IPI00022745.1 MVD 11 14 5 2.522 0.039 19 
IPI00007858.1 MYH13 3 31 13 2.148 0.082 44 
IPI00027255.1 MYL6B 24 62 25 2.234 0.060 87 
IPI00747787.2 NCAPD3 9 3 9 3.331 0.111 12 
IPI00641645.1 NFIA 5 3 8 2.961 0.144 11 
IPI00643720.3 OGDHL 6 13 3 3.903 0.096 16 
IPI00015143.1 ORC5L 17 4 9 2.498 0.153 13 
IPI00014301.3 OXA1L 4 8 3 2.402 0.091 11 
IPI00432527.1 PABPCP2 8 15 6 2.252 0.181 21 
IPI00027009.2 PACSIN2 16 5 13 2.887 0.007 18 
IPI00240675.2 PDCD4 26 16 31 2.151 0.001 47 
IPI00168698.1 PDZD8 6 3 8 2.961 0.054 11 
IPI00219568.4 PGK2 13 50 18 2.502 0.018 68 
IPI00025463.3 PHLDA1 8 5 10 2.220 0.076 15 
IPI00022149.1 PIP5K1A 10 13 4 2.927 0.045 17 
IPI00030362.1 PLP2 8 18 36 2.220 0.014 54 
IPI00024129.1 PPIC 8 10 4 2.252 0.159 14 
IPI00006298.2 PPIG 5 7 14 2.220 0.006 21 
IPI00045550.4 PPP1R9B 14 10 2 4.504 0.016 12 
IPI00026994.3 PRAF2 11 3 8 2.961 0.127 11 
IPI00027704.5 PRIM1 20 5 10 2.220 0.153 15 
IPI00295988.4 PROM2 10 13 30 2.562 0.001 43 
IPI00028006.1 PSMB2 30 10 4 2.252 0.165 14 
IPI00107831.4 PTPRF 9 4 15 4.163 0.005 19 
IPI00014376.5 RAB31 12 6 13 2.405 0.010 19 
IPI00102752.2 RBM15 17 9 23 2.837 0.000 32 
IPI00000686.2 RBM19 9 4 8 2.220 0.064 12 
IPI00021626.2 RBM42 9 12 22 2.035 0.010 34 
IPI00154352.2 RER1 27 3 11 4.071 0.036 14 
IPI00465059.4 RHOT2 16 5 10 2.220 0.029 15 
IPI00002408.4 RPAP3 26 8 20 2.776 0.058 28 
IPI00893680.1 RPL10 22 54 15 3.243 0.004 69 
IPI00868816.1 RPL12P38 38 32 12 2.402 0.030 44 
IPI00219153.4 RPL22 32 56 22 2.293 0.053 78 
IPI00030179.3 RPL7P32 40 122 54 2.035 0.022 176 
IPI00008527.3 RPLP1 68 20 6 3.002 0.024 26 
IPI00013296.3 RPS18 39 176 79 2.007 0.054 255 
IPI00012493.1 RPS20 26 100 30 3.002 0.010 130 
IPI00187140.1 RPS26P11 19 33 12 2.477 0.073 45 
IPI00746004.2 RPS27L 35 44 16 2.477 0.020 60 
IPI00302740.8 RPS4Y1 24 94 42 2.016 0.001 136 
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IPI00017526.1 S100P 39 35 11 2.866 0.025 46 
IPI00329108.4 SCEL 14 18 3 5.404 0.002 21 
IPI00106642.4 SDF2L1 23 22 3 6.605 0.005 25 
IPI00871605.2 SELT 28 5 10 2.220 0.189 15 
IPI00216139.3 SEPT6 13 13 24 2.050 0.014 37 
IPI00307733.5 SETD2 3 13 4 2.927 0.122 17 
IPI00103419.4 SF4 12 4 9 2.498 0.086 13 
IPI00022649.3 SLC12A2 7 7 14 2.220 0.070 21 
IPI00015473.3 SLC1A3 11 6 13 2.405 0.019 19 
IPI00023035.2 SLC20A1 5 9 4 2.027 0.088 13 
IPI00154528.3 SMC6 14 6 14 2.590 0.105 20 
IPI00297714.2 SNCG 48 14 6 2.102 0.139 20 
IPI00438170.3 SNX12 12 5 10 2.220 0.079 15 
IPI00012645.1 SPTBN2 16 27 53 2.179 0.002 80 
IPI00219168.7 SPTBN5 2 9 2 4.053 0.036 11 
IPI00218486.5 SSH3 10 12 3 3.603 0.049 15 
IPI00004312.1 STAT2 9 9 2 4.053 0.023 11 
IPI00299149.1 SUMO2 35 55 21 2.359 0.038 76 
IPI00328144.6 TAF2 9 5 11 2.442 0.021 16 
IPI00159322.4 TCF20 5 4 10 2.776 0.041 14 
IPI00296099.6 THBS1 25 128 36 3.203 0.003 164 
IPI00478062.2 TLE2 9 11 3 3.303 0.089 14 
IPI00743888.2 TMUB2 11 9 4 2.027 0.163 13 
IPI00170752.5 TNS4 9 12 0 2.709 0.000 12 
IPI00941588.1 TOM1 12 10 3 3.002 0.030 13 
IPI00328178.3 TOM1L2 19 6 12 2.220 0.068 18 
IPI00016676.1 TOMM20 16 4 9 2.498 0.093 13 
IPI00301631.5 TOR3A 7 3 8 2.961 0.044 11 
IPI00004324.1 TRAPPC3 28 6 13 2.405 0.103 19 
IPI00426252.1 TRIM27 14 4 13 3.608 0.023 17 
IPI00297113.1 TRIM32 4 11 3 3.303 0.126 14 
IPI00003505.3 TRIP13 14 5 10 2.220 0.132 15 
IPI00216293.6 TST 14 6 11 2.035 0.024 17 
IPI00300504.5 UPF2 7 6 11 2.035 0.147 17 
IPI00009329.2 UTRN 8 8 15 2.082 0.021 23 
IPI00334159.6 VBP1 33 21 8 2.364 0.016 29 
IPI00090327.1 VPS45 15 19 36 2.104 0.055 55 
IPI00017160.3 VTA1 21 16 7 2.059 0.110 23 
IPI00002564.3 XRCC1 9 7 13 2.062 0.056 20 
IPI00477949.1 ZMYM4 9 6 12 2.220 0.193 18 
IPI00418316.6 ZMYND8 9 3 8 2.961 0.110 11 
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Table B2.  Gefitinib inhibition signature.  Accession numbers, spectral counts, 
fold changes, and p-values for proteins identified from QuasiTel comparison of 
EGF stimulated and gefitinib-treated cell proteomes.  Results were filtered to 
have at least 11 spectra across all analysis, ≥ 2.0 fold change (base 2 log rate 
ratio of 1.0) and a p-value ≤ 0.20.  rev_ prefix indicates reverse database hit.  
Protein-level FDR = 9.2%  
Protein HUGO Coverage 
EGF 
counts 
GEF 
counts 
Fold 
change 
Quasi 
p-value 
Total 
Counts 
rev_IPI00007175.3 14 32 9 3.354 0.024 41 
rev_IPI00010903.2 2 15 3 4.716 0.003 18 
rev_IPI00023868.1 1 12 1 11.319 0.012 13 
rev_IPI00027180.1 4 70 26 2.540 0.019 96 
rev_IPI00102678.2 1 10 1 9.433 0.101 11 
rev_IPI00171087.7 7 8 3 2.515 0.165 11 
rev_IPI00217602.5 8 8 3 2.515 0.191 11 
rev_IPI00291800.1 2 10 27 2.862 0.019 37 
rev_IPI00301395.4 4 19 6 2.987 0.041 25 
rev_IPI00302270.3 1 10 2 4.716 0.041 12 
rev_IPI00642259.2 2 9 3 2.830 0.180 12 
rev_IPI00741537.5 2 20 5 3.773 0.035 25 
IPI00015826.2 ABCB10 6 3 11 3.887 0.020 14 
IPI00329245.7 ANKLE2 19 9 2 4.245 0.120 11 
IPI00253323.3 ANKRD57 24 3 8 2.827 0.093 11 
IPI00014232.1 ARL6IP1 8 19 1 17.922 0.003 20 
IPI00328526.6 ARPP19 39 6 13 2.297 0.109 19 
IPI00940046.1 ASAH1 11 7 15 2.272 0.005 22 
IPI00102575.4 ATAD5 6 3 8 2.827 0.147 11 
IPI00289499.3 ATIC 31 18 38 2.238 0.062 56 
IPI00034277.1 ATP13A1 8 1 11 11.661 0.005 12 
IPI00847139.1 ATP13A3 6 4 9 2.385 0.189 13 
IPI00294158.1 BLVRA 7 3 8 2.827 0.142 11 
IPI00020017.1 C10orf116 67 42 17 2.330 0.016 59 
IPI00016925.1 C12orf57 34 4 9 2.385 0.143 13 
IPI00107728.4 C16orf62 5 4 8 2.120 0.199 12 
IPI00554560.4 C16orf88 17 13 30 2.446 0.048 43 
IPI00016634.1 C20orf11 29 6 13 2.297 0.014 19 
IPI00797771.1 C20orf117 9 10 3 3.144 0.101 13 
IPI00027898.3 C21orf70 16 5 10 2.120 0.152 15 
IPI00299387.3 C3orf1 24 15 33 2.332 0.006 48 
IPI00419575.6 C7orf20 11 5 11 2.332 0.110 16 
IPI00514301.3 CASK 11 7 21 3.180 0.004 28 
IPI00220857.3 CAST 28 37 70 2.006 0.007 107 
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IPI00302647.4 CC2D1A 7 12 5 2.264 0.130 17 
IPI00641630.1 CC2D1B 9 3 10 3.534 0.008 13 
IPI00217059.5 CCDC50 16 3 9 3.180 0.136 12 
IPI00334743.4 CCNY 13 6 12 2.120 0.087 18 
IPI00185371.5 CCNYL1 11 4 9 2.385 0.023 13 
IPI00298851.4 CD151 8 10 4 2.358 0.163 14 
IPI00374740.3 CD47 8 9 4 2.122 0.043 13 
IPI00657752.1 CD81 11 3 10 3.534 0.009 13 
IPI00005822.2 CDC23 14 5 12 2.544 0.017 17 
IPI00465387.2 CDCA2 7 2 9 4.771 0.062 11 
IPI00303099.2 CDCA8 9 3 10 3.534 0.006 13 
IPI00031681.1 CDK2 23 14 6 2.201 0.089 20 
IPI00009384.5 CDKN1A 18 14 1 13.206 0.001 15 
IPI00101532.5 CEP55 15 6 12 2.120 0.027 18 
IPI00238469.6 CEP97 6 3 8 2.827 0.022 11 
IPI00306853.2 CHST3 8 8 3 2.515 0.159 11 
IPI00021944.1 CLDN4 12 12 5 2.264 0.159 17 
IPI00101942.1 CLMN 6 8 3 2.515 0.146 11 
IPI00291262.3 CLU 26 17 36 2.245 0.026 53 
IPI00303158.3 CMAS 16 15 7 2.021 0.048 22 
IPI00430812.6 CNBP 29 41 13 2.975 0.010 54 
IPI00216682.5 CNN3 17 24 10 2.264 0.029 34 
IPI00807339.2 COBLL1 8 3 10 3.534 0.059 13 
IPI00009365.3 COX16 20 6 12 2.120 0.091 18 
IPI00645310.1 CPNE2 9 30 7 4.043 0.011 37 
IPI00295469.5 CPNE6 4 29 6 4.559 0.006 35 
IPI00332395.2 CPNE9 3 29 6 4.559 0.006 35 
IPI00027713.1 CREB1 17 14 6 2.201 0.042 20 
IPI00797918.1 CRELD2 13 3 8 2.827 0.066 11 
IPI00019918.5 DDX19A 20 5 10 2.120 0.074 15 
IPI00008943.3 DDX19B 18 5 10 2.120 0.179 15 
IPI00007208.4 DDX41 17 13 25 2.039 0.015 38 
IPI00015799.2 DGAT1 10 3 10 3.534 0.087 13 
IPI00909589.1 DHX38 15 4 10 2.650 0.115 14 
IPI00006433.6 DNAJC16 8 10 1 9.433 0.021 11 
IPI00010348.1 DNASE2 6 9 2 4.245 0.046 11 
IPI00816460.2 DST 10 13 39 3.180 0.000 52 
IPI00029658.1 EFEMP1 12 3 9 3.180 0.116 12 
IPI00096972.5 EHMT2 4 3 13 4.594 0.011 16 
IPI00374054.3 ENAH 23 17 33 2.058 0.023 50 
IPI00029631.1 ERH 31 70 31 2.130 0.027 101 
IPI00024167.1 ESF1 14 9 19 2.238 0.048 28 
IPI00019427.4 EXOC1 7 3 10 3.534 0.042 13 
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IPI00070643.6 FAF1 21 13 25 2.039 0.063 38 
IPI00031670.6 FAM114A1 10 4 9 2.385 0.178 13 
IPI00178750.3 FAM192A 25 5 15 3.180 0.017 20 
IPI00030098.5 FAM50A 13 5 10 2.120 0.158 15 
IPI00302641.1 FAT2 11 35 68 2.060 0.000 103 
IPI00216159.14 GFPT2 8 4 8 2.120 0.125 12 
IPI00010130.3 GLUL 6 4 10 2.650 0.053 14 
IPI00328744.6 GNA12 7 19 7 2.560 0.019 26 
IPI00027243.1 GNA15 14 3 8 2.827 0.134 11 
IPI00031115.4 GOLGA1 9 5 10 2.120 0.139 15 
IPI00186721.2 GOPC 10 3 8 2.827 0.047 11 
IPI00218002.6 GPR110 8 4 10 2.650 0.017 14 
IPI00011989.1 GRIN1 3 5 11 2.332 0.159 16 
IPI00016725.2 GTF3C4 21 11 22 2.120 0.016 33 
IPI00010463.5 GTPBP1 10 5 10 2.120 0.129 15 
IPI00021924.1 H1FX 22 26 11 2.230 0.114 37 
IPI00220994.3 H2AFY2 21 12 25 2.209 0.000 37 
IPI00014220.2 HAUS5 5 3 8 2.827 0.070 11 
IPI00170924.2 HINT3 35 5 10 2.120 0.028 15 
IPI00171903.2 HNRNPM 50 441 199 2.090 0.003 640 
IPI00555957.1 HSP90AA4P 17 87 37 2.218 0.035 124 
IPI00555915.1 HSP90AB6P 7 31 12 2.437 0.026 43 
IPI00008494.4 ICAM1 13 38 17 2.109 0.036 55 
IPI00446765.2 INTS4 6 3 10 3.534 0.032 13 
IPI00099650.2 JAG1 5 10 4 2.358 0.126 14 
IPI00008965.1 JUN 13 21 7 2.830 0.025 28 
IPI00289547.4 JUND 10 10 3 3.144 0.069 13 
IPI00748360.2 KIAA1797 4 4 8 2.120 0.163 12 
IPI00044751.5 KIF20B 12 7 18 2.726 0.019 25 
IPI00375910.2 KRT26 7 153 63 2.291 0.023 216 
IPI00019359.4 KRT9 13 72 28 2.426 0.011 100 
IPI00296922.4 LAMB2 8 5 11 2.332 0.134 16 
IPI00009030.1 LAMP2 4 31 11 2.658 0.003 42 
IPI00005724.1 LANCL1 8 3 8 2.827 0.101 11 
IPI00939286.1 LDHA 47 315 148 2.008 0.006 463 
IPI00148061.3 LDHAL6A 10 69 24 2.712 0.031 93 
IPI00554498.3 LDHC 8 65 23 2.666 0.035 88 
IPI00004758.5 LDLRAP1 15 3 8 2.827 0.124 11 
IPI00029397.5 LEPROTL1 9 3 9 3.180 0.028 12 
IPI00791938.1 LLGL1 6 4 9 2.385 0.059 13 
IPI00847670.1 LOC440043 20 53 16 3.125 0.012 69 
IPI00397575.3 LRRC41 5 11 4 2.594 0.049 15 
IPI00007321.2 LYPLA1 9 5 11 2.332 0.104 16 
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IPI00152900.2 LZIC 36 5 11 2.332 0.036 16 
IPI00301082.1 MAGEA1 7 13 4 3.066 0.058 17 
IPI00046955.9 MAGEB17 3 8 3 2.515 0.106 11 
IPI00065350.1 MAGEB18 8 8 3 2.515 0.106 11 
IPI00297989.4 MAGEB6 5 9 3 2.830 0.080 12 
IPI00299085.3 MAGEC1 1 8 3 2.515 0.106 11 
IPI00025323.7 MAP9 3 11 2 5.188 0.087 13 
IPI00297191.2 MED14 5 9 4 2.122 0.097 13 
IPI00027310.5 MEGF8 3 3 9 3.180 0.053 12 
IPI00783001.1 METT5D1 14 4 8 2.120 0.135 12 
IPI00293276.10 MIF 16 53 16 3.125 0.009 69 
IPI00455518.5 MORC2 15 8 17 2.253 0.072 25 
IPI00218495.3 MPG 17 3 8 2.827 0.102 11 
IPI00007001.1 MRPL11 25 5 11 2.332 0.149 16 
IPI00032872.3 MRPS16 26 3 8 2.827 0.030 11 
IPI00006440.6 MRPS7 28 11 22 2.120 0.026 33 
IPI00030273.1 MST1R 6 3 8 2.827 0.030 11 
IPI00027255.1 MYL6B 24 62 17 3.440 0.002 79 
IPI00018968.2 NAE1 13 9 17 2.002 0.111 26 
IPI00747787.2 NCAPD3 9 3 9 3.180 0.102 12 
IPI00644022.5 NCAPH2 8 4 8 2.120 0.162 12 
IPI00005966.6 NDUFA12 16 4 9 2.385 0.080 13 
IPI00180559.3 NET1 4 12 5 2.264 0.139 17 
IPI00004845.4 NIPSNAP3 17 11 5 2.075 0.100 16 
IPI00432527.1 PABPCP2 8 15 5 2.830 0.065 20 
IPI00027009.2 PACSIN2 16 5 10 2.120 0.114 15 
IPI00014808.1 PAFAH1B3 10 4 8 2.120 0.037 12 
IPI00030009.4 PAPSS2 18 17 7 2.291 0.018 24 
IPI00064457.4 PARP10 4 5 10 2.120 0.031 15 
IPI00640304.1 PBRM1 13 14 30 2.272 0.009 44 
IPI00240675.2 PDCD4 26 16 38 2.518 0.000 54 
IPI00022095.3 PEG10 5 3 8 2.827 0.145 11 
IPI00004534.4 PFAS 6 3 9 3.180 0.144 12 
IPI00219568.4 PGK2 13 50 17 2.774 0.018 67 
IPI00382788.6 PHF15 9 4 13 3.445 0.019 17 
IPI00022149.1 PIP5K1A 10 13 6 2.044 0.032 19 
IPI00010676.1 PLAUR 19 10 2 4.716 0.038 12 
IPI00440688.4 POLDIP3 22 3 8 2.827 0.145 11 
IPI00031960.2 POLR1A 11 13 25 2.039 0.044 38 
IPI00006113.1 POLR2I 30 1 11 11.661 0.001 12 
IPI00024698.1 PQBP1 11 10 20 2.120 0.060 30 
IPI00027704.5 PRIM1 20 5 11 2.332 0.090 16 
IPI00012322.1 PRKG2 4 35 16 2.063 0.010 51 
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IPI00329538.3 PRSS8 11 5 12 2.544 0.071 17 
IPI00171199.5 PSMA3 22 26 9 2.725 0.002 35 
IPI00926491.1 PTCD1 6 12 2 5.660 0.006 14 
IPI00016373.3 RAB13 25 88 39 2.128 0.002 127 
IPI00028481.1 RAB8A 26 71 22 3.044 0.001 93 
IPI00024282.1 RAB8B 19 65 23 2.666 0.006 88 
IPI00449923.1 RAI1 5 2 10 5.301 0.016 12 
IPI00643041.3 RANP1 33 152 70 2.048 0.001 222 
IPI00102752.2 RBM15 17 9 20 2.356 0.000 29 
IPI00000686.2 RBM19 9 4 8 2.120 0.178 12 
IPI00017367.6 RDX 19 100 29 3.253 0.000 129 
IPI00154352.2 RER1 27 3 9 3.180 0.039 12 
IPI00926466.1 RHOA 27 17 8 2.004 0.066 25 
IPI00641330.1 RING1 17 4 8 2.120 0.174 12 
IPI00017373.1 RPA3 33 18 7 2.426 0.013 25 
IPI00002408.4 RPAP3 26 8 17 2.253 0.159 25 
IPI00893680.1 RPL10 22 54 14 3.638 0.001 68 
IPI00868816.1 RPL12P38 38 32 10 3.019 0.011 42 
IPI00219153.4 RPL22 32 56 24 2.201 0.008 80 
IPI00010153.5 RPL23 41 128 49 2.464 0.003 177 
IPI00456758.4 RPL27A 32 74 21 3.324 0.001 95 
IPI00219335.10 RPL3L 11 46 6 7.232 0.001 52 
IPI00030179.3 RPL7P32 40 122 36 3.197 0.001 158 
IPI00013296.3 RPS18 39 176 63 2.635 0.002 239 
IPI00012493.1 RPS20 26 100 23 4.101 0.001 123 
IPI00218606.7 RPS23 31 18 8 2.122 0.140 26 
IPI00012750.3 RPS25 37 70 24 2.751 0.007 94 
IPI00187140.1 RPS26P11 19 33 13 2.394 0.041 46 
IPI00746004.2 RPS27L 35 44 19 2.184 0.025 63 
IPI00302740.8 RPS4Y1 24 94 43 2.062 0.001 137 
IPI00465287.2 RREB1 8 13 5 2.453 0.198 18 
IPI00021766.5 RTN4 8 41 16 2.417 0.007 57 
IPI00418394.2 RXRA 12 5 11 2.332 0.091 16 
IPI00017526.1 S100P 39 35 6 5.502 0.017 41 
IPI00303343.7 SCAF1 9 7 17 2.575 0.014 24 
IPI00002441.2 SDC1 15 24 47 2.076 0.004 71 
IPI00301618.6 SDCCAG1 10 9 17 2.002 0.163 26 
IPI00307733.5 SETD2 3 13 4 3.066 0.156 17 
IPI00005978.8 SFRS2 27 107 39 2.588 0.002 146 
IPI00022649.3 SLC12A2 7 7 15 2.272 0.081 22 
IPI00010420.2 SLC25A31 11 34 10 3.207 0.006 44 
IPI00007188.5 SLC25A5 45 306 143 2.018 0.007 449 
IPI00291467.7 SLC25A6 44 262 111 2.226 0.002 373 
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IPI00029267.1 SNRPB2 24 45 21 2.021 0.002 66 
IPI00016572.1 SNRPG 24 17 37 2.307 0.016 54 
IPI00045914.1 SPEN 9 13 35 2.854 0.002 48 
IPI00012645.1 SPTBN2 16 27 59 2.317 0.028 86 
IPI00219168.7 SPTBN5 2 9 2 4.245 0.034 11 
IPI00004312.1 STAT2 9 9 4 2.122 0.066 13 
IPI00386786.5 STX5 22 2 13 6.891 0.020 15 
IPI00299149.1 SUMO2 35 55 14 3.706 0.004 69 
IPI00216137.4 SYCP1 3 10 3 3.144 0.011 13 
IPI00154565.14 SYTL1 6 4 9 2.385 0.085 13 
IPI00296099.6 THBS1 25 128 59 2.046 0.019 187 
IPI00742863.2 THEMIS 7 15 5 2.830 0.188 20 
IPI00063729.4 THOC3 16 3 10 3.534 0.020 13 
IPI00328985.1 THOC6 19 3 10 3.534 0.030 13 
IPI00221206.1 TLE3 10 9 4 2.122 0.047 13 
IPI00063334.3 TMEM41A 8 2 10 5.301 0.004 12 
IPI00386760.2 TMEM48 9 5 10 2.120 0.027 15 
IPI00419856.1 TNPO2 6 6 12 2.120 0.029 18 
IPI00170752.5 TNS4 9 12 3 3.773 0.053 15 
IPI00016676.1 TOMM20 16 4 12 3.180 0.022 16 
IPI00000980.1 TOMM7 31 4 9 2.385 0.099 13 
IPI00395631.3 TRAF7 10 3 12 4.241 0.012 15 
IPI00004324.1 TRAPPC3 28 6 19 3.357 0.004 25 
IPI00426252.1 TRIM27 14 4 8 2.120 0.195 12 
IPI00297113.1 TRIM32 4 11 4 2.594 0.173 15 
IPI00024151.3 TRUB2 21 3 8 2.827 0.027 11 
IPI00000171.1 TSC22D4 13 9 3 2.830 0.097 12 
IPI00386354.1 TTLL3 40 13 4 3.066 0.102 17 
IPI00017454.4 TUBA4B 18 114 38 2.830 0.010 152 
IPI00908469.1 TUBB6 37 243 102 2.247 0.010 345 
IPI00409659.2 UBQLN2 8 4 9 2.385 0.131 13 
IPI00305303.3 UFSP2 11 6 14 2.474 0.003 20 
IPI00000733.4 UTP18 6 4 8 2.120 0.159 12 
IPI00009329.2 UTRN 8 8 19 2.518 0.014 27 
IPI00031804.1 VDAC3 38 103 41 2.370 0.002 144 
IPI00063784.3 VTI1B 17 2 9 4.771 0.057 11 
IPI00170786.1 WBP11 16 17 33 2.058 0.024 50 
IPI00218240.3 WHSC1 5 2 12 6.361 0.002 14 
IPI00009326.1 YAP1 11 4 9 2.385 0.122 13 
IPI00004337.2 ZBTB11 7 3 8 2.827 0.155 11 
IPI00329547.3 ZC3H13 6 4 13 3.445 0.009 17 
IPI00010833.1 ZNF148 14 6 16 2.827 0.021 22 
IPI00011631.6 ZW10 15 2 13 6.891 0.007 15 
211 
 
Table B3.  Cetuximab inhibition signature.  Accession numbers, spectral 
counts, fold changes, and p-values for proteins identified from QuasiTel 
comparison of EGF-stimulated and cetuximab-treated cell proteomes.  Results 
were filtered to have at least 11 spectra across all analysis, ≥ 2.0 fold change 
(base 2 log rate ratio of 1.0) and a p-value ≤ 0.20.  rev_ prefix indicates reverse 
database hit.  Protein-level FDR = 10.0%  
Protein HUGO Coverage 
EGF 
counts 
GEF 
counts 
Fold  
Change 
quasi 
p-value 
Total 
Counts 
rev_IPI00003923.1 6 9 3 2.931 0.067 12 
rev_IPI00023283.3 2 20 8 2.442 0.080 28 
rev_IPI00023868.1 1 12 5 2.345 0.170 17 
rev_IPI00740019.2 4 3 8 2.730 0.092 11 
rev_IPI00302270.3 1 10 3 3.256 0.071 13 
rev_IPI00642126.3 1 4 11 2.815 0.105 15 
rev_IPI00012345.2 5 8 3 2.605 0.150 11 
IPI00002938.1 ABT1 16 9 4 2.198 0.063 13 
IPI00020226.2 ACOX3 9 5 10 2.047 0.035 15 
IPI00019353.4 AGK 12 8 3 2.605 0.066 11 
IPI00152898.1 AP1S1 23 5 14 2.866 0.050 19 
IPI00031030.1 APLP2 7 2 9 4.606 0.025 11 
IPI00021841.1 APOA1 25 0 15 3.704 0.032 15 
IPI00186903.4 APOL1 13 19 6 3.094 0.006 25 
IPI00042580.4 APOO 17 15 6 2.442 0.040 21 
IPI00218648.2 ARID4A 6 3 9 3.071 0.046 12 
IPI00328526.6 ARPP19 39 6 13 2.218 0.039 19 
IPI00008161.8 ATP12A 4 8 20 2.559 0.073 28 
IPI00647099.2 ATP1A4 13 8 21 2.687 0.061 29 
IPI00012851.2 ATP8B1 4 11 5 2.149 0.110 16 
IPI00180154.4 ATXN2 6 3 10 3.412 0.011 13 
IPI00554756.2 BLK 3 7 15 2.193 0.101 22 
IPI00218054.2 C11orf31 25 3 8 2.730 0.104 11 
IPI00031526.3 C19orf43 26 8 17 2.175 0.010 25 
IPI00816419.1 C1orf151 44 7 14 2.047 0.067 21 
IPI00797771.1 C20orf117 9 10 4 2.442 0.082 14 
IPI00015101.2 C9orf167 16 16 7 2.233 0.030 23 
IPI00641630.1 CC2D1B 9 3 8 2.730 0.062 11 
IPI00217059.5 CCDC50 16 3 9 3.071 0.075 12 
IPI00298851.4 CD151 8 10 3 3.256 0.055 13 
IPI00017529.1 CD58 13 11 5 2.149 0.162 16 
IPI00007811.1 CDK4 12 9 18 2.047 0.077 27 
IPI00023530.7 CDK5 7 7 14 2.047 0.147 21 
IPI00009384.5 CDKN1A 18 14 3 4.559 0.002 17 
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IPI00021944.1 CLDN4 12 12 3 3.908 0.025 15 
IPI00303158.3 CMAS 16 15 7 2.093 0.056 22 
IPI00807339.2 COBLL1 8 3 8 2.730 0.137 11 
IPI00027988.1 CTCF 12 16 6 2.605 0.006 22 
IPI00216003.4 CUL5 7 2 12 6.142 0.013 14 
IPI00013892.1 CYTH3 8 8 3 2.605 0.090 11 
IPI00291032.7 CYTSB 9 11 4 2.687 0.027 15 
IPI00027547.2 DCD 61 0 15 2.659 0.000 15 
IPI00335385.4 DCPS 16 11 5 2.149 0.057 16 
IPI00063408.7 DHTKD1 11 12 5 2.345 0.074 17 
IPI00031508.1 DHX8 13 19 9 2.062 0.002 28 
IPI00004459.1 DIMT1L 13 10 4 2.442 0.100 14 
IPI00010348.1 DNASE2 6 9 3 2.931 0.074 12 
IPI00015905.1 EXOSC2 23 12 3 3.908 0.028 15 
IPI00745613.2 EXOSC4 8 4 8 2.047 0.194 12 
IPI00216605.1 FGFR2 2 7 15 2.193 0.095 22 
IPI00170778.4 FNBP4 7 8 3 2.605 0.115 11 
IPI00217490.5 FNDC3B 8 9 3 2.931 0.091 12 
IPI00552587.1 GADD45GIP1 35 13 27 2.126 0.002 40 
IPI00292753.7 GAPVD1 10 8 16 2.047 0.011 24 
IPI00296635.5 GBE1 10 4 10 2.559 0.096 14 
IPI00028565.4 GBP2 10 9 2 4.396 0.092 11 
IPI00789740.1 GEMIN4 10 10 4 2.442 0.026 14 
IPI00216159.14 GFPT2 8 4 11 2.815 0.017 15 
IPI00002496.2 GMPPB 5 5 10 2.047 0.058 15 
IPI00005677.1 GNPAT 6 4 10 2.559 0.096 14 
IPI00011989.1 GRIN1 3 5 13 2.661 0.086 18 
IPI00008494.4 ICAM1 13 38 16 2.320 0.010 54 
IPI00018305.4 IGFBP3 21 8 3 2.605 0.155 11 
IPI00399007.7 IGHG2 14 0 59 65.235 0.000 59 
IPI00941837.1 IGHM 8 0 55 42.126 0.000 55 
IPI00423463.1 IGHV4-31 16 1 90 92.126 0.000 91 
IPI00185146.5 IPO9 10 13 29 2.283 0.028 42 
IPI00099650.2 JAG1 5 10 3 3.256 0.040 13 
IPI00008965.1 JUN 13 21 10 2.052 0.051 31 
IPI00289547.4 JUND 10 10 3 3.256 0.017 13 
IPI00060715.1 KCTD12 13 5 10 2.047 0.167 15 
IPI00154283.4 KIAA1524 12 17 7 2.373 0.006 24 
IPI00299554.3 KIF14 9 9 18 2.047 0.003 27 
IPI00004758.5 LDLRAP1 15 3 8 2.730 0.060 11 
IPI00552510.2 LMO7 18 30 10 2.931 0.002 40 
IPI00025489.1 MAK 3 7 14 2.047 0.147 21 
IPI00005741.1 MAPK13 16 8 3 2.605 0.123 11 
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IPI00028932.7 MAST3 5 4 8 2.047 0.185 12 
IPI00028954.1 MCM3AP 10 5 16 3.276 0.021 21 
IPI00556494.3 MED4 20 11 5 2.149 0.150 16 
IPI00000784.1 MEF2D 12 5 10 2.047 0.143 15 
IPI00300763.4 METAP2 24 18 8 2.198 0.089 26 
IPI00073713.3 MSI2 21 3 9 3.071 0.046 12 
IPI00031109.4 NDUFAF2 30 10 1 9.769 0.014 11 
IPI00012315.2 NME3 10 3 8 2.730 0.078 11 
IPI00604756.2 NRBP1 5 8 3 2.605 0.118 11 
IPI00010196.1 NRIP1 3 8 3 2.605 0.042 11 
IPI00306305.9 OBSL1 6 4 8 2.047 0.150 12 
IPI00014301.3 OXA1L 4 8 3 2.605 0.161 11 
IPI00030009.4 PAPSS2 18 17 8 2.076 0.023 25 
IPI00064457.4 PARP10 4 5 12 2.457 0.018 17 
IPI00072541.4 PCID2 16 9 3 2.931 0.125 12 
IPI00922194.1 PCTK1 10 7 14 2.047 0.147 21 
IPI00394661.4 PCTK3 11 7 15 2.193 0.093 22 
IPI00552367.3 PDLIM5 26 8 3 2.605 0.123 11 
IPI00419263.3 PECI 24 12 1 11.723 0.003 13 
IPI00025463.3 PHLDA1 8 5 11 2.252 0.122 16 
IPI00019551.1 PHLDA2 35 7 14 2.047 0.015 21 
IPI00001813.5 PHRF1 9 9 4 2.198 0.198 13 
IPI00010676.1 PLAUR 19 10 3 3.256 0.110 13 
IPI00007948.2 POLR3C 14 10 2 4.885 0.057 12 
IPI00301689.7 PPFIBP2 4 12 4 2.931 0.037 16 
IPI00045550.4 PPP1R9B 14 10 3 3.256 0.018 13 
IPI00027704.5 PRIM1 20 5 11 2.252 0.065 16 
IPI00219616.7 PRPS1 23 6 12 2.047 0.138 18 
IPI00028006.1 PSMB2 30 10 4 2.442 0.134 14 
IPI00000787.1 PSMB9 9 7 19 2.778 0.004 26 
IPI00218604.6 PTPN6 15 17 8 2.076 0.089 25 
IPI00550882.3 PYCR1 19 5 11 2.252 0.162 16 
IPI00102752.2 RBM15 17 9 20 2.275 0.000 29 
IPI00009737.1 RRAGD 11 8 3 2.605 0.101 11 
IPI00412713.4 SAMM50 14 9 18 2.047 0.009 27 
IPI00023649.3 SBNO1 5 3 8 2.730 0.165 11 
IPI00303343.7 SCAF1 9 7 15 2.193 0.055 22 
IPI00103419.4 SF4 12 4 9 2.303 0.163 13 
IPI00015476.1 SLC1A4 10 10 4 2.442 0.147 14 
IPI00024305.1 SMAD3 13 8 3 2.605 0.087 11 
IPI00386786.5 STX5 22 2 11 5.630 0.010 13 
IPI00216137.4 SYCP1 3 10 2 4.885 0.006 12 
IPI00159322.4 TCF20 5 4 8 2.047 0.172 12 
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IPI00005563.1 TINAGL1 4 5 12 2.457 0.131 17 
IPI00221206.1 TLE3 10 9 2 4.396 0.015 11 
IPI00307572.1 TMEM165 20 5 16 3.276 0.040 21 
IPI00180240.2 TMSL3 41 11 2 5.373 0.156 13 
IPI00016676.1 TOMM20 16 4 8 2.047 0.177 12 
IPI00166704.1 TOMM5 31 9 4 2.198 0.150 13 
IPI00004324.1 TRAPPC3 28 6 13 2.218 0.095 19 
IPI00018971.8 TRIM21 10 5 12 2.457 0.048 17 
IPI00297113.1 TRIM32 4 11 2 5.373 0.068 13 
IPI00005634.3 TTC37 8 6 12 2.047 0.194 18 
IPI00385712.3 TTF1 10 2 9 4.606 0.048 11 
IPI00033516.1 TUBGCP3 10 10 4 2.442 0.144 14 
IPI00305303.3 UFSP2 11 6 16 2.730 0.008 22 
IPI00300504.5 UPF2 7 6 12 2.047 0.114 18 
IPI00020515.3 USE1 20 9 4 2.198 0.040 13 
IPI00419844.3 USP39 12 17 8 2.076 0.003 25 
IPI00376439.1 VPS13B 2 4 10 2.559 0.151 14 
IPI00418316.6 ZMYND8 9 3 9 3.071 0.106 12 
IPI00328737.2 ZNF598 14 7 16 2.340 0.013 23 
IPI00011631.6 ZW10 15 2 9 4.606 0.018 11 
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Table B4.  Up- and down-regulated proteins from Venn diagram (Figure III-
3) overlaps.   
Proteins 
common in  all 
three 
signatures        
EGFR inhibition 
Signature   (13) 
Proteins common  
between 
stimulation and 
cetuximab 
inhibition 
signature (15) 
Proteins shared 
between 
cetuximab and 
gefitinib 
inhibition 
signature (18) 
Proteins shared between gefitinib              
inhibition signature and stimulation 
signature (57) 
CCDC50 ATXN2 ARPP19 ARL6IP1 HSP90AB6P RPAP3 
CDKN1A C11orf31 C20orf117 BLVRA KIF20B RPL10 
CLDN4 CYTH3 CC2D1B C21orf70 LOC440043 RPL12P38 
COBLL1 FGFR2 CD151 CD81 LYPLA1 RPL22 
GFPT2 GADD45GIP1 CMAS CDC23 MAGEA1 RPL7P32 
JAG1 GNPAT DNASE2 CDCA8 MAGEB18 RPS18 
JUN KIF14 GRIN1 CEP55 MAGEB6 RPS20 
JUND OXA1L ICAM1 CEP97 MAP9 RPS26P11 
PRIM1 PHLDA1 LDLRAP1 CLU MST1R RPS27L 
RBM15 PPP1R9B PAPSS2 CNN3 MYL6B RPS4Y1 
TOMM20 PSMB2 PARP10 CRELD2 NCAPD3 S100P 
TRAPPC3 SF4 PLAUR DGAT1 PABPCP2 SETD2 
TRIM32 TCF20 SCAF1 DNAJC16 PACSIN2 SLC12A2 
UPF2 STX5 DST PDCD4 SPTBN2 
ZMYND8 SYCP1 EHMT2 PGK2 SPTBN5 
TLE3 FAM114A1 PIP5K1A STAT2 
UFSP2 FAM192A RBM19 SUMO2 
ZW10 GOPC RER1 THBS1 
TNS4 TRIM27 UTRN 
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Table B5.   A431 EGFR inhibition signature MRM data depicted in Figure III-4.  Pre. m/z = precursor mass to charge 
ratio, Protein = HUGO name, NPA = normalized peak area, Std. D. = standard deviation, CV = coefficient of variation.  
Pro = proliferating cells, EGF = EGF-stimulated (30 nM for 4 h), GEF = gefitinib (500 nM) and EGF-treated, CET = 
cetuximab (10 µg/mL) and EGF-treated.  Data is representative of three separate cultures.   All precursor m/z have a 
charge of 2+ unless otherwise noted. 
      
      
     
Peptide Sequence Protein Pre. m/z NPA 
Std. 
D. 
CV 
(%) 
NPA 
Std. 
D. 
CV 
(%) 
NPA 
Std. 
D. 
CV 
(%) 
NPA 
Std. 
D. 
CV 
(%) 
   
PRO PRO PRO EGF EGF EGF GEF GEF GEF CET CET CET 
DQEWYDAEIAR CCDC50 698.3124 0.042 0.003 6.88 0.031 0.001 3.52 0.043 0.007 16.77 0.044 0.003 6.31 
SGEQAEGSPGGPGDSQGR CDKN1A 836.8615 0.001 0.000 54.89 0.012 0.003 23.58 0.002 0.001 20.60 0.001 0.000 29.18 
CTNCLEDESAK CLDN4 663.7687 0.052 0.002 3.65 0.159 0.015 9.32 0.064 0.005 7.14 0.062 0.002 2.78 
DQTASAPATPLVNK COBL1 706.8726 0.049 0.001 1.95 0.044 0.002 3.63 0.055 0.002 2.76 0.061 0.001 2.01 
DLESAQSLNR JAG1 566.7833 0.278 0.025 9.02 0.424 0.030 6.99 0.314 0.020 6.39 0.359 0.013 3.60 
NVTDEQEGFAEGFVR JUN 849.3919 0.035 0.009 24.80 0.057 0.010 17.28 0.038 0.002 5.75 0.031 0.003 9.74 
SQNTELASTASLLR JUND 745.8941 0.034 0.002 5.55 0.059 0.001 1.58 0.041 0.003 7.76 0.047 0.001 3.12 
VFEHFLENLDK PRIM1 695.8537 0.025 0.001 4.23 0.019 0.003 14.33 0.027 0.003 11.01 0.018 0.005 27.69 
LWVGGLGPWVPLAALAR RBM15 888.5196 0.067 0.003 4.69 0.052 0.023 43.87 0.095 0.002 1.80 0.124 0.021 17.35 
LPTISQR TOMM20 407.7427 1.061 0.087 8.23 1.098 0.061 5.59 1.274 0.042 3.28 1.406 0.078 5.51 
GALEMVQMAVEAK TRAPPC3 688.8493 0.047 0.002 3.46 0.061 0.001 2.63 0.099 0.010 10.54 0.101 0.004 2.49 
ELTLQDVELLK TRIM32 650.8716 0.017 0.002 8.79 0.028 0.006 23.18 0.020 0.002 8.08 0.016 0.001 6.78 
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Figure B4.  MRM and spectral count data for analysis of EGFR inhibition 
signature proteins using a second unique peptide in A431 cells.  Each panel 
shows both MRM data (red bar-normalized to β-actin labeled reference peptide) 
and spectral count data (teal bar-total spectra identified in global proteome 
analyses) for each protein of interest across four A431 cell treatment conditions 
(see Table I legend for treatment conditions). MRM data shows normalized peak 
area quantified from one unique peptide for each target protein across three 
separate cultures.   (*) Denotes significant difference between EGF-treated A431 
cells as determined by Student’s two-tailed, unpaired t-test.-----------------------------  
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Table B6.  A431 EGFR inhibition signature MRM data depicted in Figure B4 for second unique peptide.  Pre. m/z = 
precursor mass to charge ratio, Protein = HUGO name, NPA = normalized peak area, Std. Dev. = standard deviation, CV 
= coefficient of variation.  Pro = proliferating cells, EGF = EGF-stimulated (30 nM for 4 h), GEF = gefitinib (500 nM) and 
EGF treated, CET = cetuximab (10 µg/mL) and EGF treated.  Data is representative of three separate cultures.   All 
precursor m/z have a charge of 2+ unless otherwise noted. 
      
Peptide Sequence Protein Pre. m/z NPA 
Std. 
Dev. 
CV 
(%) 
NPA 
Std. 
Dev. 
CV 
(%) 
NPA 
Std. 
Dev. 
CV 
(%) 
NPA 
Std. 
Dev. 
CV 
(%) 
   
PRO PRO PRO EGF EGF EGF GEF GEF GEF CET CET CET 
LQEEELLATQVDMR CCDC50 837.9220++ 0.061 0.002 2.52 0.046 0.006 12.46 0.065 0.006 8.78 0.068 0.004 5.16 
VYDSLLALPQDLQAAR CLDN4 886.9807++ 0.046 0.001 3.08 0.075 0.006 7.63 0.055 0.003 6.21 0.047 0.008 17.45 
DYQSQEPLDLTK COBL1 718.8488++ 0.046 0.002 4.76 0.040 0.001 3.29 0.052 0.005 9.72 0.046 0.004 7.60 
QNTGVAHFEYQIR JAG1 781.8891++ 0.025 0.002 7.13 0.077 0.001 1.51 0.039 0.004 11.24 0.027 0.001 2.58 
NSDLLTSPDVGLLK JUN 736.4038++  0.024 0.003 13.09 0.116 0.008 7.04 0.084 0.002 2.95 0.090 0.005 5.86 
VAASEEQEFAEGFVK JUND 820.8938++  0.016 0.001 9.43 0.034 0.000 1.27 0.024 0.003 12.25 0.026 0.004 14.83 
SGIVEYLSLVK PRIM1 604.3503++ 0.215 0.019 8.76 0.183 0.010 5.37 0.241 0.010 4.04 0.165 0.032 19.44 
TAATSVPAYEPLDSLDR RBM15 903.4494++ 0.054 0.003 8.10 0.043 0.005 11.05 0.064 0.004 4.06 0.060 0.003 2.50 
IVSAQSLAEDDVE TOMM20 688.3330++ 0.012 0.001 0.66 0.015 0.002 0.66 0.029 0.003 10.37 0.030 0.003 8.87 
LIEDFLAR TRAPPC3 488.7767++  0.292 0.011 3.75 0.234 0.001 0.22 0.320 0.037 11.62 0.314 0.039 12.25 
 
 
 
 
  
219 
 
 
 
Figure B5.  MRM and spectral count data for analysis of additional proteins in A431 cells.  Each panel shows both MRM data 
(red bar-normalized to β-actin labeled reference peptide) and spectral count data (teal bar-total spectra identified in global proteome 
analyses) for each protein of interest across four A431 cell treatment conditions (see Table I legend for treatment conditions). MRM 
data shows normalized peak area quantified from one unique peptide for each target protein across three separate cultures.   (*) 
Denotes significant difference between EGF-treated A431 cells as determined by Student’s two-tailed, unpaired t-test.    
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Table B7.  A431 MRM data for additional proteins depicted in Figure B5.  Pre. m/z = precursor mass to charge ratio, 
Protein = HUGO name, NPA = normalized peak area, Std. Dev. = standard deviation, CV = coefficient of variation.  Pro = 
proliferating cells, EGF = EGF-stimulated (30 nM for 4 h), GEF = gefitinib (500 nM) and EGF-treated, CET = cetuximab 
(10 µg/mL) and EGF-treated.  Data is representative of three separate cultures.   All precursor m/z have a charge of 2+ 
unless otherwise noted. 
 
Peptide Sequence Protein Pre. m/z NPA 
Std. 
Dev 
CV 
(%) 
NPA 
Std. 
Dev 
CV 
(%) 
NPA 
Std. 
Dev 
CV 
(%) 
NPA 
Std. 
Dev 
CV 
(%) 
   
PRO PRO PRO EGF EGF EGF GEF GEF GEF CET CET CET 
AAQVTIQSSGTFSSK A2MG 756.3886++  0.3667 0.0150 4.08 0.3085 0.0260 8.44 0.3093 0.0188 6.09 0.2615 0.0145 5.53 
FALSSNSQDEVR HMGCR 676.8257++ 0.0150 0.0023 15.25 0.0463 0.0017 3.60 0.0477 0.0040 8.46 0.0489 0.0026 5.34 
VLEEEENKPNPVTQR HMGCR 891.4550++ 0.0021 0.0002 7.82 0.0082 0.0006 7.16 0.0098 0.0011 11.21 0.0095 0.0007 7.29 
IGVFSYGSGLAATLYSLK HMCS1 924.0011++ 0.0377 0.0038 10.05 0.1069 0.0031 2.94 0.1164 0.0252 21.60 0.1075 0.0050 4.61 
NSIYSGLEAFGDVK HMCS1 750.3725++ 0.0741 0.0063 8.57 0.2116 0.0140 6.61 0.2257 0.0203 9.01 0.1716 0.0027 1.56 
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Table B8.  DiFi cell EGFR inhibition signature MRM data depicted in Figure III-5.  Pre. m/z = precursor mass to 
charge ratio, Protein = HUGO name, NPA = normalized peak area, Std. Dev. = standard deviation, CV = coefficient of 
variation.  Pro = proliferating cells, EGF = EGF-stimulated (30 nM for 4 h), GEF = gefitinib (500 nM) and EGF-treated, 
CET = cetuximab (10 µg/mL) and EGF-treated.  Data is representative of three separate cultures.   All precursor m/z have 
a charge of 2+ unless otherwise noted. 
 
Peptide Sequence Protein Pre. m/z NPA 
Std. 
Dev. 
CV 
(%) 
NPA 
Std. 
Dev. 
CV 
(%) 
NPA 
Std. 
Dev. 
CV 
(%) 
NPA 
Std. 
Dev. 
CV 
(%) 
   
PRO PRO PRO EGF EGF EGF GEF GEF GEF CET CET CET 
DQEWYDAEIAR CCDC50 698.3124++ 0.045 0.003 7.14 0.037 0.004 10.50 0.057 0.005 8.90 0.050 0.003 5.56 
CTNCLEDESAK CLDN4 663.7687++ 0.040 0.002 4.73 0.046 0.004 8.73 0.031 0.002 6.47 0.035 0.004 11.45 
DQTASAPATPLVNK COBL1 706.8726++ 0.011 0.001 5.39 0.009 0.000 2.31 0.010 0.000 1.61 0.011 0.000 0.44 
DLESAQSLNR JAG1 566.7833++ 0.159 0.002 1.10 0.186 0.013 7.17 0.125 0.005 4.13 0.145 0.011 7.88 
NVTDEQEGFAEGFVR JUN 849.3919++ 0.024 0.001 3.16 0.030 0.002 6.77 0.023 0.000 1.21 0.024 0.001 2.12 
SQNTELASTASLLR JUND 745.8941++ 0.017 0.001 5.34 0.016 0.001 5.06 0.018 0.002 12.02 0.016 0.001 6.40 
VFEHFLENLDK PRIM1 695.8537++ 0.094 0.015 15.72 0.092 0.006 6.83 0.089 0.010 10.91 0.073 0.050 67.90 
LWVGGLGPWVPLAALAR RBM15 888.5196++ 0.015 0.001 7.46 0.013 0.001 4.83 0.016 0.000 1.17 0.017 0.001 5.87 
GALEMVQMAVEAK TRAPPC3 688.8493++ 0.065 0.002 3.73 0.046 0.001 1.60 0.051 0.001 1.53 0.054 0.002 2.94 
ELTLQDVELLK TRIM32 650.8716++ 0.019 0.001 3.29 0.022 0.000 0.44 0.019 0.001 7.80 0.019 0.000 2.63 
LPTISQR TOMM20 407.7427++ 0.673 0.052 7.79 0.536 0.028 5.24 0.601 0.017 2.83 0.641 0.027 4.13 
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Table B9.  HCT-116 cells EGFR inhibition signature MRM data depicted in Figure III-6.   Pre. m/z = precursor mass 
to charge ratio, Protein = HUGO name, NPA = normalized peak area, Std. Dev. = standard deviation, CV = coefficient of 
variation.  Pro = proliferating cells, EGF = EGF-stimulated (30 nM for 4 h), GEF = gefitinib (500 nM) and EGF-treated, 
CET = cetuximab (10 µg/mL) and EGF-treated.  Data is representative of three separate cultures.   All precursor m/z have 
a charge of 2+ unless otherwise noted.     
 
Peptide Sequence Protein Pre. m/z NPA 
Std. 
Dev. 
CV 
(%) NPA 
Std. 
Dev. 
CV 
(%) NPA 
Std. 
Dev. 
CV 
(%) NPA 
Std. 
Dev. 
CV 
(%) 
   
PRO PRO PRO EGF EGF EGF GEF GEF GEF CET CET CET 
DQEWYDAEIAR CCDC50 698.3124++ 0.018 0.002 8.781 0.016 0.001 3.835 0.019 0.001 4.009 0.020 0.002 9.861 
CTNCLEDESAK CLDN4 663.7687++ 0.018 0.002 11.012 0.021 0.003 16.189 0.020 0.003 15.486 0.019 0.002 9.239 
DLESAQSLNR JAG1 566.7833++ 0.173 0.023 13.317 0.178 0.014 7.606 0.166 0.021 12.716 0.161 0.019 12.002 
NVTDEQEGFAEGFVR JUN 849.3919++ 0.021 0.001 4.257 0.026 0.003 10.257 0.025 0.002 8.971 0.021 0.003 15.174 
SQNTELASTASLLR JUND 745.8941++ 0.021 0.002 8.732 0.027 0.003 10.541 0.020 0.000 2.354 0.023 0.003 12.982 
GALEMVQMAVEAK TRAPPC3 688.8493++ 0.057 0.003 4.759 0.047 0.024 52.209 0.060 0.003 5.823 0.056 0.001 1.197 
ELTLQDVELLK TRIM32 650.8716++ 0.029 0.001 2.949 0.030 0.002 7.284 0.030 0.000 0.757 0.030 0.003 8.906 
LPTISQR TOMM20 407.7427++ 0.882 0.013 1.426 0.849 0.043 5.086 0.898 0.096 10.672 0.898 0.096 10.672 
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Table B10.   DiFi xenograft MRM data depicted in Figure III-8.   Pre. m/z = precursor mass to charge ratio, Protein = 
HUGO name, NPA = normalized peak area, Std. Dev. = standard deviation, CV = coefficient of variation.  Tumor bearing 
mice were treated with 40 mg/kg cetuximab (CET) or saline (vehicle) intraperitoneally every three days for one week 
(three total injections).  Data is representative of four separate tissue biopsies.   All precursor m/z have a charge of 2+ 
unless otherwise noted. 
  
Peptide Sequence Protein Pre. m/z NPA 
Std. 
Dev. 
CV (%) NPA 
Std. 
Dev. 
CV (%) 
   
Vehicle Vehicle Vehicle CET CET CET 
DQEWYDAEIAR CCDC50 698.3124++ 0.0069 0.0026 37.1862 0.0072 0.0026 36.4968 
CTNCLEDESAK CLDN4 663.7687++ 0.0125 0.0014 11.5945 0.0079 0.0009 11.4793 
DQTASAPATPLVNK COBL1 706.8726++ 0.0025 0.0004 15.9557 0.0043 0.0020 45.6175 
DLESAQSLNR JAG1 566.7833++ 0.0890 0.0037 4.1588 0.0697 0.0046 6.5510 
NVTDEQEGFAEGFVR JUN 849.3919++ 0.0058 0.0006 10.9894 0.0041 0.0003 7.7912 
LWVGGLGPWVPLAALAR RBM15 888.5196++ 0.0052 0.0009 17.1928 0.0043 0.0006 14.0857 
GALEMVQMAVEAK TRAPPC3 688.8493++ 0.0109 0.0009 8.0546 0.0140 0.0011 8.1909 
ELTLQDVELLK TRIM32 650.8716++ 0.0085 0.0009 10.3832 0.0048 0.0014 29.4158 
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Table B11.   HCT-116 xenograft MRM data depicted in Figure III-9.   Pre. m/z = precursor mass to charge ratio,  
Protein = HUGO name, NPA = normalized peak area, Std. Dev. = standard deviation, CV = coefficient of variation.   
Tumor bearing mice were treated with 40 mg/kg cetuximab (CET)  or saline (vehicle) intraperitoneally every three 
days for one week (three total injections).     Data is representative of four separate tissue biopsies.   All precursor  
m/z have a charge of 2+ unless otherwise noted. 
 
 
Peptide Sequence Protein Pre. m/z NPA 
Std. 
Dev. 
CV (%) NPA 
Std. 
Dev. 
CV (%) 
   
Vehicle Vehicle Vehicle CET CET CET 
DQEWYDAEIAR CCDC50 698.3124++ 0.0055 0.0013 24.4692 0.0052 0.0014 26.4362 
CTNCLEDESAK CLDN4 663.7687++ 0.0048 0.0012 25.5800 0.0046 0.0006 13.3858 
DLESAQSLNR JAG1 566.7833++ 0.0500 0.0045 9.0159 0.0504 0.0030 5.9767 
NVTDEQEGFAEGFVR JUN 849.3919++ 0.0031 0.0004 14.0274 0.0030 0.0003 8.7231 
LWVGGLGPWVPLAALAR RBM15 888.5196++ 0.0011 0.0004 38.8846 0.0027 0.0008 30.3899 
GALEMVQMAVEAK TRAPPC3 688.8493++ 0.0046 0.0008 18.3772 0.0071 0.0015 21.5939 
ELTLQDVELLK TRIM32 650.8716++ 0.0036 0.0007 20.4497 0.0039 0.0007 17.0449 
LPTISQR TOMM20 407.7427++ 0.0509 0.0094 18.5009 0.0651 0.0066 10.1000 
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Table B12.  MRM data from Ménétrier's disease patient for EGFR inhibition signature proteins depicted in Figure 
III-11.  Pre. m/z = precursor mass to charge ratio, Protein = HUGO name, NPA = normalized peak area, Std. Dev. = 
standard deviation, CV = coefficient of variation.  All precursor m/z have a charge of 2+ unless otherwise noted. 
Normalized peak areas, standard deviations and CVs from are shown for each of the three separate biopsies (from a 
single patient); and the average, standard deviation, and %CV have been calculated for each timepoint. Baseline = prior 
to cetuximab-treatment, 1 day, 1 week, 1 month and 4 months = time post initial cetuximab treatment.         
 
Peptide Sequence Protein Pre. m/z NPA 
Std. 
Dev. 
CV (%) NPA 
Std. 
Dev. 
CV (%) NPA 
Std. 
Dev. 
CV (%) 
   
Baseline Baseline Baseline 1 day 1 day 1 day 1 week 1 week 1 week 
DQEWYDAEIAR CCDCC50 698.3124++ 0.0051 0.0007 14.2532 0.0037 0.0003 6.8715 0.0038 0.0006 17.1559 
CTNCLEDESAK CLDN4 663.7687++ 0.0078 0.0005 6.8395 0.0051 0.0001 2.6273 0.0056 0.0009 16.3332 
DQTASAPATPLVNK COBL1 706.8726++ 0.0066 0.0003 4.6491 0.0050 0.0004 7.2467 0.0060 0.0008 13.8583 
DLESAQSLNR JAG1 566.7833++ 0.0410 0.0026 6.2662 0.0292 0.0032 10.8415 0.0328 0.0041 12.4525 
NVTDEQEGFAEGFVR JUN 849.3919++ 0.0014 0.0002 16.8748 0.0014 0.0002 16.8748 0.0015 0.0003 17.5052 
SQNTELASTASLLR JUND 745.8941++ 0.0030 0.0007 24.3173 0.0022 0.0001 6.6875 0.0027 0.0006 21.3102 
GALEMVQMAVEAK TRAPPC3 688.8493++ 0.0100 0.0022 21.9320 0.0145 0.0027 18.7889 0.0164 0.0014 8.6232 
ELTLQDVELLK TRIM32 650.8716++ 0.0024 0.0008 32.7586 0.0017 0.0014 80.6941 0.0039 0.0012 31.0642 
LPTISQR TOMM20 407.7427++ 7.9892 1.2856 16.0912 3.7432 0.1697 4.5340 4.5989 1.2768 27.7624 
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APPENDIX C 
 
Data to Chapter IV: 
 
SITE-SPECIFIC, QUANTITATIVE COMPARISON OF EGFR 
PHOSPHORYLATION CHANGES INDUCED BY EGF AND INHIBITORS 
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Table C1.  EGFR phosphorylated and nonphosphorylated peptides and transitions selected for LC-pSRM-MS.  
Peptides marked with p are phosphorylated.  Those marked with ^ are isotopically labeled at the indicated amino acid.   
), 548.3 (y 9 
2+)
NLQEILHGAVR 625.4 894.5 (y8), 765.5 (y7) , 652.4 (y 6), 539.3 (y5), 402.3 (y4)
EISDGDVIISGNK 673.8 1104.6 (y11), 631.4 (y6), 518.3 (y 5 ), 405.2 (y 4), 502.2 (b 5
2+)
GLWIPEGEK 514.8 858.4 (y7), 672.4 (y 6 ), 559.3 (y 5), 429.7 (y7 
2+), 470.3 (b 4 )
ITDFGLAK 432.7 751.4 (y7), 650.4 (y 6 ), 535.3 (y 5), 388.3 (y4 ), 215.1 (b 2)
MHLPSPTDSNFpY R^ 827.9 1273.5 (y10), 1089.4 (y 8 ), 776.3 (y5 ), 693.8 (y11
2+), 382.2 (b 3)
RPAGSVQNPVpYHNQPLNPAPSR^ 830.4 1483.7 (y12), 1118.5 (y 20
2+), 1083.0 (y 19
2+), 897.4 (y15
2+), 976.9 (b 17
2+)
GSHQISLDNPDpY QQDFFPK^ 775.3 1275.5 (y9), 1160.5 (y 8 ), 807.3 (y12
2+), 743.8 (y11
2+), 686.8 (y10
2+)
GSTAENAEpYLR^ 650.8 855.4 (y6), 741.3 (y5 ), 670.3 (y4), 541.2 (y3 ), 578.8 (y9 
2+)
Peptide1 Precursor m/z Product m/z
MHLPSPTDSNF pYR 822.8 1263.5 (y10), 1079.4 (y8 ), 766.3 (y 5), 688.8 (y11
2+), 382.2 (b3 )
MHLPSPTDSNFYR 782.9 1296.6 (y11), 1183.5 (y10), 648.8 (y11
2+), 592.3 (y 10
2+), 1390.6 (b 12)
MHLPpS PTDSNFYR – MS3 822.84  773.85 534.7 (y9 
2+), 639.8 (y 11
2+), 861.4 (b 8), 1165.5 (y10), 1278.6 (y11)
RPAGSVQNPV pYHNQPLNPAPSR 827.1 1473.7 (y 12), 1113.5 (y20
2+), 1078.0 (y19
2+), 892.4 (y 15
2+), 977.0 (b17
2+)
RPAGSVQNPVYHNQPLNPAPSR 800.4 851.5 (y8 ), 1009.5 (y18
2+), 710.9 (b 13
2+), 774.9 (b 14
2+), 937.0 (b 17
2+)
GSHQISLDNPD pYQQDFFPK 772.7 1267.5 (y 9 ), 1152.5 (y8 ), 797.3 (y 12
2+), 739.8 (y11
2+), 682.8 (y10
2+)
GSHQISLDNPDYQQDFFPK 746.0 1072.5 (y8 ), 642.8 (y 10
2+), 952.5 (b 9), 923.4 (b16
2+), 996.9(b 17
2+)
GSHQIpSLDNPDYQQDFFPK – MS3 772.7 
 
740.01 914.4 (b16
2+), 934.4 (b 9), 987.9 (b 17
2+)
GSTAENAEpYLR 645.8 845.4 (y6 ), 731.3 (y 5), 660.3 (y 4), 531.2 (y3 ), 573.8 (y 9
2+)
GSTAENAEYLR 605.78 894.4 (y7 ), 765.4 (y 6), 580.3 (y 4), 451.3 (y3 ), 533.8 (y 9
2+)
IPLENLQIIR 604.9 998.6 (y8), 885.5 (y 7 ), 756.5 (y6), 529.4 (y4 
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Figure C1.  Median CV plots for peptide MHLPSPTDSNFpYR. The CV’s were calculated by the technical replicate 
analysis on a per treatment basis for each internal reference and stable isotope labeled peptide. (A-C) All data (three 
technical replicates for each treatment) was used to calculate median CV’s for biological replicate one (A), two (B) and 
three (C). The black dashed line represents 15% CV, and the red dashed line represents 30% CV.  Data was not detected 
in proliferating or gefitinib co-treated samples. 
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Figure C2.  Median CV plots for peptide GSHQISLDNPDpYQQDFFPK. The CV’s were calculated by the technical 
replicate analysis on a per treatment basis for each internal reference and stable isotope labeled peptide. (A-C) All data 
(three technical replicates for each treatment) was used to calculate median CV’s for biological replicate one (A), two (B) 
and three (C). The black dashed line represents 15% CV, and the red dashed line represents 30% CV.   
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Figure C3.  Median CV plots for peptide GSTAENAEpYLR. The CV’s were calculated by the technical replicate 
analysis on a per treatment basis for each internal reference and stable isotope labeled peptide. (A-C) All data (three 
technical replicates for each treatment) was used to calculate median CV’s for biological replicate one (A), two (B) and 
three (C). The black dashed line represents 15% CV, and the red dashed line represents 30% CV.   
  
R
.IP
LE
N
LQ
IIR
.G
R
.N
LQ
E
IL
H
G
A
V
R
.F
K
.E
IS
D
G
D
VI
IS
G
N
K
.N
K
.G
LW
IP
E
G
E
K
.V
K
.IT
D
FG
LA
K
.L
S
ID
0
50
100
150
R
.IP
LE
N
LQ
IIR
.G
R
.N
LQ
E
IL
H
G
A
V
R
.F
K
.E
IS
D
G
D
VI
IS
G
N
K
.N
K
.G
LW
IP
E
G
E
K
.V
K
.IT
D
FG
LA
K
.L
S
ID
0
50
100
150
R
.IP
LE
N
LQ
IIR
.G
R
.N
LQ
E
IL
H
G
A
V
R
.F
K
.E
IS
D
G
D
VI
IS
G
N
K
.N
K
.G
LW
IP
E
G
E
K
.V
K
.IT
D
FG
LA
K
.L
S
ID
0
50
100
150
M
e
d
i
a
n
 
%
C
V
A B C
Cetuximab + EGF
EGF
Proliferating
Gefitinib + EGF
231 
 
 
Figure C4.  Median CV plots for MS3 of MHLPpSPTDSNFYR peptide. The CV’s were calculated by the technical 
replicate analysis on a per treatment basis for each internal reference and stable isotope labeled peptide. (A-C) All data 
(three technical replicates for each treatment) was used to calculate median CV’s for biological replicate one (A), two (B) 
and three (C). The black dashed line represents 15% CV, and the red dashed line represents 30% CV.   
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Figure C5.  Median CV plots for MS3 of GSHQIpSLDNPDYQQDFFPK peptide. The CV’s were calculated by the 
technical replicate analysis on a per treatment basis for each internal reference and stable isotope labeled peptide. (A-C) 
All data (three technical replicates for each treatment) was used to calculate median CV’s for biological replicate one (A), 
two (B) and three (C). The black dashed line represents 15% CV, and the red dashed line represents 30% CV. 
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Figure C6.  Normalized pSRM plots of MHLPSPTDSNFpYR for each internal 
reference peptide and SID peptide. (P – proliferating, E – EGF-stimulated, G + 
E – gefitinib-treatment followed by EGF and C + E – Cetuximab-treatment 
followed by EGF). Data from biological replicate one (biological replicate two and 
three generate similar results), three technical replicates. Data was “not 
detected” for P and G + E samples. 
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Figure C7.  Normalized pSRM plots of RPAGSVQNPVpYHNQPLNPAPSR for 
each internal reference peptide and SID peptide.  (P – proliferating, E – EGF 
stimulated, G + E – Gefitinib-treatment followed by EGF and C+ E – Cetuximab-
treatment followed by EGF). Data from biological replicate one (biological 
replicate two and three generate similar results), three technical replicates. 
pY1110 - IPLENLQIIR
P E
G
 +
 E
C
 +
 E
0.000
0.001
0.002
0.003
0.004
0.01
0.02
0.03
N
o
rm
a
li
z
e
d
 p
S
R
M
 S
ig
n
a
l
pY1110 - NLQEILHGAVR
P E
G
 +
 E
C
 +
 E
0.00
0.05
0.10
0.2
0.3
0.4
0.5
N
o
rm
a
li
z
e
d
 p
S
R
M
 S
ig
n
a
l
pY1110 - EISDGDVIISGNK
P E
G
 +
 E
C
 +
 E
0.00
0.01
0.02
0.05
0.10
0.15
0.20
N
o
rm
a
li
z
e
d
 p
S
R
M
 S
ig
n
a
l
pY1110 - GLWIPEGEK
P E
G
 +
 E
C
 +
 E
0.00
0.02
0.04
0.06
0.08
0.10
0.15
0.30
0.45
N
o
rm
a
li
z
e
d
 p
S
R
M
 S
ig
n
a
l
pY1110 - ITDFGLAK
P E
G
 +
 E
C
 +
 E
0.000
0.005
0.010
0.03
0.09
0.15
N
o
rm
a
li
z
e
d
 p
S
R
M
 S
ig
n
a
l
pY1110 - SID
P E
G
 +
 E
C
 +
 E
0.0
0.2
0.4
0.6
0.8
1.0
1.2
10
12
N
o
rm
a
li
z
e
d
 p
S
R
M
 S
ig
n
a
l
235 
 
 
Figure C8.  Normalized pSRM plots of GSHQISLDNPDpYQQDFFPK for each 
internal reference peptide and SID peptide.  P – proliferating, E – EGF-
stimulated, G + E – gefitinib-treatment followed by EGF and C + E – cetuximab-
treatment followed by EGF).  Data from biological replicate one, three technical 
replicates (biological replicate two and three generate similar results). 
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Figure C9.  Normalized pSRM plots (GSTAENAEpYLR) for each internal 
reference peptide and SID peptide P – proliferating, E – EGF-stimulated, G + E 
– gefitinib-treatment followed by EGF and C + E – cetuximab-treatment followed 
by EGF).  Data from biological replicate one, three technical replicates (biological 
replicate two and three generate similar results).  
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Figure C10.  Normalized MS3 pSRM plots (MHLPpSPTDSNFYR) for each 
internal reference peptide and pY peptide complement. (P – proliferating, E – 
EGF-stimulated, G + E – Gefitinib-treatment followed by EGF and C + E – 
Cetuximab-treatment followed by EGF). Data from biological replicate two, three 
technical replicates. The underlined amino acid indicates which amino acid was 
stable isotope labeled.  
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Figure C11.  Normalized MS3 pSRM plots (GSHQIpSLDNPDYQQDFFPK) for 
each internal reference peptide and pY peptide complement. (P – 
proliferating, E – EGF-stimulated, G + E – Gefitinib-treatment followed by EGF-
and C + E – Cetuximab-treatment followed by EGF). Data from biological 
replicate two, three technical replicates. The underlined amino acid indicates 
which amino acid was stable isotope labeled. 
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